WO2005104745A2 - Muscarinic acetylcholine receptor antagonists - Google Patents

Muscarinic acetylcholine receptor antagonists Download PDF

Info

Publication number
WO2005104745A2
WO2005104745A2 PCT/US2005/014386 US2005014386W WO2005104745A2 WO 2005104745 A2 WO2005104745 A2 WO 2005104745A2 US 2005014386 W US2005014386 W US 2005014386W WO 2005104745 A2 WO2005104745 A2 WO 2005104745A2
Authority
WO
WIPO (PCT)
Prior art keywords
methyl
azoniabicyclo
hydroxy
octane bromide
diphenyl
Prior art date
Application number
PCT/US2005/014386
Other languages
French (fr)
Other versions
WO2005104745A3 (en
Inventor
Dramane I. Laine
Michael R. Palovich
Brent W. Mccleland
Christopher E. Neipp
Sonia M. Thomas
Original Assignee
Glaxo Group Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35242158&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=WO2005104745(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority to KR1020117001909A priority Critical patent/KR101152032B1/en
Application filed by Glaxo Group Limited filed Critical Glaxo Group Limited
Priority to PT121704027T priority patent/PT2570128T/en
Priority to BRPI0510170A priority patent/BRPI0510170B8/en
Priority to DK05746609.6T priority patent/DK1740177T3/en
Priority to AP2006003746A priority patent/AP2213A/en
Priority to PL12170402T priority patent/PL2570128T3/en
Priority to EA200601991A priority patent/EA015033B1/en
Priority to NZ549997A priority patent/NZ549997A/en
Priority to US11/568,330 priority patent/US7498440B2/en
Priority to ES12170402.7T priority patent/ES2600405T3/en
Priority to SI200531605T priority patent/SI1740177T1/en
Priority to JP2007510915A priority patent/JP5014121B2/en
Priority to DK12170402.7T priority patent/DK2570128T3/en
Priority to MXPA06012405A priority patent/MXPA06012405A/en
Priority to HUE12170402A priority patent/HUE031304T2/en
Priority to EP12170402.7A priority patent/EP2570128B1/en
Priority to EP05746609A priority patent/EP1740177B1/en
Priority to CA2564742A priority patent/CA2564742C/en
Priority to AU2005237576A priority patent/AU2005237576B2/en
Priority to PL05746609T priority patent/PL1740177T3/en
Priority to ES05746609.6T priority patent/ES2392848T4/en
Publication of WO2005104745A2 publication Critical patent/WO2005104745A2/en
Publication of WO2005104745A3 publication Critical patent/WO2005104745A3/en
Priority to IL178152A priority patent/IL178152A/en
Priority to ZA2006/08565A priority patent/ZA200608565B/en
Priority to EC2006006940A priority patent/ECSP066940A/en
Priority to NO20065417A priority patent/NO338959B1/en
Priority to HK07106891.0A priority patent/HK1102423A1/en
Priority to US11/774,867 priority patent/US7488827B2/en
Priority to US12/353,436 priority patent/US8183257B2/en
Priority to US13/401,890 priority patent/US8309572B2/en
Priority to US13/627,007 priority patent/US8575347B2/en
Priority to HRP20120832TT priority patent/HRP20120832T1/en
Priority to US14/052,816 priority patent/US8853404B2/en
Priority to US14/476,940 priority patent/US9045469B2/en
Priority to NL300694C priority patent/NL300694I2/nl
Priority to CY2014043C priority patent/CY2014043I1/en
Priority to US14/707,543 priority patent/US9144571B2/en
Priority to US14/849,775 priority patent/US20160002220A1/en
Priority to CY20161101008T priority patent/CY1118082T1/en
Priority to HRP20161385TT priority patent/HRP20161385T1/en
Priority to NO2017017C priority patent/NO2017017I1/en
Priority to NO2017018C priority patent/NO2017018I2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/452—Piperidinium derivatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Definitions

  • This invention relates to novel quinuclidines derivatives, pharmaceutical compositions, and use thereof in treating muscarinic acetylcholine receptor mediated diseases of the respiratory tract.
  • mAChRs Muscarinic acetylcholine receptors
  • Muscarinic acetylcholine receptors are widely distributed in vertebrate organs where they mediate many of the vital functions. Muscarinic receptors can mediate both inhibitory and excitatory actions. For example, in smooth muscle found in the airways, M3 mAChRs mediate contractile responses. For review, please see Caulfield (1993
  • mAChRs have been localized to smooth muscle in the trachea and bronchi, the submucosal glands, and the parasympathetic ganglia. Muscarinic receptor density is greatest in parasympathetic ganglia and then decreases in density from the submucosal glands to tracheal and then bronchial smooth muscle. Muscarinic receptors are nearly absent from the alveoli.
  • M 3 mAChRs located on airway smooth muscle, mediate muscle contraction. Stimulation of M 3 mAChRs activates the enzyme phospholipase C via binding of the stimulatory G protein Gq/11 (Gs), leading to liberation of phosphatidyl inositol-4,5-bisphosphate, resulting in phosphorylation of contractile proteins.
  • Gq/11 stimulatory G protein Gq/11
  • M 3 mAChRs are also found on pulmonary submucosal glands. Stimulation of this population of M 3 mAChRs results in mucus secretion.
  • M 2 mAChRs make up approximately 50-80% of the cholinergic receptor population on airway smooth muscles. Although the precise function is still unknown, they inhibit catecholaminergic relaxation of airway smooth muscle via inhibition of cAMP generation.
  • Neuronal M 2 mAChRs are located on postganglionic parasympathetic nerves. Under normal physiologic conditions, neuronal M 2 mAChRs provide tight control of acetylcholine release from parasympathetic nerves. Inhibitory M 2 mAChRs have also been demonstrated on sympathetic nerves in the lungs of some species. These receptors inhibit release of noradrenaline, thus decreasing sympathetic input to the lungs.
  • Mi mAChRs are found in the pulmonary parasympathetic ganglia where they function to enhance neurotransmission. These receptors have also been localized to the peripheral lung parenchyma, however their function in the parenchyma is unknown.
  • Muscarinic acetylcholine receptor dysfunction in the lungs has been noted in a variety of different pathophysiological states.
  • COPD chronic obstructive pulmonary disease
  • inflammatory conditions lead to loss of inhibitory M2 muscarinic acetylcholine autoreceptor function on parasympathetic nerves supplying the pulmonary smooth muscle, causing increased acetylcholine release following vagal nerve stimulation (Fryer et al. 1999 Life Sci 64 (6-7) 449-55).
  • This mAChR dysfunction results in airway hyperreactivity and hyperresponsiveness mediated by increased stimulation of M3 mAChRs.
  • COPD ulcerative colitis
  • COPD chronic bronchitis, chronic bronchiolitis and emphysema
  • Smoking is the major risk factor for the development of COPD; nearly 50 million people in the U.S. alone smoke cigarettes, and an estimated 3,000 people take up the habit daily.
  • COPD is expected to rank among the top five as a world-wide health burden by the year 2020.
  • Inhaled anti-cholinergic therapy is currently considered the "gold standard" as first line therapy for COPD (Pauwels et al. 2001 Am. J. Respir. Crit. Care Med. 163:1256-1276).
  • relatively few anti-cholinergic compounds are available for use in the clinic for pulmonary indications.
  • Combivent ⁇ in combination with albuterol is currently the only inhaled anti- cholinergic marketed for the treatment of airway hyperreactive diseases. While this compound is a potent anti-muscarinic agent, it is short acting, and thus must be administered as many as four times daily in order to provide relief for the COPD patient, hi Europe and Asia, the long-acting anti-cholinergic Tiotropium Bromide
  • This invention provides for a method of treating a muscarinic acetylcholine receptor (mAChR) mediated disease, wherein acetylcholine binds to an mAChR and which method comprises administering an effective amount of a compound of Formula (I) or a pharmaceutically acceptable salt thereof.
  • This invention also relates to a method of inhibiting the binding of acetylcholine to its receptors in a mammal in need thereof which comprises administering to aforementioned mammal an effective amount of a compound of Formula (I).
  • the present invention also provides for the novel compounds of Formula (I), and pharmaceutical compositions comprising a compound of Formula (I), and a pharmaceutical carrier or diluent.
  • Compounds of Formula (I) useful in the present invention are represented by the structure:
  • Rl is selected from the group consisting of Cl-15 alkyl, halosubstituted Cl-15 alkyl, Cl-15 alkyl cycloalkyl, cycloalkyl, C2-15 alkenyl, hydroxy substituted Cl-15 alkyl, Cl-15 alkyl aryl, Cl-15 alkyl heteroaryl, (CR7R7)qNRaRa, (CR7R7)qNC(O)Ra, (CR7R7)qC(O)NRaRa, (CR7R7)qC(O)Ra, (CR7R7)qOC (O)Ra, (CR7R7)qNRaC(O)NRaRa, (CR7R7)qORc and (CR7R7)qNS(O) 2 Ra
  • Rl is selected from the group consisting of:
  • Rl is selected from the group consisting of:
  • R2 and R3 are independently selected from the group consisting of aryl, Cl-4 alkyl aryl, heteroaryl, Cl-4 alkyl heteroaryl, heterocyclic and a Cl-4 alkyl heterocyclic moiety, all of which moieties may be optionally substituted;
  • Ra is selected from the group consisting of hydrogen, Cl-15 alkyl, Cl-15 alkoxy, aryl, Cl-15 alkyl aryl, heteroaryl, Cl-15 alkyl heteroaryl, heterocyclic and a Cl-15 alkyl heterocyclic moiety, all of which moieties may be optionally substituted;
  • Re is selected from the group consisting of hydrogen, Cl-15 alkyl, Cl-15 alkoxy, heterocyclic and a Cl-15 alkyl heterocyclic moiety, all of which moieties may be optionally substituted;
  • R4 and R5 are independently selected from the group consisting of hydrogen, halogen, Cl-4 alkyl, aryl, Cl-4 alkyl aryl, cyano, nitro, (CR7R7)pORb, (CR7R7)pNRbRb, or R4 and R5 together may form a 5 to 6 membered saturated or unsaturated ring; and wherein the alkyl, aryl, arylalkyl, heteroaryl, heteroalkyl, heterocyclic, heterocyclicalkyl groups may be optionally substituted;
  • R6 is selected from the group consisting of hydrogen, Cl-4 alkyl
  • X, Y, Z and W are independently selected from the group consisting of hydrogen, Cl-4 alkyl;
  • V is selected from the group consisting of CH 2 , O, S, andNRb;
  • M is O or CH 2
  • Rb is selected from the group consisting of hydrogen, Cl-4 alkyl, aryl and Cl-4 alkyl aryl;
  • R7 is selected from the group consisting of hydrogen, Cl-4 alkyl, halosubstituted Cl-4 alkyl, and hydroxysubstituted Cl-4 alkyl;
  • X- is a physiologically acceptable anion, such as chloride, bromide, iodide, hydroxide, sulfate, nitrate, phosphate, acetate, trifluoroacetate, fumarate, citrate, tartrate, oxalate, succinate, mandelate, methanesulfonate and p-toluenesulfonate.
  • This invention related to novel bi-aryl 8-azoniabicyclo[3.2.1]octane compounds, pharmaceutical compositions, processes for their preparation, and use thereof in treating mAChR mediated diseases.
  • the compound is of formula
  • Rl is selected from the group consisting of Cl-10 alkyl, halosubstituted Cl-10 alkyl, Cl-10 alkyl aryl, Cl-10 alkyl cycloalkyl, cycloalkyl, hydroxy substituted Cl-10 alkyl, C2-10 alkenyl, (CR7R7)qORc; (CR7R7)qOC (O)Ra and (CR7R7)qNS(O) 2 Ra;
  • Rl is selected from the group consisting of:
  • R2 and R3 are, independently, selected from the group consisting of:
  • F, G, H, K and L are independently selected from the group consisting of hydrogen, halogen, Cl-4 alkyl, halosubstituted Cl-4 alkyl, hydoxysubstituted Cl-4 alkyl, and Cl- 4 alkoxy;
  • Ra is selected from the group consisting of hydrogen, Cl-10 alkyl, Cl-10 alkoxy, aryl and heteroaryl, all of which moieties may be optionally substituted;
  • Re is selected from the group consisting of hydrogen, Cl-5 alkyl, Cl-5 alkoxy, all of which moieties may be optionally substituted;
  • R4 and R5 are independently selected from the group consisting of hydrogen, halogen,
  • Cl-4 alkyl, aryl, Cl-4 alkyl aryl, cyano, nitro, (CR7R7)pORb, (CR7R7)pNRbRb, or R4 and R5 together may form a 5 to 6 membered saturated or unsaturated ring;
  • V is O, or CH 2;
  • R6 is selected from the group consisting of hydrogen, Cl-4 alkyl
  • M is O or CH 2
  • Rb is selected from the group consisting of hydrogen, Cl-4 alkyl, and aryl Cl-4 alkyl
  • R7 is selected from the group consisting of hydrogen, and Cl-4 alkyl
  • X- is a physiologically acceptable anion, such as chloride, bromide, iodide, hydroxide, sulfate, nitrate, phosphate, acetate, trifluoroacetate, fumarate, citrate, tartrate, oxalate, succinate, mandelate, methanesulfonate and p-toluenesulfonate. All of the aryl, heteroaryl, and heterocyclic containing moieties may be optionally substituted as defined herein below. For use herein the .
  • the aryl, heteroaryl, and heterocyclic containing moieties refers to both the ring and the alkyl, or if included, the alkenyl rings, such as aryl, arylalkyl, and aryl alkenyl rings.
  • the term “moieties” and “rings” may be interchangeably used throughout.
  • halogen such as fluorine, chlorine, bromine or iodine
  • hydroxy hydroxy substituted C ⁇ _ioalkyl
  • Cl-io alkoxy such as methoxy or ethoxy
  • S(O) m Cl- 10 alkyl, wherein m' is 0, 1 or 2, such as methyl thio, methyl sulfinyl or methyl sulfonyl
  • halo all halogens, that is chloro, fluoro, bromo and iodo.
  • C _ ⁇ oalkyl or “alkyl” - both straight and branched chain moieties of 1 to 10 carbon atoms, unless the chain length is otherwise limited, including, but not limited to, methyl, ethyl, ra-propyl, wo-propyl, rc-butyl, sec-butyl, iso-butyl, fert-butyl, «-pentyl and the like.
  • cycloalkyl is used herein to mean cyclic moiety, preferably of 3 to 8 carbons, including but not limited to cyclopropyl, cyclopentyl, cyclohexyl, and the like.
  • alkenyl is used herein at all occurrences to mean straight or branched chain moiety of 2-10 carbon atoms, unless the chain length is limited thereto, including, but not limited to ethenyl, 1-propenyl, 2-propenyl, 2-methyl-l-propenyl, 1-butenyl, 2- butenyl and the like.
  • aryl - phenyl and naphthyl; • “heteroaryl” (on its own or in any combination, such as “heteroaryloxy", or “heteroaryl alkyl”) - a 5-10 membered aromatic ring system in which one or more rings contain one or more heteroatoms selected from the group consisting of N, O or S, such as, but not limited, to pyrrole, pyrazole, furan, thiophene, quinoline, isoquinoline, quinazolinyl, pyridine, pyrimidine, oxazole, tetrazole, thiazole, thiadiazole, triazole, imidazole, indole or benzimidazole.
  • heterocyclic (on its own or in any combination, such as “heterocyclicalkyl”) - a saturated or partially unsaturated 4-10 membered ring system in which one or more rings contain one or more heteroatoms selected from the group consisting of N, O, or S; such as, but not limited to, pyrrolidine, piperidine, piperazine, morpholine, tetrahydropyran, thiomorpholine, or imidazolidine.
  • sulfur may be optionally oxidized to the sulfone or the sulfoxide.
  • arylalkyl or “heteroarylalkyl” or “heterocyclicalkyl” is used herein to mean
  • Illustrative compounds of Formula (I) include: l-(2- ⁇ [(3-fluorophenyl)methyl]oxy ⁇ ethyl)-4-[hydroxy(diphenyl)methyl]-l- azoniabicyclo[2.2.2]octane bromide
  • the preferred compounds useful in the present invention include: 1 -(2- ⁇ [(3 -fluorophenyl)methyl] oxy ⁇ ethyl)-4- [hydroxy (diphenyl)methyl] - 1 - azoniabicyclo [2.2.2] octane bromide
  • the more preferred compounds useful in the present invention include:
  • the most preferred compounds useful in the present invention include:
  • the compounds of Formula (I) may be obtained by applying synthetic procedures, some of which are illustrated in the Schemes below.
  • the synthesis provided in this Scheme is applicable for producing compounds of Formula (I) having a variety of different Rl, R2 and R3 groups which are reacted, employing substituents which are suitably protected, to achieve compatibility with the reactions outlined herein. Subsequent deprotection, in those cases, then affords compounds of the nature generally disclosed. While the Schemes are shown with compounds only of Formula (I), this is merely for illustration purpose only.
  • the desired compounds of Formula (I) can be prepared in four synthetic steps from the commercially available ethyl 4-piperidinecarboxylate precursor 1.
  • Compound 1 is reacted with l-bromo-2-chloroethane following standard alkylation procedures well known in the art such as potassium carbonate in acetone followed by reaction of the intermediate with lithium diisopropylamide in an aprotic solvent such as tetrahydrofurann to give the quinuclidine intermediate 2.
  • Reagents and conditions a) l-bromo-2-chloroethane, K 2 CO 3 , acetone; b) LDA, THF; c) R 2 M then R 3 M, THF; d) R1X, ACN, CHC1 3 .
  • Example 3 Preparation of 4-[hydroxy(diphenyI)methyl]-l-[2-(phenyloxy)ethyl]- l-azoniabicyclo[2.2.2]octane bromide.
  • Example 6 Preparation of 4-[hydroxy(diphenyl)methyl]-l-[3-(phenyloxy)propyl]- l-azoniabicycIo[2.2.2]octane bromide.
  • Example 7 Preparation of 4-[hydroxy(diphenyl)methyl]-l-[4-(phenyloxy)butyl]- 1-azoniabicy clo [2.2.2] octane bromide.
  • Example 10 Preparation of 4-[hydroxy(diphenyl)methyl]-l- ⁇ 3- [(phenylmethy ⁇ )oxy]propyl ⁇ -l-azoniabicyclo[2.2.2]octane bromide.
  • Example 11 Preparation of l- ⁇ 2-[(2,4-dibromophenyl)oxy]ethyl ⁇ -4- [hydroxy(diphenyl)methyl]-l ⁇ azoniabicyclo[2.2.2]octane bromide.
  • Example 13 Preparation of 4-[hydroxy(dipheny ⁇ )methyl]-l-(tetrahydro-2 J fiT- pyran-2-ylmethyI)-l ⁇ azoniabicyclo [2.2.2] octane bromide.
  • Example 14 Preparation of l-(l,3-dioxolan-2-ylmethyl)-4- [hydroxy(diphenyl)methyl]-l-azoniabicyclo[2.2.2]octane bromide.
  • Example 15 Preparation of l-ethyI-4-[hydroxy(diphenyI)methyl]-l- azoniabicyclo [2.2.2] octane bromide.
  • Example 17 Preparation of 4-[hydroxy(diphenyl)methyl]-l-(4-penten-l-yI)-l- azoniabicyclo [2.2.2] octane bromide.
  • Example 18 Preparation of 4-[hydroxy(diphenyl)methyl]-l-(2-hydroxyethyl)-l- azoniabicyclo [2.2.2] octane bromide.
  • Example 19 Preparation of l-(5-hexen-l-yl)-4-[hydroxy(diphenyl)methyl]-l- azoniabicy clo [2.2.2] octane bromide.
  • Example 21 Preparation of 4-[hydroxy(diphenyl)methyl]-l-[2-(methyloxy)ethyl]- l-azoniabicycIo[2.2.2]octane bromide.
  • Example 22 Preparation of l-[2-(l,3-dioxo-l,3-dihydro-2H-isoindol-2-yl)ethyl]-4- [hydroxy(diphenyl)methyl]-l-azoniabicyclo[2.2.2]octane bromide.
  • Example 23 Preparation of l-[3-(l,3-dioxo-l,3-dihydro-2H-isoindol-2-yl)propyl]- 4 ⁇ [hydroxy(diphenyl)methyl]-l-azoniabicycIo[2.2.2]oetane bromide.
  • Example 25 Preparation of 4-[hydroxy(diphenyI)methyl]-l-(2- ⁇ [2- (methyIoxy)ethyl]oxy ⁇ ethyl)-l-azoniabicyclo[2.2.2]octane bromide.
  • Example 26 Preparation of l-[4-(ethyloxy)-4-oxobutyl]-4- [hydroxy(diphenyl)methyl]-l-azoniabicyclo[2.2.2]octane bromide.
  • Example 27 Preparation of l-azabicycIo[2.2.2]oct-4-yl(di-2-thienyI)methanol.
  • Example 28 Preparation of 4-[hydroxy(di-2-thienyl)methyl]-l-[2- (phenyloxy)ethyl]-l-azoniabicyclo[2.2.2]octane bromide.
  • Example 29 Preparation of 4-[hydroxy(di-2-thienyl)methyl]-l-[3- (phenyloxy)propyl]-l-azoniabicyclo[2.2.2]octane bromide.
  • Example 30 Preparation of 4-[hydroxy(di-2-thienyI)methyl]-l-(2-phenyIethyI)-l- azoniabic clo [2.2.2] octane bromide.
  • Example 32 Preparation of l-butyl-4-[hydroxy(di ⁇ 3-thienyI)methyl]-l- azoniabicyclo [2.2.2] octane bromide.
  • Example 33 Preparation of l-azabicyclo[2.2.2]oct-4-yl(di-3-thienyl)methanol.
  • Example 34 Preparation of 4-[hydroxy(di-3-thienyl)methyl]-l-[2- (phenyloxy)ethyl]-l-azoniabicyclo[2.2.2]octane bromide.
  • Example 35 Preparation of 4-[hydroxy(di-3-thienyl)methyl] ⁇ l-[3 ⁇ (phenyloxy)propyl]-l-azoniabicyclo[2.2.2]octane bromide.
  • Example 36 Preparation of l ⁇ butyl-4-[hydroxy(diphenyl)methyl]-l- azoniabic clo [2.2.2] octane bromide.
  • Example 37 Preparation of l-hexyl-4-[hydroxy(diphenyl)methyl]-l- azoniabicy clo [2.2.2] octane bromide.
  • Example 38 Preparation of 4-[hydroxy(dipheny ⁇ )methyl]-l-propyl-l- azoniabicyclo [2.2.2] octane bromide.
  • Example 39 Preparation of 4-[hydroxy(diphenyl)methyl]-l-(3- ⁇ [2- (methyloxy)phenyl] oxy ⁇ propyl)-l-azoniabicyclo [2.2.2] octane bromide.
  • Example 40 Preparation of 4-[hydroxy(diphenyl)methyI]-l- ⁇ 3-[(2- hydroxyphenyl)oxy]propyl ⁇ -l-azoniabicyclo[2.2.2]octane bromide.
  • Example 42 Preparation of l- ⁇ 3-[(3-chlorophenyl)oxy]propyl ⁇ -4- [hydroxy(dipheny ⁇ )methyl]-l-azoniabicyclo[2.2.2]octane bromide.
  • Example 43 Preparation of l ⁇ 3-[(4-bromophenyl)oxy]propyl ⁇ -4- [hydroxy(diphenyl)methyl]-l-azoniabicyclo[2.2.2]octane bromide.
  • Example 44 Preparation of 4-[hydroxy(diphenyl)methyl]-l- ⁇ 3-[(4- nitropheny ⁇ )oxy]propyl ⁇ -l-azoniabicyclo[2.2.2]octane bromide.
  • Example 45 Preparation of 4-[hydroxy(diphenyl)methyl]-l-[3-( ⁇ 2- [(phenylmethyl)oxy]phenyl ⁇ oxy)propyl]-l-azoniabicyclo[2.2.2]octane bromide.
  • Example 46 Preparation of l- ⁇ 3-[(2-bromophenyl)oxy]propyl ⁇ -4- [hydroxy(diphenyl)methyl]-l-azoniabicyclo[2.2.2]octane bromide.
  • Example 47 Preparation of 4-[hydroxy(diphenyl)methyl]-l-[3-( ⁇ 4- [(phenylmethyl)oxy]phenyl ⁇ oxy)propyl]-l-azoniabicyclo[2.2.2]octane bromide.
  • Example 48 Preparation of 4-[hydroxy(diphenyl)methyl]-l-[3- (methyloxy)propyl]-l-azoniabicyclo[2.2.2]octane bromide.
  • Example 49 Preparation of 4-[hydroxy(dipheny ⁇ )methyl]-l-(2-propen-l-yl)-l- azoniabicyclo [2.2.2] octane bromide.
  • Example 50 Preparation of 4-[hydroxy(diphenyl)methyl]-l-(3- ⁇ [4- (methyloxy)phenyl]oxy ⁇ propyl)-l-azoniabicyclo[2.2.2]octane bromide. Following the general procedure outlined in Example 3, l-azabicyclo[2.2.2]oct-4- yl(diphenyl)methanol (0.0483 g, 0.164 mmol) and l-[(3-bromopropyl)oxy]-4- (methyloxy)benzene (0.052 g, 0.21 mmol) in 2 CH 3 CN / 3 CHC1 3 (4.0 mL) were reacted to give the desired product (0.0687 g, 77.5%). EI-MS m/z 458(M + ) Rt (2.03 • min).
  • Example 51 Preparation of [l-(2-aminoethy ⁇ )-l-azoniabicyclo[2.2.2]oct-4- yl](dipheny ⁇ )n ⁇ ethanoIate trifluoroacetate.
  • l-[2-(l,3-dioxo-l,3-dihydro-2H-isoindol-2-yl)ethyl]-4- [hydroxy(diphenyl)methyl]-l -azoniabicy clo [2.2.2] octane bromide (0.078g, 0.142 mmol) in EtOH (4.0 mL) was added hydrazine (0.25 mL, 7.96 mmol).
  • Example 54 Preparation of 4-(hydroxy ⁇ bis[3-(methyloxy)phenyl] ⁇ methyl)-l-[3- (phenyloxy)propyl]-l-azoniabicyclo[2.2.2]octane bromide.
  • Example 55 Preparation of 4-(hydroxy ⁇ bis[3-(methyIoxy)phenyI] ⁇ methy ⁇ )-l- ⁇ 2- [(phenylmethyl)oxy] ethyl ⁇ -l-azoniabic clo [2.2.2] octane bromide.
  • Example 56 Preparation of 4-(hydroxy ⁇ bis[4-(methyloxy)phenyl] ⁇ methyl)-l-[3- (phenyloxy)propyl]-l-azoniabicyclo[2.2.2]octane bromide.
  • Example 57 Preparation of 4-(hydroxy ⁇ bis[4-(methyIoxy)phenyl] ⁇ methyI)-l- ⁇ 2- [(phenylmethyl)oxy]ethyl ⁇ -l-azoniabicyclo[2.2.2]octane bromide.
  • Example 58 Preparation of 4-[bis(3-fluorophenyl)(hydroxy)methyl]-l-[3- (phenyloxy)propyl]-l-azoniabicyclo[2.2.2]octane bromide.
  • Example 59 Preparation of 4-[bis(3-fluoropheny ⁇ )(hydroxy)methyI]-l- ⁇ 2- [(phenylmethyl)oxy]ethyl ⁇ -l-azoniabicyclo[2.2.2]octane bromide.
  • Example 61 Preparation of 4- ⁇ hydroxy[bis(3-methylphenyl)]methyl ⁇ -l- ⁇ 2- [(phenylmethyl)oxy]ethyl ⁇ -l ⁇ azoniabicyclo[2.2.2]octane bromide.
  • Example 63 Preparation of 4- ⁇ hydroxy[bis(4-methylpheny ⁇ )]methyI ⁇ -l- ⁇ 2- [(phenylmethyl)oxy]ethyl ⁇ -l-azoniabicyclo[2.2.2] octane bromide.
  • Example 64 Preparation of 4-[hydroxy(di-2-naphthalenyl)methyl]-l-[3- (phenyloxy)propyl] -1-azoniabicy clo [2.2.2] octane bromide.
  • Example 65 Preparation of 4-[hydroxy(di-2-naphthalenyl)methyl]-l- ⁇ 2- [(phenylmethyl)oxy]ethyl ⁇ -l-azoniabicyclo[2.2.2]octane bromide.
  • Example 66 Preparation of l- ⁇ 3-[(2-fluorophenyl)oxy]propyl ⁇ -4- [hydroxy(diphenyl)methyl]-l-azoniabicyclo[2.2.2]octane bromide.
  • the organic layer was dried through a phase separator and concentrated under vacuum.
  • Example 68 Preparation of l- ⁇ 3-[(4-fluoropheny ⁇ )oxy]propyl ⁇ -4- [hydroxy(diphenyl)methyl]-l-azoniabicyclo[2.2.2]octane bromide.
  • Example 69 Preparation of l-[3-(3-biphenylyloxy)propyl]-4- [hydroxy(diphenyl)methyl]-l-azoniabicyclo[2.2.2]octane bromide.
  • Example 70 Preparation of l-[3-(4-biphenylyloxy)propyl]-4- [hydroxy(diphenyl)methyl]-l-azoniabicyclo[2.2.2]octane bromide.
  • the organic layer was dried through a phase separator and concentrated under vacuum.
  • Example 72 Preparation of 4-[hydroxy(dipheny ⁇ )methyl]-l- ⁇ 3-[(2- methylphenyl)oxy]propyl ⁇ -l-azoniabicyc!o[2.2.2]octane bromide.
  • the organic layer was dried through a phase separator and concentrated under vacuum.
  • Example 73 Preparation of l-(3- ⁇ [3-(diethylamino)phenyI]oxy ⁇ propy ⁇ )-4- [hydroxy (diphenyl)methyl] -1-azoniabicyclo [2.2.2] octane bromide.
  • Example 74 Preparation of l- ⁇ 3-[(4-cyanophenyl)oxy]propyl ⁇ -4- [hydroxy(dipheny ⁇ )methyl]-l-azoniabicy clo [2.2.2] octane bromide.
  • the reaction vessel was wrapped in aluminum foil and stirred at rt for 20 h.
  • the reaction was filtered through a SPE cartridge (5 g silica) eluting with the following 10 mL fractions: DCM (fraction 1), 30% EtOAc/hexanes (fraction 2), and 50% EtOAc/hexanes (fraction 3) to give the title compound (160 mg).
  • the product was characterized by H NMR (400 MHz) in CDCI3.
  • Example 76 Preparation of l-[2-( ⁇ [4-(l,l- dimethylethyl)pheny 1] methyl ⁇ oxy)ethyl] -4- [hydroxy (diphenyl)methyl] -1 - azoniabicyclo [2.2.2] octane bromide.
  • Example 78 Preparation of l-(2- ⁇ [(4-chlorophenyl)methyl]oxy ⁇ ethyI)-4- [hydroxy(diphenyl)methyl]-l-azoniabicyclo[2.2.2]octane bromide.
  • Example 79 Preparation of l-(2- ⁇ [(4-bromophenyl)methyI]oxy ⁇ ethyl)-4- [hydroxy(diphenyl)methyl]-l-azoniabicyclo[2.2.2]octane bromide.
  • Example 80 Preparation of l-(2- ⁇ [(4-cyanophenyl)methyl]oxy ⁇ ethyl)-4- [hydroxy(diphenyl)methyl]-l-azoniabicyclo[2.2.2]octane bromide.
  • the aqueous layer was extracted with EtOAc (l x l mL), and the combined organic layers were concentrated.
  • the crude product was purified on a SPE cartridge (5 g silica) eluting with the following 10 mL fractions: 10% EtOAc/hexanes (fractions 1,2), 30% EtOAc/hexanes (fractions 3,4), 50% EtOAc/hexanes (fractions 5-7), and 75% EtOAc/hexanes (fraction 8) to give the title compound (95 mg, 36%).
  • the product was characterized by *H NMR (400 MHz) in CDCI3.
  • Example 81 Preparation of 4-[hydroxy(diphenyl)methyl]-l- ⁇ 2-[(2- naphthalenylmethyl)oxy]ethyl ⁇ -l-azoniabicyclo[2.2.2]octane bromide.
  • the aqueous layer was extracted with EtOAc (3 x 1 mL), and the combined orgamc layers were washed with saturated NaCl (1 2 mL), dried (Na2SO4), and concentrated.
  • the crude product was purified on a SPE cartridge (5 g silica) eluting with the following 10 mL fractions: 30% EtOAc/hexanes (fractions 1,2), 50% EtOAc/hexanes (fraction 3), and 75% EtOAc/hexanes (fraction 4) to give the title compound (76.2 mg, 25%).
  • the product was characterized by H NMR (400 MHz) in CDCI3.
  • Example 83 Preparation of 4-[hydroxy(diphenyl)methyl]-l- ⁇ 2-[(l-methyl-l- phenylethyI)oxy]ethyI ⁇ -l-azoniabicyclo[2.2.2]octane bromide.
  • a catalytic amount of either j>-toluene sulfonic acid* H 2 O or Bio-Rad SCX resin (analytical grade, 5.1 meq/g, AG 50W-X8) was added to D-methylstyrene (0.5 mL, 3.85 mmol) and ethylene glycol (0.21 mL, 3.85 mmol), and the reaction was stirred at rt for 5 days.
  • the reaction mixture was loaded directly onto a SPE cartridge (10 g silica) and eluted with the following 10 mL fractions: 10% EtOAc/hexanes (fractions 1,2), 30% EtOAc/hexanes (fractions 3,4), and 50% EtOAc/hexanes (fractions 5,6) to give the title compound (30.5 mg, 4%) for both conditions.
  • the product was characterized by iH NMR (400 MHz) in CDC1 3 .
  • Example 84 Preparation of 4-[hydroxy(diphenyl)methyl]-l- ⁇ 2- [(phenylmethyl)oxy]ethyl ⁇ -l-azoniabicyclo[2.2.2]octane bromide.
  • Method A l-Azabicyclo[2.2.2]oct-4-yl(diphenyl)methanol (0.020 g, 0.068 mmol) was diluted in CHC1 3 (1.8 mL) and dispensed directly into a 1 dram vial containing 2- bromoethyl phenylmethyl ether (0.022 g, 0.102 mmol). CH 3 CN (1.2 mL) was added; the vial was fitted with a stirring bar and capped. The reaction was stirred and heated at 60 °C for 24 h. The contents of the vial were transferred (after removal of stirring bar) into a polypropylene tube and concenfrated under Nitrogen.
  • Example 112 Preparation of l-[2-(l-benzofuran-2-yl)-2-oxoethyl]-4- [hydroxy(diphenyl)methyl]-l-azoniabicyclo[2.2.2]octane bromide.
  • l-azabicyclo[2.2.2]oct-4-yl(diphenyl)methanol (0.022 g, 0.075 mmol) was diluted in CHC1 3 (1.8 mL) and dispensed directly into a 1 dram vial containing l-(l-benzofuran- 2-yl)-2-bromoethanone (0.027 g, 0.112 mmol).
  • inhibitory effects of compounds at the M3 mAChR of the present invention are determined by the following in vitro and in vivo functional assays:
  • mice were pre-treated with 50 ⁇ l of compound (0.003-10 ⁇ g/mouse) in 50 ⁇ l of vehicle (10% DMSO) intranasally (i.n.) and were then placed in the plethysmography chamber a given amount of time following drug administration (15 min - 96 h). For potency determination, a dose response to a given drug was performed, and all measurements were taken 15 min following i.n. drug administration. For duration of action determination, measurements were taken anywhere from 15 min to 96 hours following i.n. drug administration. Once in the chamber, the mice were allowed to equilibrate for 10 min before taking a baseline Penh measurement for 5 minutes.
  • mice were then challenged with an aerosol of methacholine (10 mg/ml) for 2 minutes. Penh was recorded continuously for 7 min starting at the inception of the methacholine aerosol, and continuing for 5 minutes afterward. Data for each mouse were analyzed and plotted by using GraphPad PRISM software. This experiment allows the determination of duration of activity of the administered compound.
  • the present compounds are useful for treating a variety of indications, including but not limited to respiratory-tract disorders such as chronic obstructive lung disease, chronic bronchitis, asthma, chronic respiratory obstruction, pulmonary fibrosis, pulmonary emphysema, and allergic rhinitis.
  • Muscarinic Receptor Radioligand Binding Assays Radioligand binding studies using 0.5 nM [ 3 H]-N-methyl scopolamine (NMS) in a SPA format is used to assess binding of muscarinic antagonists to Mi, M 2 , M 3 , V and M 5 muscarinic acetylcholine receptors.
  • NMS N-methyl scopolamine
  • the SPA beads are pre- incubated with receptor-containing membrane for 30 min at 4 °C. Then 50 mM HEPES and the test compound are added and incubated at room temperature (shaking) for 2 hours. The beads are then spun down and counted using a scintillation counter.
  • Tissues were then rinsed every 15 minutes over 1 hour until reaching baseline tone. The preparations were then left for at least 30 minutes before the start of the experiment. Concentration-response curves were obtained by a cumulative addition of carbachol in half-log increments (Van Rossum, 1963, Arch. Int. Pharmacodyn., 143:299), initiated at 1 nM. Each concentration was left in contact with the preparation until the response plateaued before the addition of the subsequent carbachol concentration. Paired tissues were exposed to mAChR antagonist compounds or vehicle for 30 min before carbachol cumulative concentration-response curves were generated. All data is given as mean ⁇ standard error of the mean (s.e.m.) with n being the number of different animals. For superfusion (duration of action) studies, the tissues were continuously superfused with Krebs-Henseleit solution at 2 ml/min for the duration of the experiment. Stock solutions of agonist and antagonist were infused (0.02 ml/min) via
  • Isoproterenol exposure was halted and the carbachol-induced tension allowed to recover.
  • Muscarinic receptor antagonists infused at a single concentration per tissue until a sustained level of inhibition was attained. The compound was then removed and, once again, the carbachol-induced tension was allowed to recover. The following parameters were determined for each concentration of antagonist, and expressed as the mean ⁇ S.E.M. for n individual animals. Inhibition of the carbachol-induced contraction was expressed as a percent of the reference response (isoproterenol) and the time required to reach one-half of this relaxation was measured (onset of response). The tension recovery following removal of the compound was determined as was the time required to reach one-half of the maximum tension recovery (offset of response).
  • Antagonist concentration-response curves were obtained by plotting the maximal relaxation data at 0, 60 and 180-min following antagonist withdrawal. Recovery, termed shift, was calculated from the ratio of the 0-min inhibition curve IC50 and the concentration of compound yielding a similar tension recovery at 60 and
  • the present invention further provides a pharmaceutical formulation comprising a compound of formula (I), or a pharmaceutically acceptable salt, solvate, or physiologically functional derivative (e.g., salts and esters) thereof, and a pharmaceutically acceptable carrier or excipient, and optionally one or more other therapeutic ingredients.
  • active ingredient means a compound of formula (I), or a pharmaceutically acceptable salt, solvate, or physiologically functional derivative thereof.
  • Compounds of formula (I) will be administered via inhalation via the mouth or nose.
  • Dry powder compositions for topical delivery to the lung by inhalation may, for example, be presented in capsules and cartridges of for example gelatine, or blisters of for example laminated aluminium foil, for use in an inhaler or insufflator.
  • Powder blend formulations generally contain a powder mix for inhalation of the compound of the invention and a suitable powder base (carrier/diluent/excipient substance) such as mono-, di- or poly-saccharides (e.g., lactose or starch), organic or inorganic salts (e.g., calcium chloride, calcium phosphate or sodium chloride), polyalcohols (e.g., mannitol), or mixtures thereof, alternatively with one or more additional materials, such additives included in the blend formulation to improve chemical and/or physical stability or performance of the formulation, as discussed below, or mixtures thereof.
  • a suitable powder base such as mono-, di- or poly-saccharides (e.g., lactose or starch),
  • Each capsule or cartridge may generally contain between 20 ⁇ g- lOmg of the compound of formula (I) optionally in combination with another therapeutically active ingredient.
  • the compound of the invention may be presented without excipients, or may be formed into particles comprising the compound, optionally other therapeutically active materials, and excipient materials, such as by co-precipitation or coating.
  • the medicament dispenser is of a type selected from the group consisting of a reservoir dry powder inhaler (RDPI), a multi-dose dry powder inhaler (MDPI), and a metered dose inhaler (MDI).
  • reservoir dry powder inhaler By reservoir dry powder inhaler (RDPI) it is meant as an inhaler having a reservoir form pack suitable for comprising multiple (un-metered doses) of medicament in dry powder form and including means for metering medicament dose from the reservoir to a delivery position.
  • the metering means may for example comprise a metering cup or perforated plate, which is movable from a first position where the cup may be filled with medicament from the reservoir to a second position where the metered medicament dose is made available to the patient for inhalation.
  • multi-dose dry powder inhaler MDPI
  • the carrier has a blister pack form, but it could also, for example, comprise a capsule-based pack form or a carrier onto which medicament has been applied by any suitable process including printing, painting and vacuum occlusion.
  • the formulation can be pre-metered (eg as in Diskus, see GB 2242134 or
  • the Diskus inhalation device comprises an elongate strip formed from a base sheet having a plurality of recesses spaced along its length and a lid sheet hermetically but peelably sealed thereto to define a plurality of containers, each container having therein an inhalable formulation containing a compound of formula (I) preferably combined with lactose.
  • the strip is sufficiently flexible to be wound into a roll.
  • the lid sheet and base sheet will preferably have leading end portions which are not sealed to one another and at least one of the said leading end portions is constructed to be attached to a winding means. Also, preferably the hermetic seal between the base and lid sheets extends over their whole width.
  • the lid sheet may preferably be peeled from the base sheet in a longitudinal direction from a first end of the said base sheet.
  • the multi-dose pack is a blister pack comprising multiple blisters for containment of medicament in diy powder form. The blisters are typically arranged in regular fashion for ease of release of medicament therefrom.
  • the multi-dose blister pack comprises plural blisters arranged in generally circular fashion on a disk-form blister pack.
  • the multi-dose blister pack is elongate in form, for example comprising a strip or a tape.
  • the multi-dose blister pack is defined between two members peelably secured to one another.
  • US Patents Nos. 5,860,419, 5,873,360 and 5,590,645 describe medicament packs of this general type.
  • the device is usually provided with an opening station comprising peeling means for peeling the members apart to access each medicament dose.
  • the device is adapted for use where the peelable members are elongate sheets which define a plurality of medicament containers spaced along the length thereof, the device being provided with indexing means for indexing each container in turn.
  • the device is adapted for use where one of the sheets is a base sheet having a plurality of pockets therein, and the other of the sheets is a lid sheet, each pocket and the adjacent part of the lid sheet defining a respective one of the containers, the device comprising driving means for pulling the lid sheet and base sheet apart at the opening station.
  • metered dose inhaler it is meant a medicament dispenser suitable for dispensing medicament in aerosol form, wherein the medicament is comprised in an aerosol container suitable for containing a propellant-based aerosol medicament formulation.
  • the aerosol container is typically provided with a metering valve, for example a slide valve, for release of the aerosol form medicament formulation to the patient.
  • the aerosol container is generally designed to deliver a predetermined dose of medicament upon each actuation by means of the valve, which can be opened either by depressing the valve while the container is held stationary or by depressing the container while the valve is held stationary.
  • Spray compositions for topical delivery to the lung by inhalation may for example be formulated as aqueous solutions or suspensions or as aerosols delivered from pressurised packs, such as a metered dose inhaler, with the use of a suitable liquefied propellant.
  • Aerosol compositions suitable for inhalation can be either a suspension or a solution and generally contain the compound of formula (I) optionally in combination with another therapeutically active ingredient and a suitable propellant such as a fluorocarbon or hydrogen-containing chlorofluorocarbon or mixtures thereof, particularly hydrofluoroalkanes, e.g. dichlorodifluoromethane, frichlorofluoromethane, dichlorotetra-fluoroethane, especially 1,1,1,2-tetrafluoroethane, 1,1,1,2,3,3,3- heptafluoro-n-propane or a mixture thereof.
  • a suitable propellant such as a fluorocarbon or hydrogen-containing chlorofluorocarbon or mixtures thereof, particularly hydrofluoroalkanes, e.g. dichlorodifluoromethane, frichlorofluoromethane, dichlorotetra-fluoroethane, especially 1,1,1,2-tetrafluoroethane
  • the aerosol composition may be excipient free or may optionally contain additional formulation excipients well known in the art such as surfactants eg oleic acid or lecithin and cosolvents eg ethanol.
  • Pressurised formulations will generally be retained in a canister (eg an aluminium canister) closed with a valve (eg a metering valve) and fitted into an actuator provided with a mouthpiece.
  • Medicaments for administration by inhalation desirably have a controlled particle size.
  • the optimum aerodynamic particle size for inhalation into the bronchial system for localized delivery to the lung is usually l-10 ⁇ m, preferably 2-5 ⁇ m.
  • the optimum aerodynamic particle size for inhalation into the alveolar region for achieving systemic delivery to the lung is approximately .5-3 ⁇ m, preferably 1-3 ⁇ m. Particles having an aerodynamic size above 20 ⁇ m are generally too large when inhaled to reach the small airways.
  • Average aerodynamic particle size of a formulation may measured by, for example cascade impaction. Average geometric particle size may be measured, for example by laser diffraction, optical means.
  • the particles of the active ingredient as produced may be size reduced by conventional means eg by controlled crystallization, micronisation or nanomilling . The desired fraction may be separated out by air classification.
  • particles of the desired size may be directly produced, for example by spray drying, controlling the spray drying parameters to generate particles of the desired size range.
  • the particles will be crystalline, although amorphous material may also be employed where desirable.
  • an excipient such as lactose
  • the particle size of the excipient will be much greater than the inhaled medicament within the present invention, such that the "coarse" carrier is non-respirable.
  • the excipient is lactose it will typically be present as milled lactose, wherein not more than 85% of lactose particles will have a MMD of 60-90 ⁇ m and not less than 15% will have a MMD of less than 15 ⁇ m.
  • Additive materials in a dry powder blend in addition to the carrier may be either respirable, i.e., aerodynamically less than 10 microns, or non-respirable, i.e., aerodynamically greater than 10 microns.
  • Suitable additive materials which may be employed include amino acids, such as leucine; water soluble or water insoluble, natural or synthetic surfactants, such as lecithin (e.g., soya lecithin) and solid state fatty acids (e.g., lauric, palmitic, and stearic acids) and derivatives thereof (such as salts and esters); phosphatidylcholines; sugar esters.
  • Additive materials may also include colorants, taste masking agents (e.g., saccharine), anti-static-agents, lubricants (see, for example, Published PCT Patent Appl. No. WO 87/905213, the teachings of which are incorporated by reference herein), chemical stabilizers, buffers, preservatives, absorption enhancers, and other materials known to those of ordinary skill.
  • Sustained release coating materials e.g., stearic acid or polymers, e.g. polyvinyl pyrolidone, polylactic acid
  • active material or active material containing particles see, for example, Patent Nos. US 3,634,582, GB 1,230,087, GB
  • Intranasal sprays may be formulated with aqueous or non-aqueous vehicles with the addition of agents such as thickening agents, buffer salts or acid or alkali to adjust the pH, isotonicity adjusting agents or anti-oxidants.
  • Solutions for inhalation by nebulation may be formulated with an aqueous vehicle with the addition of agents such as acid or alkali, buffer salts, isotonicity adjusting agents or antimicrobials. They may be sterilised by filtration or heating in an autoclave, or presented as a non-sterile product.
  • Preferred unit dosage formulations are those containing an effective dose, as herein before recited, or an appropriate fraction thereof, of the active ingredient.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Indole Compounds (AREA)

Abstract

Muscarinic Acetylcholine Receptor Antagonists and methods of using them are provided.

Description

MUSCARINIC ACETYLCHOLINE RECEPTOR ANTAGONISTS FIELD OF THE INVENTION
This invention relates to novel quinuclidines derivatives, pharmaceutical compositions, and use thereof in treating muscarinic acetylcholine receptor mediated diseases of the respiratory tract. "
BACKGROUND OF THE INVENTION Acetylcholine released from cholinergic neurons in the peripheral and central nervous systems affects many different biological processes through interaction with two major classes of acetylcholine receptors - the nicotinic and the muscarinic acetylcholine receptors. Muscarinic acetylcholine receptors (mAChRs) belong to the superfamily of G-protein coupled receptors that have seven transmembrane domains. There are five subtypes of mAChRs, termed M1-M5, and each is the product of a distinct gene. Each of these five subtypes displays unique pharmacological properties. Muscarinic acetylcholine receptors are widely distributed in vertebrate organs where they mediate many of the vital functions. Muscarinic receptors can mediate both inhibitory and excitatory actions. For example, in smooth muscle found in the airways, M3 mAChRs mediate contractile responses. For review, please see Caulfield (1993
Pharmac. Then 58:319-79). In the lungs, mAChRs have been localized to smooth muscle in the trachea and bronchi, the submucosal glands, and the parasympathetic ganglia. Muscarinic receptor density is greatest in parasympathetic ganglia and then decreases in density from the submucosal glands to tracheal and then bronchial smooth muscle. Muscarinic receptors are nearly absent from the alveoli. For review of mAChR expression and function in the lungs, please see Fryer and Jacoby (1998 Am JRespir Crit Care Med 158(5, pt 3) S 154-60). Three subtypes of mAChRs have been identified as important in the lungs, Mi, M2 and M3 mAChRs. The M3 mAChRs, located on airway smooth muscle, mediate muscle contraction. Stimulation of M3 mAChRs activates the enzyme phospholipase C via binding of the stimulatory G protein Gq/11 (Gs), leading to liberation of phosphatidyl inositol-4,5-bisphosphate, resulting in phosphorylation of contractile proteins. M3 mAChRs are also found on pulmonary submucosal glands. Stimulation of this population of M3 mAChRs results in mucus secretion. M2 mAChRs make up approximately 50-80% of the cholinergic receptor population on airway smooth muscles. Although the precise function is still unknown, they inhibit catecholaminergic relaxation of airway smooth muscle via inhibition of cAMP generation. Neuronal M2 mAChRs are located on postganglionic parasympathetic nerves. Under normal physiologic conditions, neuronal M2 mAChRs provide tight control of acetylcholine release from parasympathetic nerves. Inhibitory M2 mAChRs have also been demonstrated on sympathetic nerves in the lungs of some species. These receptors inhibit release of noradrenaline, thus decreasing sympathetic input to the lungs. Mi mAChRs are found in the pulmonary parasympathetic ganglia where they function to enhance neurotransmission. These receptors have also been localized to the peripheral lung parenchyma, however their function in the parenchyma is unknown.
Muscarinic acetylcholine receptor dysfunction in the lungs has been noted in a variety of different pathophysiological states. In particular, in asthma and chronic obstructive pulmonary disease (COPD), inflammatory conditions lead to loss of inhibitory M2 muscarinic acetylcholine autoreceptor function on parasympathetic nerves supplying the pulmonary smooth muscle, causing increased acetylcholine release following vagal nerve stimulation (Fryer et al. 1999 Life Sci 64 (6-7) 449-55). This mAChR dysfunction results in airway hyperreactivity and hyperresponsiveness mediated by increased stimulation of M3 mAChRs. Thus the identification of potent mAChR antagonists would be useful as therapeutics in these mAChR-mediated disease states. COPD is an imprecise term that encompasses a variety of progressive health 1 problems including chronic bronchitis, chronic bronchiolitis and emphysema, and it is a major cause of mortality and morbidity in the world. Smoking is the major risk factor for the development of COPD; nearly 50 million people in the U.S. alone smoke cigarettes, and an estimated 3,000 people take up the habit daily. As a result, COPD is expected to rank among the top five as a world-wide health burden by the year 2020. Inhaled anti-cholinergic therapy is currently considered the "gold standard" as first line therapy for COPD (Pauwels et al. 2001 Am. J. Respir. Crit. Care Med. 163:1256-1276). Despite the large body of evidence supporting the use of anti-cholinergic therapy for the treatment of airway hyperreactive diseases, relatively few anti- cholinergic compounds are available for use in the clinic for pulmonary indications.
More specifically, in United States, Ipratropium Bromide (Atrovent©' and
Combivent©, in combination with albuterol) is currently the only inhaled anti- cholinergic marketed for the treatment of airway hyperreactive diseases. While this compound is a potent anti-muscarinic agent, it is short acting, and thus must be administered as many as four times daily in order to provide relief for the COPD patient, hi Europe and Asia, the long-acting anti-cholinergic Tiotropium Bromide
(Spiriva©) was recently approved, however this product is currently not available in the United States. Thus, there remains a need for novel compounds that are capable of causing blockade at mAChRs which are long acting and can be administered once-daily for the treatment of airway hyperreactive diseases such as asthma and COPD. Since mAChRs are widely distributed throughout the body, the ability to apply anti-cholinergics locally and/or topically to the respiratory tract is particularly advantageous, as it would allow for lower doses of the drug to be utilized. Furthermore, the ability to design topically active drugs that have long duration of action, and in particular, are retained either at the receptor or by the lung, would allow the avoidance of unwanted side effects that may be seen with systemic anti-cholinergic use.
SUMMARY OF THE INVENTION
This invention provides for a method of treating a muscarinic acetylcholine receptor (mAChR) mediated disease, wherein acetylcholine binds to an mAChR and which method comprises administering an effective amount of a compound of Formula (I) or a pharmaceutically acceptable salt thereof. This invention also relates to a method of inhibiting the binding of acetylcholine to its receptors in a mammal in need thereof which comprises administering to aforementioned mammal an effective amount of a compound of Formula (I). The present invention also provides for the novel compounds of Formula (I), and pharmaceutical compositions comprising a compound of Formula (I), and a pharmaceutical carrier or diluent. Compounds of Formula (I) useful in the present invention are represented by the structure:
Figure imgf000005_0001
wherein:
Rl is selected from the group consisting of Cl-15 alkyl, halosubstituted Cl-15 alkyl, Cl-15 alkyl cycloalkyl, cycloalkyl, C2-15 alkenyl, hydroxy substituted Cl-15 alkyl, Cl-15 alkyl aryl, Cl-15 alkyl heteroaryl, (CR7R7)qNRaRa, (CR7R7)qNC(O)Ra, (CR7R7)qC(O)NRaRa, (CR7R7)qC(O)Ra, (CR7R7)qOC (O)Ra, (CR7R7)qNRaC(O)NRaRa, (CR7R7)qORc and (CR7R7)qNS(O)2Ra
Rl is selected from the group consisting of:
Figure imgf000005_0002
Rl is selected from the group consisting of:
Figure imgf000005_0003
R2 and R3 are independently selected from the group consisting of aryl, Cl-4 alkyl aryl, heteroaryl, Cl-4 alkyl heteroaryl, heterocyclic and a Cl-4 alkyl heterocyclic moiety, all of which moieties may be optionally substituted; Ra is selected from the group consisting of hydrogen, Cl-15 alkyl, Cl-15 alkoxy, aryl, Cl-15 alkyl aryl, heteroaryl, Cl-15 alkyl heteroaryl, heterocyclic and a Cl-15 alkyl heterocyclic moiety, all of which moieties may be optionally substituted;
Re is selected from the group consisting of hydrogen, Cl-15 alkyl, Cl-15 alkoxy, heterocyclic and a Cl-15 alkyl heterocyclic moiety, all of which moieties may be optionally substituted;
R4 and R5 are independently selected from the group consisting of hydrogen, halogen, Cl-4 alkyl, aryl, Cl-4 alkyl aryl, cyano, nitro, (CR7R7)pORb, (CR7R7)pNRbRb, or R4 and R5 together may form a 5 to 6 membered saturated or unsaturated ring; and wherein the alkyl, aryl, arylalkyl, heteroaryl, heteroalkyl, heterocyclic, heterocyclicalkyl groups may be optionally substituted;
R6 is selected from the group consisting of hydrogen, Cl-4 alkyl;
q is 0 or an integer having a value of 1 to 15; n is an integer having a value of 1 to 14; m is an integer having a value of 1 to 15; 1 is an integer having a value of 1 to 4; t is 0 or an integer having a value of 1 to 5; p is 0 or an integer having a value of 1 to 4;
X, Y, Z and W are independently selected from the group consisting of hydrogen, Cl-4 alkyl;
V is selected from the group consisting of CH2, O, S, andNRb;
M is O or CH2;
Rb is selected from the group consisting of hydrogen, Cl-4 alkyl, aryl and Cl-4 alkyl aryl;
R7 is selected from the group consisting of hydrogen, Cl-4 alkyl, halosubstituted Cl-4 alkyl, and hydroxysubstituted Cl-4 alkyl; X- is a physiologically acceptable anion, such as chloride, bromide, iodide, hydroxide, sulfate, nitrate, phosphate, acetate, trifluoroacetate, fumarate, citrate, tartrate, oxalate, succinate, mandelate, methanesulfonate and p-toluenesulfonate. DETAILED DESCRIPTION OF THE INVENTION
This invention related to novel bi-aryl 8-azoniabicyclo[3.2.1]octane compounds, pharmaceutical compositions, processes for their preparation, and use thereof in treating mAChR mediated diseases. In a preferred embodiment of the present invention the compound is of formula
(I) herein below:
Figure imgf000007_0001
(I) wherein:
Rl is selected from the group consisting of Cl-10 alkyl, halosubstituted Cl-10 alkyl, Cl-10 alkyl aryl, Cl-10 alkyl cycloalkyl, cycloalkyl, hydroxy substituted Cl-10 alkyl, C2-10 alkenyl, (CR7R7)qORc; (CR7R7)qOC (O)Ra and (CR7R7)qNS(O)2Ra;
or Rl is selected from the group consisting of:
Figure imgf000007_0002
R2 and R3 are, independently, selected from the group consisting of:
Figure imgf000008_0001
F, G, H, K and L are independently selected from the group consisting of hydrogen, halogen, Cl-4 alkyl, halosubstituted Cl-4 alkyl, hydoxysubstituted Cl-4 alkyl, and Cl- 4 alkoxy; Ra is selected from the group consisting of hydrogen, Cl-10 alkyl, Cl-10 alkoxy, aryl and heteroaryl, all of which moieties may be optionally substituted;
Re is selected from the group consisting of hydrogen, Cl-5 alkyl, Cl-5 alkoxy, all of which moieties may be optionally substituted;
R4 and R5 are independently selected from the group consisting of hydrogen, halogen,
Cl-4 alkyl, aryl, Cl-4 alkyl aryl, cyano, nitro, (CR7R7)pORb, (CR7R7)pNRbRb, or R4 and R5 together may form a 5 to 6 membered saturated or unsaturated ring;
q is 0 or an integer having a value of 1 to 5; n is an integer having a value of 1 to 4; m is an integer having a value of 1 to 5;
1 is 1 or 2; t is 0, 1 or 2; p is 0, 1 or 2;
V is O, or CH2;
R6 is selected from the group consisting of hydrogen, Cl-4 alkyl;
M is O or CH2;
Rb is selected from the group consisting of hydrogen, Cl-4 alkyl, and aryl Cl-4 alkyl R7 is selected from the group consisting of hydrogen, and Cl-4 alkyl; X- is a physiologically acceptable anion, such as chloride, bromide, iodide, hydroxide, sulfate, nitrate, phosphate, acetate, trifluoroacetate, fumarate, citrate, tartrate, oxalate, succinate, mandelate, methanesulfonate and p-toluenesulfonate. All of the aryl, heteroaryl, and heterocyclic containing moieties may be optionally substituted as defined herein below. For use herein the. term "the aryl, heteroaryl, and heterocyclic containing moieties" refers to both the ring and the alkyl, or if included, the alkenyl rings, such as aryl, arylalkyl, and aryl alkenyl rings. The term "moieties" and "rings" may be interchangeably used throughout. As used herein, "optionally substituted" unless specifically defined shall mean such groups as halogen, such as fluorine, chlorine, bromine or iodine; hydroxy; hydroxy substituted Cι_ioalkyl; Cl-io alkoxy, such as methoxy or ethoxy; S(O)m" Cl- 10 alkyl, wherein m' is 0, 1 or 2, such as methyl thio, methyl sulfinyl or methyl sulfonyl; amino, mono & di-substituted amino, such as in the NRioRl 1 group;
NHC(O)R9; C(O)NRioRli; C(O)OH; S(O)2NRι0Rli; NHS(O)2R9, Cμio alkyl, such as methyl, ethyl, propyl, isopropyl, or t-butyl; halosubstituted Cl-io alkyl, such CF3; an optionally substituted aryl, such as phenyl, or an optionally substituted arylalkyl, such as benzyl or phenethyl, optionally substituted heterocylic, optionally substituted heterocyclicalkyl, optionally substituted heteroaryl, optionally substituted heteroaryl alkyl, wherein these aryl , heteroaryl, or heterocyclic moieties may be substituted one to two times by halogen; hydroxy; hydroxy substituted alkyl; Cl-io alkoxy; S(O)m'C _ o alkyl; amino, mono & di-substituted alkyl amino, such as in the NRioRl 1 group; Cl-io alkyl, or halosubstituted Cl-io alkyl, such as CF3. The following terms, as used herein, refer to: • "halo" - all halogens, that is chloro, fluoro, bromo and iodo. • "C _ιoalkyl" or "alkyl" - both straight and branched chain moieties of 1 to 10 carbon atoms, unless the chain length is otherwise limited, including, but not limited to, methyl, ethyl, ra-propyl, wo-propyl, rc-butyl, sec-butyl, iso-butyl, fert-butyl, «-pentyl and the like. • "cycloalkyl" is used herein to mean cyclic moiety, preferably of 3 to 8 carbons, including but not limited to cyclopropyl, cyclopentyl, cyclohexyl, and the like. • "alkenyl" is used herein at all occurrences to mean straight or branched chain moiety of 2-10 carbon atoms, unless the chain length is limited thereto, including, but not limited to ethenyl, 1-propenyl, 2-propenyl, 2-methyl-l-propenyl, 1-butenyl, 2- butenyl and the like. • "aryl" - phenyl and naphthyl; • "heteroaryl" (on its own or in any combination, such as "heteroaryloxy", or "heteroaryl alkyl") - a 5-10 membered aromatic ring system in which one or more rings contain one or more heteroatoms selected from the group consisting of N, O or S, such as, but not limited, to pyrrole, pyrazole, furan, thiophene, quinoline, isoquinoline, quinazolinyl, pyridine, pyrimidine, oxazole, tetrazole, thiazole, thiadiazole, triazole, imidazole, indole or benzimidazole. • "heterocyclic" (on its own or in any combination, such as "heterocyclicalkyl") - a saturated or partially unsaturated 4-10 membered ring system in which one or more rings contain one or more heteroatoms selected from the group consisting of N, O, or S; such as, but not limited to, pyrrolidine, piperidine, piperazine, morpholine, tetrahydropyran, thiomorpholine, or imidazolidine. Furthermore, sulfur may be optionally oxidized to the sulfone or the sulfoxide. • "arylalkyl" or "heteroarylalkyl" or "heterocyclicalkyl" is used herein to mean
Cl-10 alkyl, as defined above, attached to an aryl, heteroaryl or heterocyclic moiety, as also defined herein, unless otherwise indicated. • "sulfinyl" - the oxide S (O) of the corresponding sulfide, the term "thio" refers to the sulfide, and the term "sulfonyl" refers to the fully oxidized S(O)2 moiety. • "wherein two Rl moieties (or two Y moieties) may together form a 5 or 6 membered saturated or unsaturated ring" is used herein to mean the formation of an aromatic ring system, such as naphthalene, or is a phenyl moiety having attached a 6 membered partially saturated or unsaturated ring such as a Cft cycloalkenyl, i.e. hexene, or a C5 cycloalkenyl moiety, such as cyclopentene.
Illustrative compounds of Formula (I) include: l-(2-{[(3-fluorophenyl)methyl]oxy}ethyl)-4-[hydroxy(diphenyl)methyl]-l- azoniabicyclo[2.2.2]octane bromide
4- [hydroxy (diphenyl)methy 1] - 1 - { 2- [(pheny lmethy 1) oxy] ethyl } - 1 - azomabicyclo [2.2.2] octane bromide 1 -(2- { [(4-bromophenyl)methyl]oxy } ethyl)-4-[hydroxy(diphenyl)methyl]- 1 - azoniabicyclo[2.2.2]octane bromide
1 -(2- { [(4-chlorophenyl)methyl] oxy} ethyl)-4- [hydroxy(diphenyl)methyl] - 1 - azomabicyclo [2.2.2] octane bromide
4- [bis(4-fluorophenyl)(hy droxy)methyl] - 1 - {2- [(phenylmethyl)oxy] ethyl } - 1 - azoniabicyclo[2.2.2]octane bromide
4- {hydroxy [bis(3 -methylphenyl)]methyl} - 1 - {2-[(phenylmethyl)oxy] ethyl } - 1 - azoniabicyclo[2.2.2]octane bromide
1 -(2- { [(4-fluorophenyl)methyl] oxy} ethyl)-4- [hydroxy(diphenyl)methyl] - 1 - azoniabicy clo [2.2.2] octane bromide 4- [hydroxy (diphenyl)methyl]- 1 - {2- [(phenylcarbonyl)oxy] ethyl } - 1 - azoniabicyclo[2.2.2]octane bromide l-{3-[(3 -fluoropheny l)oxy] propyl } -4- [hydroxy (diphenyl)methy 1] - 1 - azoniabicyclo [2.2.2] octane bromide
4- {hydroxy [bis(4-methylphenyl)]methyl } - 1 - {2- [(phenylmethyl)oxy] ethyl} - 1 - azoniabicyclo[2.2.2]octane bromide
4-[hy droxy (diphenyl)methyl] - 1 - { 3 -[(methylsulfonyl)amino]propyl } - 1 - azoniabicy clo [2.2.2] octane bromide
4-[bis(3-fluorophenyl)(hydroxy)methyl]-l-{2-[(phenylmethyl)oxy]ethyl}-l- azoniabicyclo[2.2.2]octane bromide 1 - { 3 - [(3 -chloropheny l)oxy]ρropyl } -4- [hydroxy (dipheny l)methyl]- 1 - azoniabicyclo[2.2.2]octane bromide
4- [hydroxy(di-2-thienyl)methyl] - 1 - [3 -(phenyloxy)propyl] - 1 -azoniabicyclo [2.2.2] octane bromide
4- [hydroxy(diphenyl)methyl] - 1 - [3 -(phenyloxy)propyl] - 1 -azoniabicyclo [2.2.2] octane bromide
1 -(2- { [(4-cyanophenyl)methyl] oxy} ethyl)-4- [hydroxy(diphenyl)methyl] - 1 - azoniabicyclo [2.2.2] octane bromide 1 - { 3 - [(4-bromophenyl)oxy]propyl } -4- [hy dr oxy (diphenyl)methy 1] - 1 - azoniabicy clo [2.2.2] octane bromide
4- [bis(4-fluorophenyl)(hydroxy)methyl] - 1 - [3 ~(phenyloxy)propyl] - 1 - azoniabicyclo [2.2.2] octane bromide 1 - { 3 - [(4-fluorophenyl)oxy]propyl } -4- [hydroxy (diphenyl)methyl]- 1 - azoniabicyclo[2.2.2]octane bromide
4- [hydroxy(diphenyl)methyl] -l-{2-[(l -methyl- 1 -phenylethyl)oxy] ethyl} - 1 - azoniabicyclo[2.2.2]octane bromide
4- [hydroxy (diphenyl)methyl] - 1 - {2- [(2-naphthalenylmethyι)oxy] ethyl} - 1 - azoniabicyclo[2.2.2]octane bromide
4-[hydroxy(di-3- ienyl)methyl]-l-[3-(phenyloxy)propyl]-l-azoniabicyclo[2.2.2]octane bromide
4- [hydroxy(diphenyl)methyl] - 1 - [2-(phenyloxy)ethyl] - 1 -azoniabicyclo [2.2.2] octane bromide 4- {hydroxy [bis(3 -methylphenyl)]methyl } - 1 - [3 -(phenyloxy)propyl]- 1 - azoniabicy clo [2.2.2] octane bromide
4- {hydroxy [bis(4-methylphenyl)]methyl} - 1 -[3 -(phenyloxy)propyl]- 1 - azoniabicyclo[2.2.2]octane bromide
4-[hydroxy(diphenyl)methyl]- 1 -(3 - { [4-(methyloxy)phenyι] oxy }propyl)- 1 - azoniabicyclo[2.2.2]octane bromide
4-[hydroxy(diphenyl)methyl]-l-[3-(2-naphthalenyloxy)propyl]-l- azoniabicyclo[2.2.2]octane bromide
4- [hydroxy (diphenyl)methyl] - 1 - [2-( { [3 -(methyloxy)phenyl]methyl} oxy)ethyl] - 1 - azoniabicyclo [2.2.2] octane bromide 4-[hydroxy(diphenyl)methyl]-l-(2-naphthalenylmethyl)-l-azoniabicyclo[2.2.2]octane bromide
4- [bis(3 -fluorophenyl)(hydroxy)methyl] - 1 - [3 -(phenyloxy)propyl] - 1 - azoniabicyclo [2.2.2] octane bromide
4- [hydroxy (di-2-thienyl)methyl] - 1 - [2-(pheny loxy)ethyl] - 1 -azoniabicyclo [2.2.2] octane bromide
4-(hydroxy {bis[3-(methyloxy)phenyl] } methyl)- 1 - {2-[(phenylmethyl)oxy] ethyl} - 1 - azoniabicyclo[2.2.2]octane bromide 4- [hydroxy (diphenyl) ethy 1] - 1 - { 3 -[(4-nitrophenyl)oxy]propyl } - 1 - azoniabicyclo [2.2.2] octane bromide
1 - { 3 - [(2-fluoropheny l)oxy ] propyl } -4- [hydroxy (dipheny l)methy 1] - 1 - azoniabicyclo [2.2.2] octane bromide 4- [hydroxy (diphenyl)methyl] - 1 - { 3 - [(3 -nitrophenyl)oxy]propyl } - 1 - azoniabicyclo[2.2.2]octane bromide
4- [hydroxy (diphenyl)methyl] - 1 -( { 3 - [(trifluoromethyl)oxy]phenyl} methyl)- 1 - azoniabicyclo[2.2.2]octane bromide
4- [hydroxy (diphenyl)methyl] - 1 - [(5-nitro-2-furanyl)methyl] - 1 - azoniabicyclo[2.2.2]octane bromide
4-[hy droxy (diphenyl)methyl] - 1 -[2-( 1 H-indol-3 -yl)ethyl] - 1 -azoniabicyclo [2.2.2] octane bromide
1 - [3 -(4-biphenylyloxy)propyl] -4- [hydroxy(diphenyl)methyl]- 1 - azoniabicyclo [2.2.2] octane bromide 4- [hydroxy(diphenyl)methyι] - 1 - { 3 - [(2-methylphenyl)oxy]ρropyl } - 1 - azoniabicyclo[2.2.2]octane bromide
4- [hydroxy (diphenyl)methyl] - 1 -(phenylmethyl)- 1 -azoniabicyclo [2.2.2] octane bromide
4- [hydroxy (diphenyl)methyl] - 1 -(2- { [2-(methyloxy)ethyl] oxy } ethyl)- 1 - azoniabicyclo[2.2.2]octane bromide 4- [hydroxy(diphenyl)methyι] - 1 - { 3 - [(phenylmethyl)oxy]propyl } - 1 - azoniabicyclo[2.2.2]octane bromide
4- [hydroxy (diphenyl)methyl] - 1 - [4-(phenyloxy)butyl] - 1 -azoniabicyclo [2.2.2] octane bromide l-(l,3-dioxolan-2-ylmethyl)-4-[hydroxy(diphenyl)methyl]-l- azoniabicyclo[2.2.2]octane bromide
4- [hydroxy (diphenyl)methyl] - 1 - { 3 - [(2-hydroxyphenyl)oxy]propyl} - 1 - azoniabicyclo[2.2.2]octane bromide
1 -hexyl-4-[hydroxy(diphenyl)methyl]-l -azoniabicyclo[2.2.2]octane bromide
4-[hydroxy(di-3-thienyl)methyl]-l-[2-(phenyloxy)ethyl]-l-azoniabicyclo[2.2.2]octane bromide
4-[hydroxy(diphenyl)methyl]-l-[3-({4-[(ρhenylmethyl)oxy]phenyl}oxy)propyl]-l- azoniabicyclo[2.2.2]octane bromide l-[(3-bromophenyl)methyl]-4-[hydroxy(diphenyl)methyl]-l-azoniabicyclo[2.2.2]octane bromide
4- [hydroxy (di-2-naphthalenyl)methyl] - 1 - {2- [(phenylmethyl)oxy] ethyl } - 1 - azoniabicyclo [2.2.2] octane bromide 4- [hydroxy(diphenyl)methyl] - 1 - [2-(methyloxy)ethyl] - 1 -azoniabicyclo [2.2.2]octane bromide
4-(hydroxy{bis[4-(methyloxy)phenyl]}methyl)-l-{2-[(phenylmethyl)oxy]ethyl}-l- azoniabicy clo [2.2.2] octane bromide
1 - { 3 - [(4-cyanophenyl)oxy]propyl} -4- [hydroxy (diphenyl)methyl] - 1 - azoniabicyclo[2.2.2]octane bromide
1 -[2-(l -benzofuran-2-yl)-2-oxoethyl]-4-[hydroxy(diphenyl)methyl]-l - azoniabicyclo[2.2.2]octane bromide l-[2-({[4-(l,l -dimethylethyl)phenyl]methyl } oxy)ethyl] -4- [hydroxy (diphenyl)methyl] -
1 -azoniabicyclo [2.2.2] octane bromide 4- [hydroxy (diphenyl)methyl] - 1 - { [3 -(methyloxy)phenyl]methyl } - 1 - azoniabicyclo[2.2.2]octane bromide
4- [hydroxy (diphenyl)methyl] - 1 -( {4- [(trifluoromethyl)oxy]phenyl } methyl)- 1 - azoniabicyclo [2.2.2] octane bromide
4- [hydroxy(diphenyl)methyl] - 1 -nonyl- 1 -azoniabicyclo [2.2.2] octane bromide 4-[hydroxy(di-2-naphthalenyl)methyl]- 1 -[3-(phenyloxy)propyl]- 1 - azoniabicyclo[2.2.2]octane bromide
1 - [(4-fluorophenyl)methyl] -4- [hydroxy(diphenyl)methyl] - 1 -azoniabicyclo [2.2.2] octane bromide
1 - [(4-bromophenyl)methyl] -4- [hydroxy(diphenyl)methyl] - 1 -azoniabicyclo [2.2.2]octane bromide
4-[hydroxy(diphenyl)methyl] - 1 - { [3 -(trifluoromethyl)phenyl]methyl } - 1 - azoniabicyclo [2.2.2] octane bromide
1 - [(2-fluorophenyl)methyl] -4- [hy droxy(diphenyl)methyl] - 1 -azoniabicyclo [2.2.2] octane bromide 4- [hydroxy(diphenyl)methyl] - 1 - { [4-(trifluoromethyl)phenyl]methyl } - 1 - azoniabicyclo[2.2.2]octane bromide
1 -(5 -hexen- 1 -yl)-4- [hydroxy(diphenyl)methyl] - 1 -azoniabicyclo [2.2.2] octane bromide l-(3-cyclohexylpropyl)-4-[hydroxy(diphenyl)methyl]-l-azoniabicyclo[2.2.2]octane bromide
4- [hydroxy (diphenyl)methyl] - 1 - [2-(tetrahydro-2H-pyran-2-yloxy)ethyl] - 1 - azoniabicyclo [2.2.2] octane bromide l-[2-(l,3-dioxo-l,3-dihydro-2H-isoindol-2-yl)ethyl]-4-[hydroxy(diρhenyl)methyl]-l- azoniabicyclo[2.2.2]octane bromide
4- [hydroxy(diphenyl)methyl]-l-(2-phenylethyl)-l-azoniabicyclo[2.2.2]octane bromide l-ethyl-4-[hydroxy(diphenyl)methyl]-l-azoniabicyclo[2.2.2]octane bromide
4- [hydroxy (diphenyl)methyl] - 1 - [(4-methylphenyl)methyl] - 1 - azoniabicyclo[2.2.2]octane bromide l-butyl-4-[hydroxy(diphenyl)methyl]-l-azoniabicyclo[2.2.2]octane bromide
4- [hydroxy (diphenyl)methyl] - 1 - [2-(3 -methyl- 1 H-pyrazol- 1 -yl)ethyl] - 1 - azoniabicyclo [2.2.2] octane bromide
4-(hy droxy {bis [4-(methyloxy)phenyl] } methyl)- 1 - [3 -(phenyloxy)propyl] - 1 - azoniabicyclo[2.2.2]octane bromide
1 - [3 -(3 -biphenylyloxy)propyl] -4- [hydroxy(diphenyl)methyl] - 1 - azoniabicyclo[2.2.2]octane bromide
4- [hydroxy (diphenyl)methyl] - 1 - [( 1 £)- 1 -methyl-2-oxo-2-(phenylamino)ethyl] - 1 - azoniabicyclo[2.2.2]octane bromide 4-[hydroxy(diphenyl)methyl]- 1 -propyl- 1 -azoniabicyclo[2.2.2]octane bromide l-{3-[(2-bromophenyl)oxy]propyl}-4-[hydroxy(diphenyl)methyl]-l- azoniabicyclo[2.2.2]octane bromide
1 - [(3 -fluorophenyl)methyl] -4- [hydroxy(diphenyl)methyl] - 1 -azoniabicyclo [2.2.2] octane bromide 1 - [(3 ,4-dichlorophenyl)methyl] -4- [hydroxy(diphenyl)methyl]- 1 - azoniabicyclo[2.2.2]octane bromide
1 - [(2-fluoro-3 -methylphenyl)methyl] -4- [hydroxy(diphenyl)methyl] - 1 - azoniabicyclo [2.2.2] octane bromide
4- [hydroxy (diphenyl)methyl] - 1 - { 4- [(phenylmethyl)oxy]butyl} - 1 - azoniabicyclo [2.2.2] octane bromide l-[(4-cyanophenyl)methyl]-4-[hydroxy(diphenyl)methyl]-l-azoniabicyclo[2.2.2]octane bromide 4-(hydroxy{bis[3-(methyloxy)phenyl] }methyl)-l -[3-(phenyloxy)propyl]-l - azoniabicyclo [2.2.2] octane bromide
1 -(3 - { [3 -(diethylamino)phenyl] oxy }propyl)-4- [hydroxy (diphenyl)methyl] - 1 - azoniabicyclo [2.2.2] octane bromide 4-[hydroxy(diphenyl)methyl]-l-(2-propen-l-yl)-l-azoniabicyclo[2.2.2]octane bromide
1 -{[4-(l , 1 -dimethylethyl)phenyl]methyl}-4-[hydroxy(diphenyl)methyl]-l - azoniabicyclo [2.2.2] octane bromide
4- [hydroxy(diphenyl)methyl] - 1 -(3 -phenylpropyl)- 1 -azoniabicyclo [2.2.2] octane bromide 1 - [(2,6-difluorophenyl)methyι] -4- [hydroxy(diphenyl)methyl] - 1 - azoniabicyclo[2.2.2]octane bromide
4- [hydroxy (diphenyl)methyl] - 1 - [2-( { [2-(phenyloxy)-3 - pyridinyl] carbonyl} amino)ethyl] - 1 -azoniabicyclo [2.2.2] octane bromide
4- [hydroxy(di-2-thienyl)methyl] - 1 -(2-phenylethyl)- 1 -azoniabicyclo [2.2.2] octane bromide
1 -(3 -bromopropyl)-4- [hy droxy(diphenyl)methyl] - 1 -azoniabicyclo [2.2.2] octane bromide
4- [hydroxy(diphenyl)methyl] - 1 -(2-hy droxy ethyl)- 1 -azoniabicyclo [2.2.2] octane bromide l-[(3-cyanophenyl)methyl]-4-[hydroxy(diphenyl)methyl]-l-azoniabicyclo[2.2.2]octane bromide
1 -[2-({ [(2,4-dichlorophenyl)amino]carbonyl} amino)ethyl]-4-
[hydroxy(diphenyl)methyl] - 1 -azoniabicyclo [2.2.2] octane bromide
4- [hydroxy(diphenyl)methyl] - 1 -(4-penten- 1 -yl)- 1 -azoniabicyclo [2.2.2] octane bromide 1 - {2- [(2,4-dibromophenyl)oxy] ethyl } -4- [hydroxy (diphenyl)methyl]- 1 - azoniabicyclo[2.2.2]octane bromide l-[(2,4-difluorophenyl)methyl]-4-[hydroxy(diphenyl)methyl]-l- azoniabicyclo[2.2.2]octane bromide
4- [hydroxy(diphenyl)methyl] - 1 - [3 -(methyloxy)propyl] - 1 -azoniabicyclo [2.2.2] octane bromide
4-[hydroxy(diphenyl)methyl]-l-[3-({2-[(phenylmethyl)oxy]phenyl}oxy)propyl]-l- azoniabicyclo [2.2.2] octane bromide [l-(2-aminoethyl)-l-azoniabicyclo[2.2.2]oct-4-yl](diphenyl)methanolate trifluoroacetate
4- [hydroxy(di-2-thienyl)methyl] - 1 -(3 -phenylpropyl)- 1 -azoniabicyclo [2.2.2] octane bromide 4-[hydroxy(diphenyl)methyl]-l-methyl-l-azoniabicyclo[2.2.2]octane bromide
4-[hydroxy(diphenyl)methyl]-l-(tetrahydro-2H-pyran-2-ylmethyl)-l- azoniabicyclo[2.2.2]octane bromide l-[(2,3-difluorophenyl)methyl]-4-[hydroxy(diphenyl)methyl]-l- azoniabicyclo [2.2.2] octane bromide l-[2-(4-biphenylyl)-2-oxoethyl]-4-[hydroxy(diphenyl)methyl]-l- azoniabicyclo[2.2.2]octane bromide
4-[hydroxy(diphenyl)methyl]-l-[2-oxo-2-(4-pentylphenyl)ethyl]-l- azoniabicyclo [2.2.2]octane bromide
1 -(2- { [(2,4-dichlorophenyι)carbonyl] amino } ethyl)-4- [hydroxy (diphenyl)methyl] - 1 - azoniabicyclo[2.2.2]octane bromide
4-[hy droxy(diphenyl)methyl] - 1 -(3 - { [2-(methyloxy)phenyl] oxy }propyl)- 1 - azoniabicyclo[2.2.2]octane bromide
4- [hydroxy(diphenyl)methyl] - 1 - [( 1 - { [(phenylmethyl)oxy] carbonyl} -4- piperidinyl)methyl] - 1 -azoniabicyclo [2.2.2] octane bromide 4-[hydroxy(diphenyl)methyl]- 1 -[2-(2-naphthalenyl)-2-oxoethyl]- 1 - azoniabicyclo[2.2.2]octane bromide
4-[hydroxy(diphenyl)methyl]-l-[(4-nitrophenyl)methyl]-l-azoniabicyclo[2.2.2]octane bromide
1 -butyl-4- [hydroxy (di-3 -thienyl)methyl] - 1 -azoniabicyclo [2.2.2] octane bromide 4-[hydroxy(diphenyl)methyl]-l-(2-oxo-2-phenylethyl)-l-azoniabicyclo[2.2.2]octane bromide
1 - [(3 ,4-difluorophenyl)methyl] -4- [hydroxy(diphenyl)methyl] - 1 - azoniabicyclo[2.2.2]octane bromide
1 -(cyclopropylmethyl)-4- [hydroxy(diphenyl)methyl] - 1 -azoniabicyclo [2.2.2] octane bromide
The preferred compounds useful in the present invention include: 1 -(2- { [(3 -fluorophenyl)methyl] oxy} ethyl)-4- [hydroxy (diphenyl)methyl] - 1 - azoniabicyclo [2.2.2] octane bromide
4- [hydroxy(diphenyl)methyl] - 1 - {2- [(phenylmethyl)oxy] ethyl } - 1 - azoniabicy clo [2.2.2] octane bromide
1 -(2- { [(4-bromophenyl)methyl] oxy} ethyl)-4- [hydroxy (diphenyl)methyl] - 1 - azoniabicyclo[2.2.2]octane bromide
1 -(2- { [(4-chlorophenyl)methyl] oxy} ethyl)-4- [hydroxy (diphenyl)methyl] -1 - azoniabicyclo[2.2.2]octane bromide 4- [bis(4-fluorophenyl)(hydroxy)methyl] - 1 - {2- [(phenylmethyl)oxy] ethyl } - 1 - azoniabicyclo[2.2.2]octane bromide
4- {hydroxy [bis(3 -methylphenyl)]methyl } - 1 - {2- [(phenylmethyl)oxy] ethyl} - 1 - azoniabicyclo[2.2.2]octane bromide
1 -(2- { [(4-fluorophenyl)methyl] oxy} ethyl)-4- [hydroxy(diphenyl)methyl] - 1 - azoniabicyclo [2.2.2] octane bromide
4-[hy droxy (diphenyl)methyl] - 1 - {2- [(phenylcarbonyl)oxy] ethyl } - 1 - azoniabicyclo[2.2.2]octane bromide
1 - { 3 - [(3 -fluorophenyl)oxy]propyl} -4- [hydroxy (diphenyl)methyl] - 1 - azoniabicyclo[2.2.2]octane bromide 4- {hydroxy [bis(4-methylphenyl)]methyl } - 1 - {2- [(pheny lmethyl)oxy] ethyl } - 1 - azoniabicyclo[2.2.2]octane bromide
4- [hydroxy (diphenyl)methyl] - 1 - { 3 - [(methylsulfonyl)amino]propyl } - 1 - azoniabicyclo [2.2.2] octane bromide
4- [bis(3 -fluorophenyl)(hydroxy)methyl] - 1 - {2- [(pheny lmethyl)oxy] ethyl } - 1 - azoniabicyclo[2.2.2]octane bromide
1 - {3 -[(3 -chlorophenyl)oxy]propyl} -4-[hydroxy(diphenyl)methyl] - 1 - azoniabicyclo [2.2.2] octane bromide
4-[hydroxy(di-2-thienyl)methyl]-l-[3-(phenyloxy)propyl]-l-azoniabicyclo[2.2.2]octane bromide 4- [hydroxy (diphenyl)methyl]- 1 - [3 -(pheny loxy)propyl] - 1 -azoniabicyclo [2.2.2]octane bromide 1 -(2- { [(4-cyanophenyl)methyl] oxy} ethyl)-4- [hydroxy(diphenyl)methyl] - 1 - azoniabicyclo [2.2.2] octane bromide
1 - { 3 - [(4-bromophenyι)oxy]propyl } -4- [hydroxy (diphenyl)methyl] - 1 - azoniabicyclo [2.2.2] octane bromide 4- [bis(4-fluorophenyl)(hy droxy )methyl] - 1 - [3 -(phenyloxy)propyl]- 1 - azoniabicyclo[2.2.2]octane bromide l-{3-[(4-fluorophenyl)oxy]propyl}-4-[hydroxy(diphenyl)methyl]-l- azoniabicy clo [2.2.2] octane bromide
4- [hydroxy(diphenyl)methyl] -l-{2-[(l -methyl- 1 -phenylethyl)oxy] ethyl } - 1 - azoniabicyclo[2.2.2]octane bromide
4- [hydroxy (diphenyl)methyl] - 1 - {2-[(2-naphthalenylmethyι)oxy] ethyl} - 1 - azoniabicyclo[2.2.2]octane bromide
4- [hydroxy (di-3 -thienyl)methyl] - 1 - [3 -(pheny loxy)propyl] - 1 -azoniabicyclo [2.2.2] octane bromide 4-[hydroxy(diphenyl)methyl]-l-[2-(phenyloxy)ethyl]-l-azoniabicyclo[2.2.2]octane bromide
4- {hydroxy [bis(3 -methylphenyl)]methyl} - 1 - [3 -(pheny loxy)propyl] - 1 - azoniabicyclo [2.2.2] octane bromide
4- {hydroxy [bis(4-methylphenyl)]methyl } - 1 - [3 -(pheny loxy)propyl] - 1 - azoniabicyclo[2.2.2]octane bromide
4-[hydroxy(diphenyl)methyl] - 1 -(3 - { [4-(methyloxy)phenyl] oxy}ρropyl)- 1 - azoniabicyclo [2.2.2] octane bromide
4- [hydroxy(diphenyl)methyl] - 1 - [3 -(2-naphthalenyloxy)propyl] - 1 - azoniabicyclo[2.2.2]octane bromide 4-[hydroxy(diphenyl)methyl]- 1 -[2-({ [3-(methyloxy)phenyl]methyl} oxy)ethyl]- 1 - azoniabicyclo[2.2.2]octane bromide
4- [hydroxy (diphenyl)methyl] - 1 -(2-naphthaleny lmethyl)- 1 -azoniabicyclo [2.2.2] octane bromide
4- [bis(3 -fluoropheny ι)(hy droxy)methyι] - 1 - [3 -(pheny loxy)propyl] - 1 - azoniabicyclo[2.2.2]octane bromide
4-[hydroxy(di-2-thienyl)methyl]-l-[2-(phenyloxy)ethyl]-l-azoniabicyclo[2.2.2]octane bromide 4-(hydroxy{bis[3-(methyloxy)phenyl]}methyl)-l-{2-[(phenylmethyl)oxy]ethyl}-l- azoniabicyclo [2.2.2] octane bromide
4- [hydroxy(diphenyl)methyl] - 1 - { 3 - [(4-nitrophenyl)oxy]propyl } - 1 - azoniabicyclo [2.2.2] octane bromide 1 - { 3 - [(2-fiuorophenyι)oxy]propyl } -4- [hydroxy(diphenyl)methyl] - 1 - azoniabicyclo[2.2.2]octane bromide
The more preferred compounds useful in the present invention include:
1 -(2- { [(3 -fluorophenyl)methyl]oxy } ethyl)-4-[hydroxy(diphenyl)methyl]- 1 - azoniabicyclo [2.2.2] octane bromide
4- [hydroxy (diphenyl)methyl] - 1 - {2- [(phenylmethyl)oxy] ethyl} - 1 - azoniabicy clo [2.2.2] octane bromide l-(2-{[(4-bromophenyl)methyl]oxy}ethyl)-4-[hydroxy(diphenyl)methyl]-l- azoniabicyclo[2.2.2]octane bromide
1 -(2- { [(4-chlorophenyl)methyl] oxy} ethyl)-4-[hydroxy(diphenyl)methyl]- 1 - azoniabicy clo [2.2.2] octane bromide
4-[bis(4-fluorophenyl)(hydroxy)methyl]-l-{2-[(phenylmethyl)oxy]ethyl}-l- azoniabicyclo [2.2.2] octane bromide 4- {hydroxy [bis(3 -methylphenyl)]methyl } - 1 - {2- [(pheny lmethyl)oxy] ethyl } - 1 - azoniabicyclo[2.2.2]octane bromide
1 -(2- { [(4-fluorophenyl)methyl] oxy } ethyl)-4- [hydroxy (diphenyl)methyl] - 1 - azoniabicyclo[2.2.2]octane bromide
4-[hydroxy(diphenyl)methyl]-l-{2-[(phenylcarbonyl)oxy]ethyl}-l- azoniabicyclo[2.2.2]octane bromide
1 - { 3 - [(3 -fluorophenyl)oxy]propyl } -4-[hy droxy (diphenyl)methyl] - 1 - azoniabicyclo[2.2.2]octane bromide
4- {hydroxy [bis(4-methylphenyl)]methyl } - 1 - {2- [(pheny lmethyl)oxy] ethyl} - 1 - azoniabicyclo[2.2.2]octane bromide 4- [hydroxy (diphenyl)methyl]- 1 - { 3 - [(methylsulfonyl)amino]propyl } - 1 - azoniabicyclo[2.2.2]octane bromide 4-[bis(3 -fluorophenyl)(hydroxy)methyl] - 1 - {2- [(phenylmethyl)oxy] ethyl } - 1 - azoniabicyclo [2.2.2] octane bromide
1 - { 3 - [(3 -chlorophenyl)oxy]propyl } -4- [hydroxy(diphenyl)methyl] - 1 - azoniabicyclo [2.2.2] octane bromide 4- [hydroxy (di-2-thienyl)methyl] - 1 - [3 -(pheny loxy)propyl] - 1 -azoniabicyclo [2.2.2] octane bromide
4- [hydroxy (diphenyl)methyl] - 1 - [3 -(pheny loxy)propyl] - 1 -azoniabicyclo [2.2.2] octane bromide
1 -(2- { [(4-cy anophenyl)methyl] oxy} ethyl)-4- [hydroxy(diphenyl)methyl] - 1 - azoniabicyclo[2.2.2]octane bromide
1 - { 3 -[(4-bromophenyl)oxy]propyl } -4-[hydroxy(diphenyl)methyl] - 1 - azoniabicy clo [2.2.2] octane bromide
4- [bis(4-fluorophenyl)(hydroxy)methyl] - 1 - [3 -(phenyloxy)propyl] - 1 - azoniabicy clo [2.2.2] octane bromide 1 - { 3 - [(4-fluorophenyl)oxy]propyl } -4- [hydroxy(diphenyl)methyι] - 1 - azoniabicyclo[2.2.2]octane bromide
4- [hydroxy (diphenyl)methyl] -l-{2-[(l -methyl- 1 -phenylethyl)oxy] ethyl} - 1 - azoniabicyclo[2.2.2]octane bromide
4-[hydroxy (diphenyl)methyl] - 1 - {2- [(2-naphthalenylmethyl)oxy] ethyl } - 1 - azoniabicyclo[2.2.2]octane bromide
4- [hydroxy (di-3 -thienyl)methyl] - 1 - [3 -(phenyl oxy)propyl] - 1 -azoniabicyclo [2.2.2] octane bromide
4- [hydroxy (diphenyl)methy 1] - 1 - [2-(phenyloxy)ethyl] - 1 -azoniabicyclo [2.2.2] octane bromide 4- {hydroxy [bis(3 -methylphenyl)]methyl } - 1 - [3 -(pheny loxy)propyl] - 1 - azoniabicyclo[2.2.2]octane bromide
The most preferred compounds useful in the present invention include:
l-(2-{[(3-fluorophenyl)methyl]oxy}ethyl)-4-[hydroxy(diphenyl)methyl]-l- azoniabicyclo[2.2.2]octane bromide 4-[hydroxy(diphenyl)methyl] - 1 - {2-[(phenylmethyl)oxy] ethyl} - 1 - azoniabicyclo[2.2.2]octane bromide l-(2-{[(4-bromophenyl)methyl]oxy}ethyl)-4-[hydroxy(diphenyl)methyl]-l- azoniabicyclo [2.2.2] octane bromide 1 -(2- { [(4-chlorophenyl)methyl]oxy } ethyl)-4- [hydroxy(diphenyl)methyl]- 1 - azoniabicyclo[2.2.2]octane bromide
4-[bis(4-fluorophenyl)(hydroxy)methyl]-l-{2-[(phenylmethyl)oxy]ethyl}-l- azoniabicyclo[2.2.2]octane bromide
4- {hydroxy [bis(3 -methylphenyl)]methyl} - 1 - {2-[(phenylmethyl)oxy]ethyl} - 1 - azoniabicyclo[2.2.2]octane bromide
1 -(2- { [(4-fluorophenyl)methyl] oxy} ethyl)-4-[hydroxy(diphenyl)methyl] - 1 - azoniabicyclo[2.2.2]octane bromide
4- [hydroxy (diphenyl)methyl] - 1 - {2- [(phenylcarbonyl)oxy] ethyl} - 1 - azoniabicyclo [2.2.2] octane bromide
METHODS OF PREPARATION.
The compounds of Formula (I) may be obtained by applying synthetic procedures, some of which are illustrated in the Schemes below. The synthesis provided in this Scheme is applicable for producing compounds of Formula (I) having a variety of different Rl, R2 and R3 groups which are reacted, employing substituents which are suitably protected, to achieve compatibility with the reactions outlined herein. Subsequent deprotection, in those cases, then affords compounds of the nature generally disclosed. While the Schemes are shown with compounds only of Formula (I), this is merely for illustration purpose only.
As shown in Scheme 1, the desired compounds of Formula (I) can be prepared in four synthetic steps from the commercially available ethyl 4-piperidinecarboxylate precursor 1. Compound 1 is reacted with l-bromo-2-chloroethane following standard alkylation procedures well known in the art such as potassium carbonate in acetone followed by reaction of the intermediate with lithium diisopropylamide in an aprotic solvent such as tetrahydrofurann to give the quinuclidine intermediate 2. Condensation of compound 2 with organometallic reagents such as a Grignard reagent or an organolithium derivative in an aprotic solvent such as tetrahydrofuran, results in the formation of the tertiary alcohol 3 of Formula (I) (Rl= nothing). Further N-alkylation of compound 3 with a suitable alkyl halide in a organic solvent such as chloroform or acetontirile gives compound 4 of Formula (I) (Rl not nothing).
Scheme 1
Figure imgf000023_0001
1 2 3 4
Reagents and conditions: a) l-bromo-2-chloroethane, K2CO3, acetone; b) LDA, THF; c) R2M then R3M, THF; d) R1X, ACN, CHC13.
SYNTHETIC EXAMPLES
The invention will now be described by reference to the following Examples which are merely illustrative and are not to be construed as a limitation of the scope of the present invention. All temperatures are given in °C. Thin layer chromatography (t.l.c.) was carried out on silica and column chromatography on silica (Flash column chromatography using Merck,9385 unless stated otherwise).
The following are the experimental conditions for the LC-MS.
LC-MS Experimental Conditions:
Liquid Chromatograph:
System: Shimadzu LC system with SCL-10A Controller and dual UV detector
Autosampler: Leap CTC with a Valco six port injector Column: Aquasil/Aquasil (C18 40xl mm)
Inj. Volume (μL): 2.0
Solvent A: H2O, 0.02% TFA Solvent B: MeCN, 0.018% TFA
Gradient: linear
Channel A: UV 214 nm
Channel B: ELS
Step Time (min) Dura, (min) Flow (μL/min) Sol.A Sol.B
0 0.00 0.00 300.00 95.00 5.00
1 0.00 0.01 300.00 95.00 5.00
2 0.01 3.20 300.00 10.00 90.00
3 3.21 1.00 300.00 10.00 90.00
4 4.21 0.10 300.00 95.00 5.00
5 4.31 0.40 300.00 95.00 5.00
Mass Spectrometer: PE Sciex Single Quadrupole LC/MS API- 150 Polarity: Positive
Acquisition mode: Profile
The preparatory HPLC was conducted using a Gilson HPLC system under the following conditions:
• Column: 75 x 33mm I. D. , S-5um, 12nm
• Flow rate: 30mL/min
• Injection Volume: 0.800 mL
• Room temperature • Solvent A: water
• Solvent B: acetonitrile
All solvents used herein are of the highest available purity and all reactions are run under anhydrous conditions under an air atmosphere unless otherwise indicated. Example 1: Preparation of 1-azabicy clo [2.2.2] oct-4-yl(diphenyl)methanol.
Ethyl l-(2-chloroethyl) -4-piperidinecarboxylate
To a solution of ethyl nipecotate (20.0 mL, 130 mmol) in acetone (180 mL) was added l-bromo-2-chloroethane (21.6 mL, 260 mmol) followed by anhydrous K CO3 (27.12 g, 196 mmol). The reaction mixture was stirred for 24 h and then concentrated under vacuum. The resulting residue was treated with H2O (75 mL) and extracted with Et2O. The combined organic layers were dried with MgSO , filtered, and concentrated under vacuum. Purification of the crude residue by flash chromatography (50% Et2O / 50% hexane) on silica gel gave the title compound (10.99 g, 38.6%). EI-MS m/z 220(M+H+) Rt (1.20 min).
Ethyl 1-azabicy clo [2.2.2 Joctane-4-carboxylate
A solution of ethyl l-(2-chloroethyl)-4-piperidinecarboxylate (20.42g, 92.9 mmol) in THF (600 mL) was cooled to -50 °C under Ar. LDA (2.0 M in heptane/THF/ethyl benzene, 70 mL,140 mmol) was slowly added to the solution at -50 °C over 25 min. The reaction was allowed to warm up to room temperature over 16 h. The reaction was quenched with K2CO3 (saturated aqueous) (500 mL) and extracted with Et2O (3 x 500mL). The combined organic layers were dried over MgSO4, filtered, and concentrated under vacuum. The resulting orange oil was co-evaporated three times with DCM to remove excess ethyl benzene, resulting in the title compound (16.29 g, 95.7%). EI-MS m/z 184(M+H+) Rt (1.08 min).
1 -Azabicyclo[2.2.2 oct-4-yl(diphenyl)methanol A solution of phenyllithium (1.5-1.7 M in 70 cyclohexane / 30 ether, 20.0 mL, 32 mmol) was chilled down to -30 °C under Ar. Ethyl 1-azabicy clo [2.2.2] octane-4- carboxylate (1.51g, 8.23 mmol) in THF (20 mL) was slowly added to the reaction mixture at -30 °C over 25 min. The reaction was allowed to warm up to room temperature over 16 h. The reaction was quenched with H2O and then evaporated to dryness under vacuum. H2O and EtOAc were added, causing a white solid to crash out.
This solid was filtered off, to give the title compound (0.79 g). The aqueous phase was further extracted with EtOAc, the combined organic layers were dried over MgSO4, filtered, and concentrated under vacuum. The crude product was treated with EtOAc and hexane and filtered to yield more of the title compound (0.67 g). Total yield (1.46 g, 60.7%). EI-MS m/z 294(M+H+) Rt (1.37 min).
Example 2; Preparation of 4-[hydroxy(diphenyl)methyl]-l-(2-phenyIethyl)-l- azoniabicyclo [2.2.2] octane bromide.
To a solution of l-azabicyclo[2.2.2]oct-4-yl(diphenyl)methanol (0.0775 g, 0.264 mmol) in CH3CN / DCM / MeOH (2 mL / 2 mL/ 1 mL) was added (2-bromoethyl)benzene (0.38 mL, 2.78 mmol). The solution was allowed to stir at room temperature for 4 days and then concentrated under vacuum to give a white solid. This residue was dissolved in DMSO and purified by preparatory HPLC to give the title compound (0.0612 g, 48.6%). EI-MS m/z 398(M+) Rt (2.06 min).
Example 3: Preparation of 4-[hydroxy(diphenyI)methyl]-l-[2-(phenyloxy)ethyl]- l-azoniabicyclo[2.2.2]octane bromide.
General procedure for salt formation without HPLC purification. To a solution of l-azabicyclo[2.2.2]oct-4-yl(diphenyl)methanol (0.055 Og, 0.187 mmol) in 2 CH3CN / 3 CHC13 (2.5 mL) was added 2-bromoethyl phenyl ether (0.06 Og, 0.29 mmol). The solution was stirred at 60 °C for 16 h. The reaction was cooled down to room temperature and then diluted with ethyl acetate and hexane causing a solid to crash out of solution. This solid was filtered off, and washed with hexane to give the title compound (0.063 g, 67.6%). EI-MS m/z 414(M+) Rt (1.94 min).
Example 4: Preparation of l-(cycϊopropyImethyl)-4-[hydroxy(diphenyl)methyl]-l- azoniabic clo [2.2.2] octane bromide.
General procedure for salt formation with HPLC purification. To a solution of l-azabicyclo[2.2.2]oct-4-yl(diphenyl)methanol (0.0552 g, 0.188 mmol) in 2 CH3CN / 3 CHC13 (2.5mL) was added (bromomethyl) cyclopropane (0.025 mL, 0.257 mmol). The solution was heated at 60 °C for 16 h, cooled down to room temperature and the solvents evaporated under vacuum. The residue was taken up in 2.5 mL of DMSO and purified by preparatory HPLC (without TFA) to give the title compound (0.031 9g, 39.9%). EI-MS m/z 348(M+) Rt (1.69 min).
Example 5: Preparation of 4-[hydroxy(diphenyl)methyl]-l-(2-oxo-2-phenyIethyI)- 1-azoniabic clo [2.2.2] octane bromide.
Following the general procedure outlined in Example 4, 1-azabicy clo [2.2.2] oct-4- yl(diphenyl)methanol (0.0567 g, 0.193 mmol) and 2-bromo-l-phenylethanone (0.0487 g, 0.245 mmol) in 2 CH3CN / 3 CHC13 (2.5 mL) were reacted to give the desired product (0.0410 g, 43.0%). EI-MS m/z 412(M+) Rt (1.90 min).
Example 6: Preparation of 4-[hydroxy(diphenyl)methyl]-l-[3-(phenyloxy)propyl]- l-azoniabicycIo[2.2.2]octane bromide.
Following the general procedure outlined in Example 3, l-azabicyclo[2.2.2]oct-4- yl(diphenyl)methanol (0.045 g, 0.153 mmol) and 3-bromopropyl phenyl ether (0.035 mL, 0.222 mmol) in 2 CH3CN / 3 CHC13 (3.0 mL) were reacted to give the desired product (0.0662 g, 86.0%). EI-MS m/z 428(M+) Rt (1.97 min).
Example 7: Preparation of 4-[hydroxy(diphenyl)methyl]-l-[4-(phenyloxy)butyl]- 1-azoniabicy clo [2.2.2] octane bromide.
Following the general procedure outlined in Example 4, 1-azabicy clo [2.2.2] oct-4- yl(diphenyl)methanol (0.0604 g, 0.206 mmol) and 4-bromobutyl phenyl ether (0.106 g, 0.463 mmol) in 2 CH3CN / 3 CHC13 (5.0 mL) were reacted to give the desired product
(0.0649 g, 64.9%). EI-MS m/z 442(M+) Rt (2.13 min). Example 8: Preparation of 4-[hydroxy(diphenyl)methyl]-l-[2-(tetrahydro-2H- pyran-2-yloxy)ethyl]-l-azoniabicyclo[2.2.2]octane bromide.
Following the general procedure outlined in Example 4, l-azabicyclo[2.2.2]oct-4- yl(diphenyl)methanol (0.0696 g, 0.237 mmol) and 2-[(2-bromoethyl)oxy]tetrahydro- 2H-pyran (0.080 mL, 0.529 mmol) in 2 CH3CN / 3 CHC13 (5.0 mL) were reacted to give the desired product (0.0348 g, 31.6%). EI-MS m/z 422(M+) Rt (1.85 min).
Example 9: Preparation of 4-[hydroxy(diphenyl)methyl]-l-{4- [(phenylmethyl)oxy]butyl}-l-azoniabicyclo[2.2.2]octane bromide.
Following the general procedure outlined in Example 4, l-azabicyclo[2.2.2]oct-4- yl(diphenyl)methanol (0.0646 g, 0.220 mmol) and 4-bromobutyl phenylmethyl ether (0.090 mL, 0.472 mmol) in 2 CH3CN / 3 CHC13 (5.0 mL) were reacted to give the desired product (0.0531 g, 48.3%). EI-MS m/z 456(M+) Rt (2.09 min).
Example 10: Preparation of 4-[hydroxy(diphenyl)methyl]-l-{3- [(phenylmethyϊ)oxy]propyl}-l-azoniabicyclo[2.2.2]octane bromide.
Following the general procedure outlined in Example 4, l-azabicyclo[2.2.2]oct-4- yl(diphenyl)methanol (0.0677 g, 0.231 mmol) and 3-bromopropyl phenylmethyl ether (0.070 mL, 0.396 mmol) in 2 CH3CN / 3 CHC13 (4.0 mL) were reacted to give the desired product (0.0663 g, 55.2%). EI-MS m/z 442(M+) Rt (2.23 min).
Example 11: Preparation of l-{2-[(2,4-dibromophenyl)oxy]ethyl}-4- [hydroxy(diphenyl)methyl]-l~azoniabicyclo[2.2.2]octane bromide.
Following the general procedure outlined in Example 4, 1-azabicyclo [2.2.2] oct-4- yl(diphenyl)methanol (0.0557 g, 0.190 mmol) and 2-bromoethyl 2,4-dibromophenyl ether (0.110 g, 0.306 mmol) in 2 CH3CN / 3 CHC13 (4.0 mL) were reacted to give the desired product (0.0525 g, 43.8%). EI-MS m/z 572(M+) Rt (2.26 min). Example 12: Preparation of l-(3-bromopropyl)-4- hydroxy(diphenyl)methyl]-l- azoniabicy clo [2.2.2] octane bromide.
Following the general procedure outlined in Example 3, l-azabicyclo[2.2.2]oct-4- yl(diphenyl)methanol (0.0979 g, 0.334 mmol) and 1,3-dibromopropane (0.35 mL,
3.448 mmol) in 2 CH3CN / 3 CHCL, (15.0 mL) were reacted to give the desired product
(0.0712 g, 43.1%). EI-MS m/z 415(M+) Rt (1.79 min).
Example 13: Preparation of 4-[hydroxy(diphenyι)methyl]-l-(tetrahydro-2JfiT- pyran-2-ylmethyI)-l~azoniabicyclo [2.2.2] octane bromide.
Following the general procedure outlined in Example 4, l-azabicyclo[2.2.2]oct-4- yl(diphenyl)methanol (0.0677 g, 0.231 mmol) and 3-(bromomethyl)tetrahydro-2H- pyran (0.050 mL, 0.390 mmol) in 2 CH3CN / 3 CHC13 (4.0 mL) were reacted to give the desired product (0.0508 g, 50.8%). EI-MS m/z 392(M+) Rt (1.84 min).
Example 14: Preparation of l-(l,3-dioxolan-2-ylmethyl)-4- [hydroxy(diphenyl)methyl]-l-azoniabicyclo[2.2.2]octane bromide.
Following the general procedure outlined in Example 4, l-azabicyclo[2.2.2]oct-4- yl(diphenyl)methanol (0.0574 g, 0.196 mmol) and 2-(bromomethyl)-l,3-dioxolane (0.040 mL, 0.386 mmol) in 2 CH3CN / 3 CHC13 (4.0 mL) were reacted to give the desired product (0.0112 g, 12.4%). EI-MS m/z 380(M+) Rt (1.64 min).
Example 15: Preparation of l-ethyI-4-[hydroxy(diphenyI)methyl]-l- azoniabicyclo [2.2.2] octane bromide.
Following the general procedure outlined in Example 3, l-azabicyclo[2.2.2]oct-4- yl(diphenyl)methanol (0.0581 g, 0.198 mmol) and bromoethane (0.030 mL, 0.402 mmol) in 2 CH3CN / 3 CHC13 (4.0 mL) were reacted to give the desired product
(0.0434 g, 54.9%). EI-MS m/z 322(M+) Rt (1.56 min). Example 16: Preparation of 4-[hydroxy(diphenyl)methyl]-l-nonyl-l- azoniabicy clo [2.2.2] octane bromide.
Following the general procedure outlined in Example 4, l-azabicyclo[2.2.2]oct-4- yl(diphenyl)methanol (0.0561 g, 0.191 mmol) and 1-bromononane (0.055 mL, 0.288 mmol) in 2 CH3CN / 3 CHC13 (4.0 mL) were reacted to give the desired product
(0.0435 g, 45.8%). EI-MS m/z 420(M+) Rt (2.34 min).
Example 17: Preparation of 4-[hydroxy(diphenyl)methyl]-l-(4-penten-l-yI)-l- azoniabicyclo [2.2.2] octane bromide.
Following the general procedure outlined in Example 3, l-azabicyclo[2.2.2]oct-4- yl(diphenyl)methanol (0.0608 g, 0.207 mmol) and 5-bromo-l-pentene (0.045 mL, 0.380 mmol) in 2 CH3CN / 3 CHC13 (4.0 mL) were reacted to give the desired product (0.0806 g, 88.6%). EI-MS m/z 362(M+) Rt (1.88 min).
Example 18: Preparation of 4-[hydroxy(diphenyl)methyl]-l-(2-hydroxyethyl)-l- azoniabicyclo [2.2.2] octane bromide.
Following the general procedure outlined in Example 3, l-azabicyclo[2.2.2]oct-4- yl(diρhenyl)methanol (0.0638 g, 0.217 mmol) and 2-bromoethanol (0.035 mL, 0.494 mmol) in 2 CH3CN / 3 CHC13 (4.0 mL) were reacted to give the desired product
(0.0541 g, 60.1%). EI-MS m/z 338(M+) Rt (1.42 min).
Example 19: Preparation of l-(5-hexen-l-yl)-4-[hydroxy(diphenyl)methyl]-l- azoniabicy clo [2.2.2] octane bromide.
Following the general procedure outlined in Example 3, l-azabicyclo[2.2.2]oct-4- yl(diphenyl)methanol (0.0637 g, 0.217 mmol) and 6-bromo-l -hexene (0.050 mL, 0.373 mmol) in 2 CH3CN / 3 CHC13 (5.0 mL) were reacted to give the desired product
(0.0664 g, 67.1%). EI-MS m/z 376(M+) Rt (1.90 min). Example 20: Preparation of 4-[hydroxy(diphenyl)methyl]-l-methyl-l- azoniabicyclo [2.2.2] octane bromide.
Following the general procedure outlined in Example 3, 1-azabicyclo [2.2.2] oct-4- yl(diphenyl)methanol (0.0638 g, 0.217 mmol) and bromomethane (2.0 M in t- Butylmethyl ether, 0.250 mL, 0.500 mmol) in 2 CH3CN / 3 CHC13 (4.0 mL) were reacted to give the desired product (0.0739 g, 88.0%). EI-MS m/z 308(M+) Rt (1.58 min).
Example 21: Preparation of 4-[hydroxy(diphenyl)methyl]-l-[2-(methyloxy)ethyl]- l-azoniabicycIo[2.2.2]octane bromide.
Following the general procedure outlined in Example 4, 1-azabicyclo [2.2.2] oct-4- yl(diphenyl)methanol (0.0597 g, 0.203 mmol) and 2-bromoethyl methyl ether (0.030 mL, 0.319 mmol) in 2 CH3CN / 3 CHC13 (4.0 mL) were reacted to give the desired product (0.0372 g, 42.8%). EI-MS m/z 352(M+) Rt (1.69 min).
Example 22: Preparation of l-[2-(l,3-dioxo-l,3-dihydro-2H-isoindol-2-yl)ethyl]-4- [hydroxy(diphenyl)methyl]-l-azoniabicyclo[2.2.2]octane bromide.
Following the general procedure outlined in Example 3, l-azabicyclo[2.2.2]oct-4- yl(diphenyl)methanol (0.0916 g, 0.312 mmol) and 2-(2-bromoethyl)-lH-isoindole- l,3(2H)-dione (0.130 g, 0.512 mmol) in 2 CH3CN / 3 CHC13 (4.0 mL) were reacted to give the desired product (0.0881 g, 51.8%). EI-MS m/z 467(M+) Rt (1.91 min).
Example 23: Preparation of l-[3-(l,3-dioxo-l,3-dihydro-2H-isoindol-2-yl)propyl]- 4~[hydroxy(diphenyl)methyl]-l-azoniabicycIo[2.2.2]oetane bromide.
Following the general procedure outlined in Example 3, l-azabicyclo[2.2.2]oct-4- yl(diphenyl)methanol (0.0861 g, 0.293 mmol) and 2-(3-bromopropyl)-lH-isoindole- l,3(2H)-dione (0.118 g, 0.440 mmol) in 2 CH3CN / 3 CHC13 (5.0 mL) were reacted to give the desired product (0.1319 g, 82.4%). EI-MS m/z 481(M+) Rt (1.90 min). Example 24: Preparation of 4-[hydroxy(diphenyϊ)methyl]-l-(3-phenylpropyl)-l- azoniabicyclo [2.2.2] octane bromide.
Following the general procedure outlined in Example 3, l-azabicyclo[2.2.2]oct-4- yl(diphenyl)methanol (0.0625 g, 0.213 mmol) and (3-bromopropyl)benzene (0.050 mL, 0.329 mmol) in 2 CH3CN / 3 CHC13 (5.0 mL) were reacted to give the desired product
(0.0722 g, 72.2%). EI-MS m/z 412(M+) Rt (2.01 min).
Example 25: Preparation of 4-[hydroxy(diphenyI)methyl]-l-(2-{[2- (methyIoxy)ethyl]oxy}ethyl)-l-azoniabicyclo[2.2.2]octane bromide.
Following the general procedure outlined in Example 3, l-azabicyclo[2.2.2]oct-4- yl(diphenyl)methanol (0.0665 g, 0.227 mmol) and l-bromo-2-{[2- (methyloxy)ethyl]oxy}ethane (0.05 5mL, 0.405 mmol) in 2 CH3CN / 3 CHC13 (4.0 mL) were reacted to give the desired product (0.0843 g, 78.8%). EI-MS m/z 396(M+) Rt (1.64 min).
Example 26: Preparation of l-[4-(ethyloxy)-4-oxobutyl]-4- [hydroxy(diphenyl)methyl]-l-azoniabicyclo[2.2.2]octane bromide.
Following the general procedure outlined in Example 4, l-azabicyclo[2.2.2]oct-4- yl(diphenyl)methanol (0.0679 g, 0.231 mmol) and ethyl 4-bromobutanoate (0.055 mL, 0.524 mmol) in 2 CH3CN / 3 CHC13 (4.0 mL) were reacted to give the desired product (0.0637 g, 57.9%). EI-MS m/z 408(M+) Rt (1.80 min).
Example 27: Preparation of l-azabicycIo[2.2.2]oct-4-yl(di-2-thienyI)methanol.
A solution of 2-thienyllithium (l.OM in THF, 9.10mL, 9.10 mmol) was chilled down to -30°C under Ar. Ethyl l-azabicyclo[2.2.2]octane-4-carboxylate (0.4196 g, 2.289 mmol) in THF (8 mL) was slowly added to the reaction mixture over 20 min. The reaction was allowed to warm up to room temperature over 16 h. The reaction was quenched with water and then evaporated to dryness. H2O and DCM were added, causing a light brown solid to crash out. This solid was filtered off to give the title compound (0.4161 g, 59.5%). EI-MS m/z 306(M+H+) Rt (1.35 min).
Example 28: Preparation of 4-[hydroxy(di-2-thienyl)methyl]-l-[2- (phenyloxy)ethyl]-l-azoniabicyclo[2.2.2]octane bromide.
Following the general procedure outlined in Example 4, l-azabicyclo[2.2.2]oct-4- yl(di-2-thienyl)methanol (0.0693 g, 0.227 mmol) and 2-bromoethyl phenyl ether (0.056 g, 0.279 mmol) in IMeOH/ 1 CHC13 (3.0 mL) were reacted to give the desired product
(0.0822 g, 74.7%). EI-MS m z 426(M+) Rt (2.00 min).
Example 29: Preparation of 4-[hydroxy(di-2-thienyl)methyl]-l-[3- (phenyloxy)propyl]-l-azoniabicyclo[2.2.2]octane bromide.
Following the general procedure outlined in Example 4, l-azabicyclo[2.2.2]oct-4- yl(di-2-thienyl)methanol (0.0578 g, 0.189 mmol) and 3-bromopropyl phenyl ether (0.033 mL, 0.209 mmol) in IMeOH/ 1 CHC13 (4.0 mL) were reacted to give the desired product (0.0448 g, 45.4%). EI-MS m/z 440(M+) Rt (1.94 min).
Example 30: Preparation of 4-[hydroxy(di-2-thienyI)methyl]-l-(2-phenyIethyI)-l- azoniabic clo [2.2.2] octane bromide.
Following the general procedure outlined in Example 4, 1 -azabicy clo [2.2.2] oct-4- yl(di-2-thienyl)methanol (0.0658 g, 0.215 mmol) and (2-bromoethyl)benzene (0.050 mL, 0.366 mmol) in IMeOH/ 1 CHC13 (4.0 mL) were reacted to give the desired product (0.051 4g, 48.9%). EI-MS m/z 410(M+) Rt (1.83 min). Example 31: Preparation of 4-[hydroxy(di-2-thienyl)methyl]-l-(3-phenylpropyι)- l-azoniabicyclo[2.2.2]octane bromide.
Following the general procedure outlined in Example 4, l-azabicyclo[2.2.2]oct-4- yl(di-2-thienyl)methanol (0.0688 g, 0.225 mmol) and (3-bromopropyl)benzene (0.070 mL, 0.460 mmol) in IMeOH/ 1 CHC13 (4.0 mL) were reacted to give the desired product (0.0685 g, 62.3%). EI-MS m/z 424(M+) Rt (1.97 min).
Example 32: Preparation of l-butyl-4-[hydroxy(di~3-thienyI)methyl]-l- azoniabicyclo [2.2.2] octane bromide.
A solution of «-Butyl lithium (2.5M in hexanes, 5.0 mL, 12.5 mmol) was chilled to -78
°C under Ar. 3-Bromothiophene (1.15 mL, 12.3 mmol) dissolved in ethyl ether (4.0 mL) was slowly added to the reaction mixture. The reaction was stirred for 30 min and then ethyl l-azabicyclo[2.2.2]octane-4-carboxylate (0.7640 g, 4.16 mmol) in THF/
Et2O (4 mL/ 4 mL) was added. The reaction was allowed to warm up from -78 °C to room temperature over 16 h then slowly quenched with water. The reaction was concentrated and the resulting brown solid was taken up in water and DCM. The organic phase was separated, dried over MgSO , filtered and concentrated under vacuum to give a brown solid. The solid was dissolved in DMSO and purified by preparatory HPLC to give the title compound (0.1736 g, 9.4%). EI-MS m/z 362(M+) Rt (1.73 min).
Example 33: Preparation of l-azabicyclo[2.2.2]oct-4-yl(di-3-thienyl)methanol.
A solution of t-Butyl lithium (1.7M in pentanes, 5.8 mL, 9.86 mmol) was chilled to -78
°C under Ar. 3-Bromothiophene (0.46 mL, 4.90 mmol) dissolved in THF (4.0 mL) was slowly added to the reaction mixture over 6 min. The reaction was stirred for 30 min and then ethyl l-azabicyclo[2.2.2]octane-4-carboxylate (0.3132 g, 1.71 mmol) in THF (4 mL) was added. The reaction was allowed to warm up from -78 °C to room temperature over 16 h. After 14 hours, the reaction was slowly quenched with water. EtOAc was added, causing a grey solid to crash out. The solid was filtered off to give the title compound (0.3375 g, 64.6%). EI-MS m/z 306(M+H)+ Rt (1.27 min).
Example 34: Preparation of 4-[hydroxy(di-3-thienyl)methyl]-l-[2- (phenyloxy)ethyl]-l-azoniabicyclo[2.2.2]octane bromide.
Following the general procedure outlined in Example 4, 1-azabicyclo [2.2.2] oct-4- yl(di-3-thienyl)methanol (0.0787 g, 0.258 mmol) and 2-bromoethyl phenyl ether (0.0839 g, 0.417 mmol) in 2MeOH7 3 CHC13 / 2 CH3CN (5.0 mL) were reacted to give the desired product (0.0709 g, 54.5%). EI-MS m/z 426(M+) Rt (1.85 min).
Example 35: Preparation of 4-[hydroxy(di-3-thienyl)methyl]~l-[3~ (phenyloxy)propyl]-l-azoniabicyclo[2.2.2]octane bromide.
Following the general procedure outlined in Example 4, l-azabicyclo[2.2.2]oct-4- yl(di-3-thienyl)methanol (0.0808 g, 0.264 mmol) and 3-bromopropyl phenyl ether (0.070 mL, 0.444 mmol) in 2MeOH/ 3 CHC13 / 2 CH3CN (5.0 mL) were reacted to give the desired product (0.0613 g, 44.7%). EI-MS m/z 440(M+) Rt (2.05 min).
Example 36: Preparation of l~butyl-4-[hydroxy(diphenyl)methyl]-l- azoniabic clo [2.2.2] octane bromide.
Following the general procedure outlined in Example 3, l-azabicyclo[2.2.2]oct-4- yl(diρhenyl)methanol (0.0496 g, 0.169 mmol) and 1-bromobutane (0.030 mL, 0.279 mmol) in 2 CH3CN / 3 CHC13 (4.0 mL) were reacted to give the desired product
(0.0509 g, 70.7%). EI-MS m/z 350(M+) Rt (1.83 min).
Example 37: Preparation of l-hexyl-4-[hydroxy(diphenyl)methyl]-l- azoniabicy clo [2.2.2] octane bromide.
Following the general procedure outlined in Example 3, l-azabicyclo[2.2.2]oct-4- yl(diphenyl)methanol (0.0498 g, 0.170 mmol) and 1-bromohexane (0.040 mL, 0.285 mmol) in 2 CH3CN / 3 CHC13 (4.0 mL) were reacted to give the desired product (0.0562 g, 73.0%). EI-MS m/z 378(M+) Rt (2.09 min).
Example 38: Preparation of 4-[hydroxy(diphenyϊ)methyl]-l-propyl-l- azoniabicyclo [2.2.2] octane bromide.
Following the general procedure outlined in Example 3, l-azabicyclo[2.2.2]oct-4- yl(diphenyl)methanol (0.0518 g, 0.176 mmol) and 1-bromopropane (0.030 mL, 0.330 mmol) in 2 CH3CN / 3 CHC13 (4.0 mL) were reacted to give the desired product (0.0548 g, 75.1%). EI-MS m/z 336(M+) Rt (1.97 min).
Example 39: Preparation of 4-[hydroxy(diphenyl)methyl]-l-(3-{[2- (methyloxy)phenyl] oxy}propyl)-l-azoniabicyclo [2.2.2] octane bromide.
Following the general procedure outlined in Example 3, l-azabicyclo[2.2.2]oct-4- yl(diphenyl)methanol (0.0467 g, 0.159 mmol) and l-[(3-bromopropyl)oxy]-2- (methyloxy)benzene (0.0541 g, 0.221 mmol) in 2 CH3CN / 3 CHC13 (4.0 mL) were reacted to give the desired product (0.0625 g, 73.5%). EI-MS m/z 458(M+) Rt (1.96 min).
Example 40: Preparation of 4-[hydroxy(diphenyl)methyI]-l-{3-[(2- hydroxyphenyl)oxy]propyl}-l-azoniabicyclo[2.2.2]octane bromide.
Following the general procedure outlined in Example 3, 1-azabicyclo [2.2.2] oct-4- yl(diphenyl)methanol (0.0505 g, 0.172 mmol) and 2-[(3-bromopropyl)oxy]phenol (0.0547 g, 0.236 mmol) in 2 CH3CN / 3 CHC13 (4.0 mL) were reacted to give the desired product (0.0675 g, 75.0%). EI-MS m/z 444(M+) Rt (1.91 min). Example 41: Preparation of 4-[hydroxy(diphenyl)methyl]-l-[3-(2- naphthalenyloxy)propyl]-l-azoniabicyclo[2.2.2]octane bromide.
Following the general procedure outlined in Example 3, l-azabicyclo[2.2.2]oct-4- yl(diphenyl)methanol (0.0472 g, 0.160 mmol) and 3-bromopropyl 2-naphthalenyl ether (0.0618 g, 0.233 mmol) in 2 CH3CN / 3 CHC13 (4.0 mL) were reacted to give the desired product (0.0567 g, 63.7%). EI-MS m/z 478(M+) Rt (2.22 min).
Example 42: Preparation of l-{3-[(3-chlorophenyl)oxy]propyl}-4- [hydroxy(diphenyι)methyl]-l-azoniabicyclo[2.2.2]octane bromide.
Following the general procedure outlined in Example 3, l-azabicyclo[2.2.2]oct-4- yl(diphenyl)methanol (0.0479 g, 0.163 mmol) and 3-bromopropyl 3-chlorophenyl ether (0.0552 g, 0.221 mmol) in 2 CH3CN / 3 CHC13 (4.0 mL) were reacted to give the desired product (0.0655 g, 74.4%). EI-MS m/z 462(M+) Rt (2.17 min).
Example 43: Preparation of l~{3-[(4-bromophenyl)oxy]propyl}-4- [hydroxy(diphenyl)methyl]-l-azoniabicyclo[2.2.2]octane bromide.
Following the general procedure outlined in Example 3, l-azabicyclo[2.2.2]oct-4- yl(diphenyl)methanol (0.0486 g, 0.165 mmol) and 4-bromophenyl 3-bromopropyl ether (0.0630 g, 0.214 mmol) in 2 CH3CN / 3 CHC13 (4.0 mL) were reacted to give the desired product (0.0731 g, 75.4%). EI-MS m/z 506(M+) Rt (2.18 min).
Example 44: Preparation of 4-[hydroxy(diphenyl)methyl]-l-{3-[(4- nitrophenyϊ)oxy]propyl}-l-azoniabicyclo[2.2.2]octane bromide.
Following the general procedure outlined in Example 3, l-azabicyclo[2.2.2]oct-4- yl(diphenyl)methanol (0.0468 g, 0.159 mmol) and 3-bromopropyl 4-nitrophenyl ether (0.0550 g, 0.211 mmol) in 2 CH3CN / 3 CHC13 (4.0 mL) were reacted to give the desired product (0.0590 g, 67.0%). EI-MS m/z 473(M+) Rt (2.06 min). Example 45: Preparation of 4-[hydroxy(diphenyl)methyl]-l-[3-({2- [(phenylmethyl)oxy]phenyl}oxy)propyl]-l-azoniabicyclo[2.2.2]octane bromide.
Following the general procedure outlined in Example 3, l-azabicyclo[2.2.2]oct-4- yl(diphenyl)methanol (0.0492 g, 0.168 mmol) and l-[(3-bromopropyl)oxy]-2-
[(phenylmethyl)oxy]benzene (0.0706 g, 0.220 mmol) in 2 CH3CN / 3 CHC13 (4.0 mL) were reacted to give the desired product (0.0735 g, 71.4%). EI-MS m/z 533(M+) Rt (2.25 min).
Example 46: Preparation of l-{3-[(2-bromophenyl)oxy]propyl}-4- [hydroxy(diphenyl)methyl]-l-azoniabicyclo[2.2.2]octane bromide.
Following the general procedure outlined in Example 3, l-azabicyclo[2.2.2]oct-4- yl(diphenyl)methanol (0.0472 g, 0.161 mmol) and 2-bromophenyl 3-bromopropyl ether (0.0648 g, 0.220 mmol) in 2 CH3CN / 3 CHC13 (4.0 mL) were reacted to give the desired product (0.0703 g, 74.8%). EI-MS m/z 507(M+) Rt (2.18 min).
Example 47: Preparation of 4-[hydroxy(diphenyl)methyl]-l-[3-({4- [(phenylmethyl)oxy]phenyl}oxy)propyl]-l-azoniabicyclo[2.2.2]octane bromide.
Following the general procedure outlined in Example 3, l-azabicyclo[2.2.2]oct-4- yl(diphenyl)methanol (0.0479 g, 0.163 mmol) and l-[(3-bromopropyl)oxy]-4- [(phenylmethyl)oxy]benzene (0.0730 g, 0.227 mmol) in 2 CH3CN / 3 CHC13 (4.0 mL) were reacted to give the desired product (0.0833 g, 83.3%). EI-MS m/z 534(M+) Rt (2.31 min).
Example 48: Preparation of 4-[hydroxy(diphenyl)methyl]-l-[3- (methyloxy)propyl]-l-azoniabicyclo[2.2.2]octane bromide.
Following the general procedure outlined in Example 3, l-azabicyclo[2.2.2]oct-4- yl(diphenyl)methanol (0.0632 g, 0.215 mmol) and 3-bromopropyl methyl ether (0.0461 g, 0.301 mmol) in 2 CH3CN / 3 CHC13 (4.0 mL) were reacted to give the desired product (0.0826 g, 86.0%). EI-MS m/z 366(M+) Rt (1.55 min).
Example 49: Preparation of 4-[hydroxy(diphenyι)methyl]-l-(2-propen-l-yl)-l- azoniabicyclo [2.2.2] octane bromide.
Following the general procedure outlined in Example 3, l-azabicyclo[2.2.2]oct-4- yl(diphenyl)methanol (0.0577 g, 0.197 mmol) and 3-bromo-l-propene (0.025 mL, 0.289 mmol) in 2 CH3CN / 3 CHC13 (4.0 mL) were reacted to give the desired product (0.0646 g, 79.8%). EI-MS m/z 334(M*) Rt (1.54 min).
Example 50: Preparation of 4-[hydroxy(diphenyl)methyl]-l-(3-{[4- (methyloxy)phenyl]oxy}propyl)-l-azoniabicyclo[2.2.2]octane bromide. Following the general procedure outlined in Example 3, l-azabicyclo[2.2.2]oct-4- yl(diphenyl)methanol (0.0483 g, 0.164 mmol) and l-[(3-bromopropyl)oxy]-4- (methyloxy)benzene (0.052 g, 0.21 mmol) in 2 CH3CN / 3 CHC13 (4.0 mL) were reacted to give the desired product (0.0687 g, 77.5%). EI-MS m/z 458(M+) Rt (2.03 • min).
Example 51: Preparation of [l-(2-aminoethyϊ)-l-azoniabicyclo[2.2.2]oct-4- yl](diphenyι)nιethanoIate trifluoroacetate. To a solution of l-[2-(l,3-dioxo-l,3-dihydro-2H-isoindol-2-yl)ethyl]-4- [hydroxy(diphenyl)methyl]-l -azoniabicy clo [2.2.2] octane bromide (0.078g, 0.142 mmol) in EtOH (4.0 mL) was added hydrazine (0.25 mL, 7.96 mmol). The solution was stirred at room temperature for 16 h and then filtered. The filtrate was concentrated and taken up in 2.5mL of DMSO and purified by preparatory HPLC (with TFA) to give the title compound (0.0200 g, 31.2%). EI-MS m/z 338(M+) Rt (1.28 min). Example 52: Preparation of 4-[bis(4-fluorophenyl)(hydroxy)methyl]-l-[3- (phenyloxy)propyl]-l-azoniabicyclo[2.2.2]octane bromide.
1-azabicyclo f2.2.2Joct-4-ylfbisf4-fluorophenyl)Jmethanol A solution of 4-fluorophenylmagnesiumbromide (1.0 M in THF, 4.4 mL, 4.4 mmol) was chilled down to 0 °C under Ar. Ethyl l-azabicyclo[2.2.2]octane-4-carboxylate
(0.1973 g, 1.08 mmol) in THF (4 mL) was slowly added to the reaction mixture at 0 °C over 20 min. The reaction was allowed to warm up to room temperature and then heated at 60 °C for 16 h. The reaction was chilled in an ice bath, quenched with saturated NH4C1, and concentrated under vacuum. The resulting residue was treated with H2O and extracted with EtOAc. The combined organic layers were dried with MgSO4, filtered, and concentrated under vacuum to yield the desired product (0.3152 g, 88.9%). EI-MS m/z 330(M+H+) Rt (1.65 min).
4-rbis(4-fluorophenyl)(hydroxy)methyl]-l-f3-(phenyloxy)propyll-l- azoniabicyclof2.2.2] octane bromide
Following the general procedure outlined in Example 3, 1-azabicyclo [2.2.2]oct-4- yl[bis(4-fluorophenyl)]methanol (0.0538 g, 0.163 mmol) and 3-bromopropyl phenyl ether (0.0386 mL, 0.245 mmol) in 2 CH3CN / 3 CHC13 (4.0 mL) were reacted to give the desired product (0.058 g, 65.2%). EI-MS m/z 464(M+) Rt (2.16 min).
Example 53: Preparation of 4-[bis(4-fluorophenyϊ)(hydroxy)methyl]~l-{2- [(phenylmethyl)oxy]ethyl}-l~azoniabicyclo[2.2.2]octane bromide.
Following the general procedure outlined in Example 3, 1-azabicyclo [2.2.2] oct-4- yl[bis(4-fluorophenyl)]methanol (0.0489 g, 0.148 mmol) and 2-bromoethyl phenylmethyl ether (0.0352 mL, 0.222 mmol) in 2 CH3CN / 3 CHC13 (4.0 mL) were reacted to give the desired product (0.0534 g, 66.1 %). EI-MS m/z 464(M+) Rt (1.99 min). Example 54: Preparation of 4-(hydroxy{bis[3-(methyloxy)phenyl]}methyl)-l-[3- (phenyloxy)propyl]-l-azoniabicyclo[2.2.2]octane bromide.
1-azabicyclo f2.2.2 Joct-4-ylfbisf3-(methyloxy)phenylJ}methanol A solution of 3-(methyloxy)phenylmagnesiumbromide (1.0 M in THF, 3.3 mL, 3.3 mmol) was chilled down to 0 °C under Ar. Ethyl 1-azabicyclo [2.2.2] octane-4- carboxylate (0.1608 g, 0.877 mmol) in THF (4 mL) was slowly added to the reaction mixture at 0 °C over 20 min. The reaction was allowed to warm up to room temperature and then heated at 60 °C for 16 h. The reaction was chilled in an ice bath, quenched with saturated NH C1, and concentrated under vacuum. The resulting residue was treated with H2O and extracted with EtOAc. The combined organic layers were dried with MgSO4, filtered, and concentrated under vacuum to yield the desired product (0.2881 g, 92.9%).' EI-MS m/z 354(M+H+) Rt (1.46 min).
4-(hydroxy{bisf3-(methyloxy)phenyll)methyl)-l-f3-(phenyloxy)propyl]-l- azoniabicyclo[2.2.21octane bromide
Following the general procedure outlined in Example 3, l-azabicyclo[2.2.2]oct-4- yl{bis[3-(methyloxy)phenyl]}methanol (0.0506 g, 0.143 mmol) and 3-bromopropyl phenyl ether (0.0338 mL, 0.214 mmol) in 2 CH3CN / 3 CHCL, (4.0 mL) were reacted to give the desired product (0.027 g, 33.2%). EI-MS m/z 488(M+) Rt (2.02 min).
Example 55: Preparation of 4-(hydroxy {bis[3-(methyIoxy)phenyI]}methyϊ)-l-{2- [(phenylmethyl)oxy] ethyl}-l-azoniabic clo [2.2.2] octane bromide.
Following the general procedure outlined in Example 3, l-azabicyclo[2.2.2]oct-4- yl{bis[3-(methyloxy)phenyl]}methanol (0.0538 g, 0.152 mmol) and 2-bromoethyl phenylmethyl ether (0.0361 mL, 0.228 mmol) in 2 CH3CN / 3 CHC13 (4.0 mL) were reacted to give the desired product (0.0292 g, 33.8%). EI-MS m/z 488(M+) Rt (2.03 min). Example 56: Preparation of 4-(hydroxy{bis[4-(methyloxy)phenyl]}methyl)-l-[3- (phenyloxy)propyl]-l-azoniabicyclo[2.2.2]octane bromide.
1-azabicyclo f2.2.2Joct-4-yl{bisf4-fmethyloxy)phenylJ}methanol A solution of 4-(methyloxy)phenylmagnesiumbromide (0.5 M in THF, 6.5 mL, 3.25 mmol) was chilled down to 0 °C under Ar. Ethyl l-azabicyclo[2.2.2]octane-4- carboxylate (0.1587 g, 0.866 mmol) in THF (4 mL) was slowly added to the reaction mixture at 0 °C over 20 min. The reaction was allowed to warm up to room temperature and then heated at 60 °C for 16 h. The reaction was chilled in an ice bath, quenched with saturated NH4C1, and concentrated under vacuum. The resulting residue was treated with H O and extracted with EtOAc. The combined organic layers were dried with MgSO4, filtered, and concentrated under vacuum to yield the desired product (0.273 g, 89.0%). EI-MS m/z 354(M+H+) Rt (1.74 min).
4-(hydroxy{bisf3-(methyloxy)phenyl]}methyl)-l-[3-(phenyloxy)propyl]-l- azoniabicyclo 2.2.2 ] octane bromide
Following the general procedure outlined in Example 3, l-azabicyclo[2.2.2]oct-4- yl{bis[4-(methyloxy)phenyl]}methanol (0.0525 g, 0.148 mmol) and 3-bromopropyl phenyl ether (0.0351 mL, 0.222 mmol) in 2 CH3CN / 3 CHC13 (4.0 mL) were reacted to give the desired product (0.0515 g, 61.0%). EI-MS m/z 488(M+) Rt (2.04 min).
Example 57: Preparation of 4-(hydroxy{bis[4-(methyIoxy)phenyl]}methyI)-l-{2- [(phenylmethyl)oxy]ethyl}-l-azoniabicyclo[2.2.2]octane bromide.
Following the general procedure outlined in Example 3, l-azabicyclo[2.2.2]oct-4- yl{bis[4-(methyloxy)phenyl]}methanol (0.0498 g, 0.141 mmol) and 2-bromoethyl phenylmethyl ether (0.0334 mL, 0.211 mmol) in 2 CH3CN / 3 CHC13 (4.0 mL) were reacted to give the desired product (0.0374 g, 46.7%). EI-MS m z 488(M+) Rt (1.94 min). Example 58: Preparation of 4-[bis(3-fluorophenyl)(hydroxy)methyl]-l-[3- (phenyloxy)propyl]-l-azoniabicyclo[2.2.2]octane bromide.
1 -azabicyclof2.2.2 Joct-4-ylfbis (3 -fluorophenyl) Jmethanol A solution of 3-fluorophenylmagnesiumbromide (1.0 M in THF, 3.3 mL, 3.3 mmol) was chilled down to 0 °C under Ar. Ethyl l-azabicyclo[2.2.2]octane-4-carboxylate (0.1756 g, 0.958 mmol) in THF (4 mL) was slowly added to the reaction mixture at 0
°C over 20 min. The reaction was allowed to warm up to room temperature and then heated at 60 °C for 16 h. The reaction was chilled in an ice bath, quenched with saturated NH4C1, and concentrated under vacuum. The resulting residue was treated with H O and extracted with EtOAc. The combined organic layers were dried with MgSO , filtered, and concentrated under vacuum to yield the desired product (0.242 g, 76.7%). EI-MS m/z 330(M+H+) Rt (1.45 min).
4-(hydroxy{bisf3-(methyloxy)phenyl]}methyl)-l-f3-(phenyloxy)propyl]-l- azoniabicyclof2.2.2 ] octane bromide
Following the general procedure outlined in Example 3, l-azabicyclo[2.2.2]oct-4- yl[bis(3-fluorophenyl)]methanol (0.0515 g, 0.156 mmol) and 3-bromopropyl phenyl ether (0.0370 mL, 0.234 mmol) in 2 CH3CN / 3 CHC13 (4.0 mL) were reacted to give the desired product (0.0381 g, 44.8%). EI-MS m/z 464(M+) Rt (2.01 min).
Example 59: Preparation of 4-[bis(3-fluorophenyϊ)(hydroxy)methyI]-l-{2- [(phenylmethyl)oxy]ethyl}-l-azoniabicyclo[2.2.2]octane bromide.
Following the general procedure outlined in Example 3, 1-azabicyclo [2.2.2] oct-4- yl[bis(3-fluorophenyl)]methanol (0.0507 g, 0.154 mmol) and 2-bromoethyl phenylmethyl ether (0.0365 mL, 0.230 mmol) in 2 CH3CN / 3 CHC13 (4.0 mL) were reacted to give the desired product (0.0362 g, 43.2%). EI-MS m z 464(M+) Rt (2.02 min). Example 60: Preparation of 4-{hydroxy[bis(3-methylphenyl)]methyl}-l-[3- (phenyloxy)propyl]-l-azoniabicyclo[2.2.2]octane bromide.
1 -azabicyclof2.2.2 ]oct-4-ylfbis(3-methylphenyl) Jmethanol A solution of 3-methylphenylmagnesiumbromide (1.0 M in THF, 3.3 mL, 3.3 mmol) was chilled down to 0 °C under Ar. Ethyl l-azabicyclo[2.2.2]octane-4-carboxylate (0.1484 g, 0.810 mmol) in THF (4 mL) was slowly added to the reaction mixture at 0
°C over 20 min. The reaction was allowed to warm up to room temperature and then heated at 60 °C for 16 h. The reaction was chilled in an ice bath, quenched with saturated NH4C1, and concentrated under vacuum. The resulting residue was treated with H2O and extracted with EtOAc. The combined organic layers were dried with MgSO , filtered, and concentrated under vacuum to yield the desired product (0.1806 g, 69.4%). EI-MS m/z 322(M+H+) Rt (1.54 min).
4-(hydroxyfbisf3-(methyloxy)phenyl]}methyl)-l-[3-(phenyloxy)propyl]-l- azoniabicyclof2.2.2] octane bromide
Following the general procedure outlined in Example 3, 1-azabicyclo [2.2.2] oct-4- yl[bis(3-methylphenyl)]methanol (0.0487 g, 0.151 mmol) and 3-bromopropyl phenyl ether (0.0358 mL, 0.227 mmol) in 2 CH3CN / 3 CHC13 (4.0 mL) were reacted to give the desired product (0.0284 g, 34.9%). EI-MS m/z 456(M+) Rt (2.14 min).
Example 61: Preparation of 4-{hydroxy[bis(3-methylphenyl)]methyl}-l-{2- [(phenylmethyl)oxy]ethyl}-l~azoniabicyclo[2.2.2]octane bromide.
Following the general procedure outlined in Example 4, 1-azabicy clo [2.2.2] oct-4- yl[bis(3-methylphenyl)]methanol (0.0496 g, 0.154 mmol) and 2-bromoethyl phenylmethyl ether (0.0364 mL, 0.230 mmol) in 2 CH3CN / 3 CHC13 (4.0 mL) were reacted to give the desired product (0.0091 g, 11.0%). EI-MS m/z 456(M+) Rt (2.20 min). Example 62: Preparation of 4-{hydroxy [bis(4~methylphenyι)]methyl}-l-[3- (phenyloxy)propyl]-l-azoniabicyclo[2.2.2]octane bromide.
1 -azάbicyclof2.2.2 ]oct-4-yl[bis(4-methylphenyl) ]methanol A solution of 4-methylphenylmagnesiumbromide (1.0 M in THF, 3.3 mL, 3.3 mmol) was chilled down to 0 °C under Ar. Ethyl l-azabicyclo[2.2.2]octane-4-carboxylate (0.1509 g, 0.823 mmol) in THF (4 mL) was slowly added to the reaction mixture at 0
°C over 20 min. The reaction was allowed to warm up to room temperature and then heated at 60 °C for 16 h. The reaction was chilled in an ice bath, quenched with saturated NH4C1, and concentrated under vacuum. The resulting residue was treated with H2O and extracted with EtOAc. The combined organic layers were dried with MgSO4, filtered, and concentrated under vacuum to yield the desired product (0.2291 g, 86.6%). EI-MS m/z 322(M+H+) Rt (1.57 min).
4-(hydroxy{bisf3-(methyloxy)phenyl]}methyl)-l-f3-(phenyloxy)propyl]-l- azoniabicyclo[2.2.2 ] octane bromide
Following the general procedure outlined in Example 3, l-azabicyclo[2.2.2]oct-4- yl[bis(4-methylphenyl)]methanol (0.0618 g, 0.192 mmol) and 3-bromopropyl phenyl ether (0.0454 mL, 0.288 mmol) in 2 CH3CN / 3 CHC13 (4.0 mL) were reacted to give the desired product (0.0427 g, 41.5%). EI-MS m/z 456(M+) Rt (1.99 min).
Example 63: Preparation of 4-{hydroxy[bis(4-methylphenyι)]methyI}-l-{2- [(phenylmethyl)oxy]ethyl}-l-azoniabicyclo[2.2.2] octane bromide.
Following the general procedure outlined in Example 3, l-azabicyclo[2.2.2]oct-4- yl[bis(4-methylphenyl)]methanol (0.0525 g, 0.163 mmol) and 2-bromoethyl phenylmethyl ether (0.0387 mL, 0.245 mmol) in 2 CH3CN / 3 CHC13 (4.0 mL) were reacted to give the desired product (0.0465 g, 53.1%). EI-MS m/z 456(M+) Rt (2.09 min). Example 64: Preparation of 4-[hydroxy(di-2-naphthalenyl)methyl]-l-[3- (phenyloxy)propyl] -1-azoniabicy clo [2.2.2] octane bromide.
l-azabicyclo[2.2.2]oct-4-yl(di-2-naphthalenyl)methanol A solution of (2-naphthalenyl)magnesiumbromide (0.5 M in THF, 6.5 mL, 3.25 mmol) was chilled down to 0 °C under Ar. Ethyl l-azabicyclo[2.2.2]octane-4-carboxylate (0.1597 g, 0.871 mmol) in THF (4 mL) was slowly added to the reaction mixture at 0
°C over 20 min. The reaction was allowed to warm up to room temperature and then heated at 60 °C for 16 h. The reaction was chilled in an ice bath, quenched with saturated NH C1, and concentrated under vacuum. The resulting residue was treated with H2O and extracted with EtOAc. The combined organic layers were dried with MgSO4, filtered, and concentrated under vacuum to yield the desired product (0.265 g, 77.3%). EI-MS m/z 394(M+H+) Rt (1.90 min).
4-(hydroxy{bisf3-(methyloxy)phenyl])methyl)-l-f3-(phenyloxy)propyl]-l- azoniabicyclo[2.2.2]octane bromide
Following the general procedure outlined in Example 3, l-azabicyclo[2.2.2]oct-4- yl(di-2-naphthalenyι)methanol (0.0547 g, 0.139 mmol) and 3-bromopropyl phenyl ether (0.0329 mL, 0.209 mmol) in 2 CH3CN / 3 CHC13 (4.0 mL) were reacted to give the desired product (0.0268 g, 31.7%). EI-MS m/z 528(M+) Rt (2.88 min).
Example 65: Preparation of 4-[hydroxy(di-2-naphthalenyl)methyl]-l-{2- [(phenylmethyl)oxy]ethyl}-l-azoniabicyclo[2.2.2]octane bromide.
Following the general procedure outlined in Example 3, 1-azabicy clo [2.2.2] oct-4- yl(di-2-naphthalenyl)methanol (0.063.7 g, 0.162 mmol) and 2-bromoethyl phenylmethyl ether (0.0384 mL, 0.243 mmol) in 2 CH3CN / 3 CHC13 (4.0 mL) were reacted to give the desired product (0.0246 g, 25.0%). EI-MS m/z 528(M+) Rt (2.36 min). Example 66: Preparation of l-{3-[(2-fluorophenyl)oxy]propyl}-4- [hydroxy(diphenyl)methyl]-l-azoniabicyclo[2.2.2]octane bromide.
3-bromopropyl 2-fluorophenyl ether To a solution of 2-fluorophenol (0.040 mL, 0.448 mmol) in acetonitrile (4 mL) was added 1,3-dibromopropane (0.450 mL, 4.43 mmol) followed by Cs2CO3 (0.232 g, 0.713 mmol). The reaction mixture was stirred for 24h and then concentrated under vacuum. The resulting residue was treated with H2O (4 mL) and extracted with DCM (8 mL). The organic layer was dried through a phase separator and concentrated under vacuum. The residue was taken up in DMSO and purified by preparatory HPLC (without TFA) to give the title compound (0.0274 g, 26.2%). EI-MS Rt (2.24 min).
l-{3-f(2-fluorophenyl)oxy]yropyl}-4-ϊhydroxy(diphenyl)methyl]-l- azoniabicyclof2.2.2 ] octane bromide Following the general procedure outlined in Example 3, 1-azabicyclo [2.2.2] oct-4- yl(diphenyl)methanol (0.0282 g, 0.0960 mmol) and 3-bromopropyl 2-fluorophenyl ether (0.0274 g, 0.118 mmol) in 2 CH3CN / 3 CHC13 (4.0 mL) were reacted to give the desired product (0.0345 g, 68.3%). EI-MS m/z 446(M+) Rt (1.96 min).
Example 67: Preparation of l-{3-[(3-fluorophenyl)oxy]propyl}-4- [hydroxy(diphenyl)methyl]-l-azoniabicyclo[2.2.2]octane bromide.
3-bromopropyl 3-fluorophenyl ether
To a solution of 3-fiuorophenol (0.040 mL, 0.448 mmol) in acetonitrile (4 mL) was added 1 ,3-dibromopropane (0.450 mL, 4.43 mmol) followed by Cs2CO3 (0.246 g, 0.756 mmol). The reaction mixture was stirred for 24 h and then concentrated under vacuum.
The resulting residue was treated with H2O (4 mL) and extracted with DCM (8 mL).
The organic layer was dried through a phase separator and concentrated under vacuum.
The residue was taken up in DMSO and purified by preparatory HPLC (without TFA) to give the title compound (0.0137 g, 13.2%). EI-MS Rt (2.28 min). l-{3-f(3-fluorophenyl)oxy]propyl}-4-[hydroxy(diphenyl)methyl]-l- azoniabicvclof2.2.2 ] octane bromide
Following the general procedure outlined in Example 3, 1 -azabicy clo [2.2.2] oct-4- yl(diphenyl)methanol (0.0137 g, 0.0467 mmol) and 3-bromopropyl 3 -fluorophenyl ether (0.0137 g, 0.0588 mmol) in 2 CH3CN / 3 CHC13 (4.0 mL) were reacted to give the desired product (0.0130 g, 53.1%). EI-MS m/z 446(M+) Rt (2.03 min).
Example 68: Preparation of l-{3-[(4-fluorophenyϊ)oxy]propyl}-4- [hydroxy(diphenyl)methyl]-l-azoniabicyclo[2.2.2]octane bromide.
3-bromopropyl 4-fluorophenyl ether
To a solution of 4-fluorophenol (0.0567 g, 0.506 mmol) in acetonitrile (4 mL) was added 1,3-dibromopropane (0.520 mL, 5.12 mmol) followed by Cs2CO3 (0.252 g, 0.774 mmol). The reaction mixture was stirred for 24 h and then concenfrated under vacuum. The resulting residue was treated with H2O (4 mL) and extracted with DCM (8 mL). The organic layer was dried through a phase separator and concentrated under vacuum. The residue was taken up in DMSO and purified by preparatory HPLC (without TFA) to give the title compound (0.0173 g, 14.7%). EI-MS Rt (2.25 min).
l-{3-f(4-fluorophenyl)oxylpropyl}-4-fhydroxy(diphenyl)methyl]-l- azoniabicyclo[2.2.2] octane bromide
Following the general procedure outlined in Example 3, 1-azabicy clo [2.2.2] oct-4- yl(diphenyl)methanol (0.0182 g, 0.0621 mmol) and 3-bromopropyl 4-fluorophenyl ether (0.0173 g, 0.0742 mmol) in 2 CH3CN / 3 CHC13 (4.0 mL) were reacted to give the desired product (0.0143 g, 43.7%). EI-MS m/z 446(M+) Rt (1.96 min).
Example 69: Preparation of l-[3-(3-biphenylyloxy)propyl]-4- [hydroxy(diphenyl)methyl]-l-azoniabicyclo[2.2.2]octane bromide.
3-biphenylyl 3-bromopropyl ether
To a solution of 3-biphenylol (0.0574 g, 0.337 mmol) in acetonitrile (4 mL) was added 1,3-dibromopropane (0.340 L, 3.35 mmol) followed by Cs2CO3 (0.172 g, 0.529 mmol). The reaction mixture was stirred for 24 h and then concentrated under vacuum. The resulting residue was treated with H2O (4 mL) and extracted with DCM (8 mL). The organic layer was dried through a phase separator and concentrated under vacuum. The residue was taken up in DMSO and purified by preparatory HPLC (without TFA) to give the title compound (0.0568 g, 57.8%). EI-MS Rt (2.59 min).
l-f3-(3-biphenylyloxy)propyl]-4-[hydroxy(diphenyl)methyl]-l- azoniabicyclof2.2.2 ] octane bromide
Following the general procedure outlined in Example 3, 1 -azabicy clo [2.2.2] oct-4- yl(diphenyl)methanol (0.0433 g, 0.148 mmol) and 3-biphenylyl 3-bromopropyl ether (0.0568 g, 0.196 mmol) in 2 CH3CN / 3 CHC13 (4.0 mL) were reacted to give the desired product (0.0610 g, 70.6%). EI-MS m/z 504(M+) Rt (2.37 min).
Example 70: Preparation of l-[3-(4-biphenylyloxy)propyl]-4- [hydroxy(diphenyl)methyl]-l-azoniabicyclo[2.2.2]octane bromide.
4-biphenylyl 3-bromopropyl ether
To a solution of 4-biphenylol (0.0514 g, 0.302 mmol) in acetonitrile (4 mL) was added
1,3-dibromopropane (0.310 mL, 3.05 mmol) followed by Cs2CO3 (0.154 g, 0.472 mmol). The reaction mixture was stirred for 24h and then concentrated under vacuum.
The resulting residue was treated with H2O (4 mL) and extracted with DCM (8 mL).
The organic layer was dried through a phase separator and concentrated under vacuum.
The residue was taken up in DMSO and purified by preparatory HPLC (without TFA) to give the title compound (0.0562 g, 64.0%). EI-MS Rt (2.62 min).
l-(3-(4-biphenylyloxy)propyl]-4-[hydroxy(diphenyl)methyll-l- azoniabicyclof2.2.21 octane bromide
Following the general procedure outlined in Example 3, l-azabicyclo[2.2.2]oct-4- yl(diphenyl)methanol (0.0437 g, 0.144 mmol) and 4-biphenylyl 3-bromopropyl ether (0.0562 g, 0.194 mmol) in 2 CH3CN / 3 CHC13 (4.0 mL) were reacted to give the desired product (0.0655 g, 75.2%). EI-MS m/z 504(M+) Rt (2.24 min). Example 71: Preparation of 4-[hydroxy(diphenyl)methyl]-l-{3-[(3- nitrophenyl)oxy]propyl}-l-azoniabicyclo[2.2.2]octane bromide.
3-bromopropyl 3-nitrophenyl ether To a solution of 3-nitrophenol (0.0689 g, 0.495 mmol) in acetonitrile (4 mL) was added 1,3-dibromopropane (0.500 mL, 3.05 mmol) followed by Cs2CO3 (0.244 g, 0.748 mmol). The reaction mixture was stirred for 24h and then concentrated under vacuum. The resulting residue was treated with H2O (4 mL) and extracted with DCM (8 mL). The organic layer was dried through a phase separator and concentrated under vacuum. The residue was taken up in DMSO and purified by preparatory HPLC (without TFA) to give the title compound (0.0730 g, 56.6%). EI-MS Rt (2.20 min).
4-fhydroxy(diphenyl)methyl]-l-{3-f(3-nitrophenyl)oxy]propyl}-l- azoniabicyclo[2.2.2 ] octane bromide Following the general procedure outlined in Example 3, l-azabicyclo[2.2.2]oct-4- yl(diphenyl)methanol (0.0608 g, 0.207 mmol) and 3-bromopropyl 3-nitrophenyl ether (0.0730 g, 0.281 mmol) in 2 CH3CN / 3 CHC13 (4.0 mL) were reacted to give the desired product (0.0942 g, 82.2%). EI-MS m/z 474(M+) Rt (2.04 min).
Example 72: Preparation of 4-[hydroxy(diphenyι)methyl]-l-{3-[(2- methylphenyl)oxy]propyl}-l-azoniabicyc!o[2.2.2]octane bromide.
3-bromopropyl 2-methylphenyl ether
To a solution of 2-methylphenol (0.0954 g, 0.924 mmol) in acetonitrile (4 mL) was added 1 ,3-dibromopropane (1.00 mL, 9.85 mmol) followed by Cs2CO3 (0.469 g, 1.44 mmol). The reaction mixture was stirred for 24h and then concentrated under vacuum.
The resulting residue was treated with H O (4 mL) and extracted with DCM (8 mL).
The organic layer was dried through a phase separator and concentrated under vacuum.
The residue was taken up in DMSO and purified by preparatory HPLC (without TFA) to give the title compound (0.0934 g, 44.1 %). EI-MS Rt (2.45 min). 4-fhydroxy(diphenyl)methyl]-l-{3-f(2-methylphenyl)oxy]propyl}-l- azoniabicyclof2.2.2 ] octane bromide
Following the general procedure outlined in Example 3, l-azabicyclo[2.2.2]oct-4- yl(diphenyl)methanol (0.0447 g, 0.152 mmol) and 3-bromopropyl 2-methylphenyl ether (0.0934 g, 0.407 mmol) in 2 CH3CN / 3 CHC13 (4.0 mL) were reacted to give the desired product (0.0586 g, 76.5%). EI-MS m/z 442(M+) Rt (2.17 min).
Example 73: Preparation of l-(3-{[3-(diethylamino)phenyI]oxy}propyϊ)-4- [hydroxy (diphenyl)methyl] -1-azoniabicyclo [2.2.2] octane bromide.
3-[(3-bromopropyl)oxy]-N,N-diethylaniline
To a solution of 3-(diethylamino)phenol (0.0104 g, 0.631 mmol) in acetonitrile (4 mL) was added 1,3-dibromopropane (0.640 mL, 6.30 mmol) followed by Cs2CO3 (0.313 g, 0.961 mmol). The reaction mixture was stirred for 24h and then concentrated under vacuum. The resulting residue was treated with H2O (4 mL) and extracted with DCM (8 mL). The organic layer was dried through a phase separator and concentrated under vacuum. The residue was taken up in DMSO and purified by preparatory HPLC (without TFA) to give the title compound (0.0314 g, 17.4%). EI-MS m/z 286(M+H+) Rt (1.59 min).
l-(3-f[3-(diethylamino)phenyl]oxy}propyl)-4-fhydroxy(diphenyl)methyl]-l- azoniabicyclof2.2.2] octane bromide
Following the general procedure outlined in Example 3, l-azabicyclo[2.2.2]oct-4- yl(diρhenyl)methanol (0.0257 g, 0.0876 mmol) and 3-[(3-bromopropyl)oxy]-N,iV- diethylaniline (0.0314 g, 0.110 mmol) in 2 CH3CN / 3 CHC13 (4.0 mL) were reacted to give the desired product (0.032.0 g, 63.0%). EI-MS m/z 500(M+) Rt (1.58 min). Example 74: Preparation of l-{3-[(4-cyanophenyl)oxy]propyl}-4- [hydroxy(diphenyϊ)methyl]-l-azoniabicy clo [2.2.2] octane bromide.
4-f(3-bromopropyl)oxy]benzonitrile To a solution of 4-hydroxybenzonitrile (0.109 g, 0.913 mmol) in acetonitrile (4 mL) was added 1,3-dibromopropane (0.930 mL, 9.16 mmol) followed by Cs2CO (0.439 g, 1.35 mmol). The reaction mixture was stirred for 24h and then concentrated under vacuum. The resulting residue was treated with H2O (4 mL) and extracted with DCM (8 mL). The organic layer was dried through a phase separator and concentrated under vacuum. The residue was taken up in DMSO and purified by preparatory HPLC (without TFA) to give the title compound (0.156 g, 71.4%). EI-MS Rt (2.10 min).
l-{3-f(4-cyanophenyl)oxy]propyl}-4-fhydroxy(diphenyl)methyl]-l- azoniabicyclof2.2.2] octane bromide Following the general procedure outlined in Example 3, l-azabicyclo[2.2.2]oct-4- yl(diphenyl)methanol (0.0520 g, 0.177 mmol) and 4-[(3-bromopropyl)oxy]benzonitrile (0.156 g, 0.652 mmol) in 2 CH3CN / 3 CHC13 (4.0 mL) were reacted to give the desired product (0.0726 g, 76.8%). EI-MS m/z 453(M+) Rt (1.86 min).
Example 75: Preparation of 4-[hydroxy(diphenyl)methyl]-l-[2-({[3-
(methyloxy)phenyl]methyl}oxy)ethyl]-l-azoniabicyclo[2.2.2]octane bromide.
2- ({f3- (methyloxy)phenyl ] methyl) oxy) ethanol
Ethylene glycol (0.084 mL, 1.5 mmol) was added to NaH (38 mg, 1.52 mmol, 95% in oil) in THF (3 mL) (caution: exotherm). m-Methoxybenzyl chloride (0.21 mL, 1.5 mmol) was added to the reaction, and the residual m-methoxybenzyl chloride was transferred to the reaction tube with additional THF (1 mL). (Bu) NI (55 mg, 0.15 mmol) was then added, and the reaction was heated at 60 °C for 18 h and then cooled to room temperature for 4 h. H2O (2 mL) and EtOAc (2 mL) were added, and the layers were separated via pipette. The aqueous layer was extracted with EtOAc (l x l mL), and the combined organic layers were concentrated. The crude product was purified on a Biotage 12+M cartridge (8 g silica) eluting with 30% EtOAc/hexanes at 5 mL/min to give the title compound (114 mg, 42%). The product was characterized by H NMR (400 MHz) in CDCI3.
1 -{[(2-bromoethyl) oxy ] methyl} -3- (methyloxy) benzene A solution of N-bromosuccinimide (272 mg, 1.53 mmol) in DCM (2.5 mL) was added resin-bound triphenylphosphine (510 mg, 1.53 mEquiv, Fluka) in DCM (2.5 mL). The reaction was stirred at room temperature for 10 min. A solution of 2-({[3- (methyloxy)phenyl]methyl}oxy)ethanol (114 mg, 0.626 mmol) in DCM (1.5 mL) was added to the reaction, and the residual alcohol was transferred with additional DCM (1.5 mL). The reaction vessel was wrapped in aluminum foil and stirred at rt for 20 h. The reaction was filtered through a SPE cartridge (5 g silica) eluting with the following 10 mL fractions: DCM (fraction 1), 30% EtOAc/hexanes (fraction 2), and 50% EtOAc/hexanes (fraction 3) to give the title compound (160 mg). The product was characterized by H NMR (400 MHz) in CDCI3.
4-lhydroxy(diphenyl)methyl]-l-f2-({[3-(methyloxy)phenyl]methyl}oxy)ethyl]-l- azoniabicyclo[2.2.2 ] octane bromide l-Azabicyclo[2.2.2]oct-4-yl(diphenyl)methanol (30 mg, 0.102 mmol) was added to a solution of l-{[(2-bromoethyl)oxy]methyl}-3-(methyloxy)benzene (35 mg, 0.143 mmol) in 2 CH3CN / 3 CHCL, (3 mL). The reaction was heated at 60 °C for 96 h. The reaction was concentrated, and the crude product was washed with EtOAc (3 x 1 mL) and then MeOH (l x l mL). The product was dried under high vacuum to give the title compound (7.7 mg, 14%). LC MS ESI Rτ 1.97 min M+ 458
Example 76: Preparation of l-[2-({[4-(l,l- dimethylethyl)pheny 1] methyl} oxy)ethyl] -4- [hydroxy (diphenyl)methyl] -1 - azoniabicyclo [2.2.2] octane bromide.
2-({[4-QJ-dimethylethyl)phenyl]methyl}oxy)ethanol Ethylene glycol (0.084 mL, 1.5 mmol) was added to NaH (38 mg, 1.52 mmol, 95% in oil) in THF (3 mL). l-(Bromomethyl)-4-(l,l-dimethylethyl)benzene (0.28 mL, 1.5 mmol) was added to the reaction, and the residual l-(bromomethyl)-4-(l,l- dimethylethyl)benzene was transferred to the reaction tube with additional THF (1 mL). (Bu) NI (55 mg, 0.15 mmol) was then added, and the reaction was heated at 60 °C for 18 h and then rt for 4 h. H2O (2 mL) and EtOAc (2 mL) were added, and the layers were separated via pipette. The aqueous layer was extracted with EtOAc (1 x 1 mL), and the combined organic layers were concentrated. The crude product was purified on a SPE cartridge (5 g silica) eluting with the following 10 mL fractions: 10% EtOAc/hexanes (fractions 1,2), 30% EtOAc/hexanes (fractions 3,4), and 50% EtOAc/hexanes (fractions 5,6) to give the title compound (312 mg, 51%). The product was characterized by * H NMR (400 MHz) in CDCI3.
l-{[(2-bromoethyl)oxy]methyl}-4-(lJ-dimethylethyl)benzene
A solution of N-bromosuccinimide (272 mg, 1.53 mmol) in DCM (2.5 mL) was added to resin-bound triphenylphosphine (510 mg, 1.53 mEquiv, Fluka) in DCM (2.5 mL), and the reaction was stirred at rt for 10 min. A solution of 2-( { [4-( 1 , 1 - dimethylethyl)phenyl]methyl}oxy)ethanol (160 mg, 0.768 mmol) in DCM (1.5 mL) was added to the reaction, and the residual alcohol was transferred with additional DCM (1.5 mL). The reaction vial was capped, wrapped in aluminum foil, and stirred at rt for 20 h. The reaction was filtered through a SPE cartridge (5 g silica) eluting with the following 10 mL fractions: DCM (fraction 1), 30% EtOAc/hexanes (fraction 2), and 50% EtOAc/hexanes (fraction 3) to give the title compound (25 mg, 12%). The product was characterized by *H NMR (400 MHz) in CDCI3.
l-[2-({[4-(lJ-dimethylethyl)phenyl]methyl)oxy)ethyl]-4-[hydroxy(diphenyl)methyl]-l- azoniabicyclo f 2.2.2 ] octane bromide l-Azabicyclo[2.2.2]oct-4-yl(diphenyl)methanol (30 mg, 0.102 mmol) was added to a solution of l-{[(2-bromoethyl)oxy]methyl}-4-(l,l-dimethylethyl)benzene (25 mg, 0.143 mmol) in 2:3 CH3CN /CHC13 (3 mL), and the reaction was heated at 60 °C for 96 h. The reaction was concentrated, and the crude product was washed with EtOAc (3 x 1 mL). The product was dried under high vacuum to give the title compound (9 mg, 16%). LC/MS ESI Rτ 2.28 min M+ 484 Example 77: Preparation of l-(2-{[(4-fluorophenyl)methyl]oxy}ethyl)-4- [hy droxy (diphenyl)methyl]-l-azoniabicy clo [2.2.2] octane bromide
2-{[(4-fluorophenyl)methyl]oxy)ethanol Ethylene glycol (0.084 mL, 1.5 mmol) was added to NaH (38 mg, 1.52 mmol, 95% in oil) in THF (3 mL). 1 -(Bromomethyl)-4-fluorobenzene (0.19 mL, 1.5 mmol) was added to the reaction, and the residual l-(bromomethyl)-4-fluorobenzene was transferred to the reaction tube with additional THF (1 mL). (Bu) NI (55 mg, 0.15 mmol) was added, and the reaction was heated at 60 °C for 18 h and then rt for 4 h. H2O (2 mL) and EtOAc (2 mL) were added, and the layers were separated via pipette. The aqueous layer was extracted with EtOAc (l x l mL), and the combined organic layers were concenfrated. The crude product was purified on a SPE cartridge (5 g silica) eluting with the following 10 mL fractions: 30% EtOAc/hexanes (fractions 1,2), 50% EtOAc/hexanes (fraction 3), and 75% EtOAc/hexanes (fraction 4) to give the title compound (122 mg, 48%). The product was characterized by H NMR (400 MHz) in CDC13.
l-{[(2-bromoethyl)oxy]methyl}-4-fluorobenzene
A solution of N-bromosuccinimide (272 mg, 1.53 mmol) in DCM (2.5 mL) was added to resin-bound triphenylphosphine (510 mg, 1.53 mEquiv, Fluka) in DCM (2.5 mL), and the reaction was stirred at rt for 10 min. A solution of 2-{[(4- fluorophenyl)methyl] oxy} ethanol (122 mg, 0.717 mmol) in DCM (1.5 mL) was added to the reaction, and the residual alcohol was transferred with additional DCM (1.5 mL). The reaction vial was capped, wrapped in aluminum foil, and stirred at rt for 20 h. The reaction was filtered through a SPE cartridge (5 g silica) eluting with the following 10 mL fractions: DCM (fraction 1), 30% EtOAc/hexanes (fraction 2), and 50% EtOAc/hexanes (fraction 3) to give the title compound (80 mg, 48%). The product was characterized by *H NMR (400 MHz) in CDCI3. l-(2-{[(4-fluorophenyl)methyl]oxy}ethyl)-4-[hydroxy(diphenyl)methyl]-l- azoniabicyclo[2.2.2] octane bromide l-Azabicyclo[2.2.2]oct-4-yl(diphenyl)methanol (30 mg, 0.102 mmol) was added to a solution of l-{[(2-bromoethyl)oxy]methyl}-4-fluorobenzene (33 mg, 0.143 mmol) in 2:3 CH3CN/CHC13 (3 mL), and the reaction was heated at 60 °C for 96 h. The reaction was concentrated, and the crude product was washed with EtOAc (3 x 1 mL). The product was dried under high vacuum to give the title compound (9 mg, 16%). LC/MS ESI Rτ 1.89 min M* 446
Example 78: Preparation of l-(2-{[(4-chlorophenyl)methyl]oxy}ethyI)-4- [hydroxy(diphenyl)methyl]-l-azoniabicyclo[2.2.2]octane bromide.
2-{[(4-chlorophenyl)methyl]oxy}ethanol
Ethylene glycol (0.084 mL, 1.5 mmol) was added to NaH (38 mg, 1.52 mmol, 95% in oil) in THF (3 mL). l-(Bromomethyl)-4-chlorobenzene (310 mg, 1.5 mmol) was added to the reaction, and the residual l-(bromomethyl)-4-chlorobenzene was transferred to the reaction tube with additional THF (1 mL). (Bu)4NI (55 mg, 0.15 mmol) was then added, and the reaction was heated at 60 °C for 18 h and then rt for 4 h. H2O (2 mL) and EtOAc (2 mL) were added, and the layers were separated via pipette. The aqueous layer was extracted with EtOAc (l x l mL), and the combined organic layers were concentrated. The crude product was purified on a SPE cartridge (5 g silica) eluting with the following 10 mL fractions: 30% EtOAc/hexanes (fractions 1,2), 50% EtOAc/hexanes (fraction 3), and 75% EtOAc/hexanes (fraction 4) to give the title compound (129 mg, 46%). The product was characterized by *H NMR (400 MHz) in CDC13.
l-{f(2-bromoethyl)oxy]methyl}-4-chlorobenzene
A solution of N-bromosuccinimide (272 mg, 1.53 mmol) in DCM (2.5 mL) was added to resin-bound triphenylphosphine (510 mg, 1.53 mEquiv, Fluka) in DCM (2.5 mL), and the reaction was stirred at rt for 10 min. A solution of 2-{[(4- chlorophenyl)methyl]oxy} ethanol (129 mg, 0.691 mmol) in DCM (1.5 mL) was added to the reaction, and the residual alcohol was transferred with additional DCM (1.5 mL). The reaction vial was capped, wrapped in aluminum foil, and stirred at rt for 20 h. The reaction was filtered through a SPE cartridge (5 g silica) eluting with the following 10 mL fractions: DCM (fraction 1), 30% EtOAc/hexanes (fraction 2), and 50% EtOAc/hexanes (fraction 3) to give the title compound (98 mg, 57%). The product was characterized by 1 H NMR (400 MHz) in CDCI3.
l-(2-{[(4-chlorophenvI)methyl]oxy}ethyl)-4-[hydroxy(diphenyl)methyl]-l- azoniabicyclo[2.2.2 ] octane bromide l-Azabicyclo[2.2.2]oct-4-yl(diphenyl)methanol (30 mg, 0.102 mmol) was added to a solution of l-{[(2-bromoethyl)oxy]methyl}-4-chlorobenzene (36 mg, 0.143 mmol) in 2:3 CH3CN/CHC13 (3 mL), and the reaction was heated at 60 °C for 96 h. The reaction was concenfrated, and the crude product was washed with EtOAc (3 1 mL). The product was dried under high vacuum to give the title compound (17.4 mg, 32%). LC/MS ESI Rτ 2.09 min M+ 462
Example 79: Preparation of l-(2-{[(4-bromophenyl)methyI]oxy}ethyl)-4- [hydroxy(diphenyl)methyl]-l-azoniabicyclo[2.2.2]octane bromide.
2-{[(4-bromophenyl)methyl] oxy} ethanol Ethylene glycol (0.084 mL, 1.5 mmol) was added to NaH (38 mg, 1.52 mmol, 95% in oil) in THF (3 mL). l-Bromo-4-(bromomethyl)benzene (370 mg, 1.5 mmol) was added to the reaction, and the residual l-bromo-4-(bromomethyl)benzene was transferred to the reaction tube with additional THF (1 mL). (Bu)4NI (55 mg, 0.15 mmol) was then added, and the reaction was heated at 60 °C for 18 h and then rt for 4 h. H2O (2 mL) and EtOAc (2 mL) were added, and the layers were separated via pipette. The aqueous layer was extracted with EtOAc (l x l mL), and the combined organic layers were concentrated. The crude product was purified on a SPE cartridge (5 g silica) eluting with the following 10 mL fractions: 30%> EtOAc/hexanes (fractions 1,2), 50% EtOAc/hexanes (fraction 3), and 75% EtOAc/hexanes (fraction 4) to give the title compound (139 mg, 40%). The product was characterized by *H NMR (400 MHz) in CDCI3. l-bromo-4-{[(2-bromoethyl)oxy]methyl}benzene
A solution of N-bromosuccinimide (272 mg, 1.53 mmol) in DCM (2.5 mL) was added to resin-bound triphenylphosphine (510 mg, 1.53 mEquiv, Fluka) in DCM (2.5 mL), and the reaction was stirred at rt for 10 min. A solution of 2-{[(4- bromophenyl)methyl]oxy} ethanol (139 mg, 0.601 mmol) in DCM (1.5 mL) was added to the reaction, and the residual alcohol was transferred with additional DCM (1.5 mL). The reaction vial was capped, wrapped in aluminum foil, and stirred at rt for 20 h. The reaction was filtered through a SPE cartridge (5 g silica) eluting with the following 10 mL fractions: DCM (fraction 1), 30% EtOAc/hexanes (fraction 2), and 50% EtOAc/hexanes (fraction 3) to give the title compound (87 mg, 49%). The product was characterized by 1H NMR (400 MHz) in CDCI3.
l-(2-{[(4-bromophenyl)methyl]oxy}ethyl)-4-[hydroxy(diphenyl)methyl]-l- azoniabicyclo[2.2.2] octane bromide 1 -Azabicyclo [2.2.2] oct-4-yl(diphenyl)methanol (30 mg, 0.102 mmol) was added to a solution of l-bromo-4-{[(2-bromoethyl)oxy]methyl}benzene (42 mg, 0.143 mmol) in 2:3 CH3CN/CHC13 (3 mL), and the reaction was heated at 60 °C for 96 h. The reaction was concentrated, and the crude product was washed with EtOAc (3 x 1 mL). The product was dried under high vacuum to give the title compound (19.4 mg, 32%). LC/MS ESI Rτ 2.07 min M+ 506
Example 80: Preparation of l-(2-{[(4-cyanophenyl)methyl]oxy}ethyl)-4- [hydroxy(diphenyl)methyl]-l-azoniabicyclo[2.2.2]octane bromide.
4-{[(2-hydroxyethyl)oxy]methyl}benzonitrile
Ethylene glycol (0.084 mL, 1.5 mmol) was added to NaH (38 mg, 1.52 mmol, 95% in oil) in THF (3 mL). 4-(Bromomethyl)benzonitrile (290 mg, 1.5 mmol) was added to the reaction, and the residual 4-(bromomethyl)benzonitrile was transferred to the reaction tube with additional THF (1 mL). (Bu)4NI (55 mg, 0.15 mmol) was then added, and the reaction was heated at 60 °C for 18 h and then rt for 4 h. H2O (2 mL) and EtOAc (2 mL) were added, and the layers were separated via pipette. The aqueous layer was extracted with EtOAc (l x l mL), and the combined organic layers were concentrated. The crude product was purified on a SPE cartridge (5 g silica) eluting with the following 10 mL fractions: 10% EtOAc/hexanes (fractions 1,2), 30% EtOAc/hexanes (fractions 3,4), 50% EtOAc/hexanes (fractions 5-7), and 75% EtOAc/hexanes (fraction 8) to give the title compound (95 mg, 36%). The product was characterized by *H NMR (400 MHz) in CDCI3.
4-{f(2-bromoethyl)oxy]methyl}benzonitrile
A solution of N-bromosuccinimide (272 mg, 1.53 mmol) in DCM (2.5 mL) was added to resin-bound triphenylphosphine (510 mg, 1.53 mEquiv, Fluka) in DCM (2.5 mL), and the reaction was stirred at rt for 10 min. A solution of 4-{[(2- hydroxyethyl)oxy]methyl}benzonitrile (95 mg, 0.536 mmol) in DCM (1.5 mL) was added to the reaction, and the residual alcohol was transferred with additional DCM (1.5 mL). The reaction vial was capped, wrapped in aluminum foil, and stirred at rt for 20 h. The reaction was filtered through a SPE cartridge (5 g silica) eluting with the following 10 mL fractions: DCM (fraction 1), 30% EtOAc/hexanes (fraction 2), and 50% EtOAc/hexanes (fraction 3) to give the title compound (60 mg, 47%). The product was characterized by H NMR (400 MHz) in CDCI3.
l-(2-{[(4-cyanophenyl)methyl]oxy}efhyl)-4- (hydrox fdiphenyl)methyl]-l- azoniabicycloF2.2.2 ] octane bromide 1- Azabicyclo [2.2.2] oct-4-yl(diphenyl)methanol (30 mg, 0.102 mmol) was added to a solution of 4-{[(2-bromoethyl)oxy]methyl}benzonitrile (34 mg, 0.143 mmol) in 2:3 CH3CN/CHC13 (3 mL), and the reaction was heated at 60 °C for 96 h. The reaction was concentrated, and the crude product was washed with EtOAc (3 x 1 mL). The product was dried under high vacuum to give the title compound (40 mg, 74%). LC/MS ESI RT 1.82 min M+ 453
Example 81: Preparation of 4-[hydroxy(diphenyl)methyl]-l-{2-[(2- naphthalenylmethyl)oxy]ethyl}-l-azoniabicyclo[2.2.2]octane bromide.
2-f(2-naphfhάlenylmethyl)oxy] ethanol
Ethylene glycol (0.084 mL, 1.5 mmol) was added to NaH (38 mg, 1.52 mmol, 95% in oil) in THF (3 mL). 2-(Bromomethyl)naphthaIene (330 mg, 1.5 mmol) was added to the reaction, and the residual 2-(bromomethyl)naphthalene was transferred to the reaction tube with additional THF (1 mL). (Bu)4NI (55 mg, 0.15 mmol) was then added, and the reaction was heated at 60 °C for 18 h and then rt for 4 h. H2O (2 mL) and EtOAc (2 mL) were added, and the layers were separated via pipette. The aqueous layer was extracted with EtOAc (l x l mL), and the combined organic layers were concentrated. The crude product was purified on a SPE cartridge (5 g silica) eluting with the following 10 mL fractions: 30% EtOAc/hexanes (fractions 1,2), 50% EtOAc/hexanes (fraction 3), and 75% EtOAc/hexanes (fraction 4) to give the title compound (101 mg, 33%). The product was characterized by H NMR (400 MHz) in CDCI3.
2-{f(2-bromoethyl)oxy]mefhyl}naphthάlene
A solution of iV-bromosuccinimide (272 mg, 1.53 mmol) in DCM (2.5 mL) was added to resin-bound triphenylphosphine (510 mg, 1.53 mEquiv, Fluka) in DCM (2.5 mL), and the reaction was stirred at rt for 10 min. A solution 2-[(2- naphthalenylmethyl)oxy] ethanol (101 mg, 0.499 mmol) in DCM (1.5 mL) was added to the reaction, and the residual alcohol was transferred with additional DCM (1.5 mL). The reaction vial was capped, wrapped in aluminum foil, and stirred at rt for 20 h. The reaction was filtered through a SPE cartridge (5 g silica) eluting with the following 10 mL fractions: DCM (fraction 1), 30% EtOAc/hexanes (fraction 2), and 50%
EtOAc hexanes (fraction 3) to give the title compound (57 mg, 43%). The product was characterized by *H NMR (400 MHz) in CDCI3.
4-rhydroxy(diphenyl)methyl]-l-{2-r(2-naphthalenylmethyl)oxy]ethyl}-l- azoniabicyclo f 2.2.2] octane bromide l-Azabicyclo[2.2.2]oct-4-yl(diphenyl)methanol (30 mg, 0.102 mmol) was added to a solution of 2-{[(2-bromoethyl)oxy]methyl}naphthalene (38 mg, 0.143 mmol) in 2:3 CH CN/CHC13 (3 mL), and the reaction was heated at 60 °C for 96 h. The reaction was concentrated, and the crude product was washed with EtOAc (3 x 1 mL). The product was dried under high vacuum to give the title compound (48.1 mg, 84%). LC/MS ESI Rτ 2.04 min M+ 478 Example 82: Preparation of l-(2-{[(3-fluorophenyl)methyl]oxy}ethyϊ)-4- [hydroxy(diphenyl)methyl]-l-azoniabicyclo[2.2.2]octane bromide.
2-{f(3-fluorophenyl)methyl]oxy}ethanol Ethylene glycol (0.1 mL, 1.79 mmol) was added to NaH (46 mg, 1.81 mmol, 95% in oil) in THF (5 mL). l-(Bromomethyl)-3-fluorobenzene (0.22 mL, 1.79 mmol) was added to the reaction, and the reaction was heated at 60 °C for 5 days. H2O (2 mL) and EtOAc (2 mL) were added, and the layers were separated via pipette. The aqueous layer was extracted with EtOAc (3 x 1 mL), and the combined orgamc layers were washed with saturated NaCl (1 2 mL), dried (Na2SO4), and concentrated. The crude product was purified on a SPE cartridge (5 g silica) eluting with the following 10 mL fractions: 30% EtOAc/hexanes (fractions 1,2), 50% EtOAc/hexanes (fraction 3), and 75% EtOAc/hexanes (fraction 4) to give the title compound (76.2 mg, 25%). The product was characterized by H NMR (400 MHz) in CDCI3.
1 - ff(2-bromoefhyl)oxy ] methyl} -3-fluorobenzene N-bromosuccinimide (146 mg, 0.820 mmol) was added to resin-bound triphenylphosphine (274 mg, 0.822 mEquiv, Fluka) and 2-{[(3- fluorophenyl)methyl] oxy} ethanol (70 mg, 0.411 mmol) in DCM (4 mL). The reaction vial was sealed with a Teflon-lined cap, wrapped in aluminum foil, and shaken at rt for 17 h. The reaction was filtered through a SPE cartridge (5 g silica) eluting with the following 10 mL fractions: DCM (fraction 1), 30% EtOAc/hexanes (fraction 2), and 50% EtOAc/hexanes (fraction 3) to give the title compound (75 mg, 78%). The product was characterized by 1H NMR (400 MHz) in CDCI3.
l-(2-{[(3-fluorophenyl)methyl]oxy}ethyl)-4-fhydroxy(diphenyl)methyl]-l- azoniabicyclo[2.2.2]octane bromide l-Azabicyclo[2.2.2]oct-4-yl(diphenyl)methanol (94 mg, 0.321 mmol) was added to a solution of l-{[(2-bromoethyl)oxy]methyl}-3-fluorobenzene (75 mg, 0.321 mmol) in 2:3 CH3CN/CHC13 (4 mL), and the reaction was heated at 60 °C for 3 days. The reaction was concentrated under reduced pressure, and the crude product was washed with EtOAc (3 x 2 mL). The product was dried under high vacuum to give the title compound (50 mg, 30%). LC/MS ESI Rτ 1.95 min M4" 446
Example 83: Preparation of 4-[hydroxy(diphenyl)methyl]-l-{2-[(l-methyl-l- phenylethyI)oxy]ethyI}-l-azoniabicyclo[2.2.2]octane bromide.
2- f(l-methyl-l-phenylethyl)oxy] ethanol
A catalytic amount of either j>-toluene sulfonic acid* H2O or Bio-Rad SCX resin (analytical grade, 5.1 meq/g, AG 50W-X8) was added to D-methylstyrene (0.5 mL, 3.85 mmol) and ethylene glycol (0.21 mL, 3.85 mmol), and the reaction was stirred at rt for 5 days. The reaction mixture was loaded directly onto a SPE cartridge (10 g silica) and eluted with the following 10 mL fractions: 10% EtOAc/hexanes (fractions 1,2), 30% EtOAc/hexanes (fractions 3,4), and 50% EtOAc/hexanes (fractions 5,6) to give the title compound (30.5 mg, 4%) for both conditions. The product was characterized by iH NMR (400 MHz) in CDC13.
{1 -f(2-bromoethyl)oxy]-l -methylethy benzene N-bromosuccinimide (119 mg, 0.666 mmol) was added to resin-bound triphenylphosphine (222 mg, 0.666 mEquiv, Fluka) and 2- [(1 -methyl- 1- phenylethyl)oxy]ethanol (60 mg, 0.333 mmol) in DCM (4 mL). The reaction vial was sealed with a Teflon-lined cap, wrapped in aluminum foil, and shaken at rt for 17 h. The reaction was filtered through a SPE cartridge (5 g silica) eluting with the following 10 mL fractions: DCM (fraction 1), 30% EtOAc/hexanes (fraction 2), and 50% EtOAc/hexanes (fraction 3) to give the title compound (34 mg, 42%). The product was characterized by H NMR (400 MHz) in CDCI3.
4-[hydroxy(diphenyl)methyl]-l-{2-f(l-methyl-l-phenylethyl)oxy]ethyl}-l- azoniabicyclo[2.2.2 ] octane bromide l-Azabicyclo[2.2.2]oct-4-yl(diphenyl)methanol (41 mg, 0.14 mmol) was added to a solution of { l-[(2-bromoethyl)oxy]-l-methylethyl}benzene (34 mg, 0.14 mmol) in 2:3
CH3CN/CHC13 (3 mL), and the reaction was heated at 60 °C for 3 days. The reaction was concenfrated under reduced pressure, and the crude product was washed with EtOAc (3 x 1 mL). The residue was taken up in 2.5mL of DMSO and purified by preparatory HPLC (without TFA) to give the title compound (18 mg, 24%). LC/MS ESI Rτ 2.09 min M+ 456
Example 84: Preparation of 4-[hydroxy(diphenyl)methyl]-l-{2- [(phenylmethyl)oxy]ethyl}-l-azoniabicyclo[2.2.2]octane bromide.
Method A: l-Azabicyclo[2.2.2]oct-4-yl(diphenyl)methanol (0.020 g, 0.068 mmol) was diluted in CHC13 (1.8 mL) and dispensed directly into a 1 dram vial containing 2- bromoethyl phenylmethyl ether (0.022 g, 0.102 mmol). CH3CN (1.2 mL) was added; the vial was fitted with a stirring bar and capped. The reaction was stirred and heated at 60 °C for 24 h. The contents of the vial were transferred (after removal of stirring bar) into a polypropylene tube and concenfrated under Nitrogen. The crude product was collected on a polypropylene tube frit. Excess bromide was removed by washing the crude product with EtOAc (5 x 2 mL) and Hexane (5 2 mL). The product was then dried under vacuum to give the title compound (0.008 g, 23.8%).
Method B: To a solution of l-azabicyclo[2.2.2]oct-4-yl(diphenyl)methanol (3.30 g, 11.2 mmol) in 2 CH3CN / 3 CHC13 (200 mL) was added 2-bromoethyl phenylmethyl ether (2.31 mL, 14.6 mmol). The solution was stirred at 60 °C for 16 h. The reaction was cooled down to room temperature and concentrated. EtOAc (200 mL) was added to the solid, and the mixture was allowed to stir for 1 hour then filtered. The resulting solid was taken up in MeOH (125 mL) and heated to 60 °C. The solution was filtered hot, and then cooled back to room temperature. The reaction was concentrated to a low volume of MeOH (~20 mL) and filtered. Water (75 mL) was then added and the resulting mixture was heated at 55 °C with brisk stirring for 40 min. After cooling to room temperature, the solid was filtered off, washed with water (20 mL) and dried in a vacuum oven at 45 °C for 16 hours to give the title compound (2.47 g, 43.3%). EI-MS m/z 428(M+) Rt (1.90 min) iHNMR (OMSO-d6) δ 7.56 (d, 4H, J=1.2), 7.28 (m, 11H), 5.95 (s, IH), 4.50 (s, 2H), 3.81 (d, 2H, J=4.0), 3.48 (t, 6H, J=7.2), 3.38 (d, 2H, J=4.0), 2.01 (t, 6H, J=7.2); Elemental analysis (C29H34NO2Br) C, H, N: calculated, 68.50, 6.74, 2.75; found, 68.28, 6.68, 2.73.
The following examples in Table 1 were prepared according to the procedure outlined in Example 84 method A.
Figure imgf000064_0001
Table 1
Figure imgf000064_0002
Figure imgf000065_0001
Figure imgf000066_0001
Figure imgf000067_0002
Example 112: Preparation of l-[2-(l-benzofuran-2-yl)-2-oxoethyl]-4- [hydroxy(diphenyl)methyl]-l-azoniabicyclo[2.2.2]octane bromide. l-azabicyclo[2.2.2]oct-4-yl(diphenyl)methanol (0.022 g, 0.075 mmol) was diluted in CHC13 (1.8 mL) and dispensed directly into a 1 dram vial containing l-(l-benzofuran- 2-yl)-2-bromoethanone (0.027 g, 0.112 mmol). Added CH3CN (1.2 mL), the vial was fitted with stirring bar and capped. The reaction was stirred and heated at 60 °C for 24 h and then concentrated under vacuum to give a white solid. This residue was dissolved in DMSO and purified by preparatory HPLC (without TFA) to give the title compound (0.022 g, 57.4%). LC/MS ESI Rτ 1.98 min, M+ 452
The following examples in Table 2 were prepared according to the procedure outlined in Example 112.
Figure imgf000067_0001
Table 2
Figure imgf000068_0001
Figure imgf000069_0001
Abbreviations Ar Argon DCM Dichloromethane DMF Dimethylformamide DMSO Dimethylsulfoxide EI/ESI Electrospray ionization HPLC High pressure liquid chromatography LC Liquid chromatography LDA Lithium Diisopropyl Amide MS Mass spectrometry NMR Nuclear magnetic resonance Rt Retention time rt room temperature SPE Solid phase extraction TEA Triethylamine TFA Trifluoroacetic acid THF Tetrahydrofuran BIOLOGICAL EXAMPLES
The inhibitory effects of compounds at the M3 mAChR of the present invention are determined by the following in vitro and in vivo functional assays:
Analysis of Inhibition of Receptor Activation by Calcium Mobilization: Stimulation of mAChRs expressed on CHO cells were analyzed by monitoring receptor-activated calcium mobilization as previously described (H. M.Sarau et αl, 1999. Mol. Pharmacol. 56, 657-663). CHO cells stably expressing M3 mAChRs were plated in 96 well black wall/clear bottom plates. After 18 to 24 hours, media was aspirated and replaced with 100 μl of load media (EMEM with Earl's salts, 0.1% RIA- grade BSA (Sigma, St. Louis MO), and 4 μM Fluo-3-acetoxymethyl ester fluorescent indicator dye (Fluo-3 AM, Molecular Probes, Eugene, OR) and incubated 1 hr at 37° C. The dye-containing media was then aspirated, replaced with fresh media (without Fluo- 3 AM), and cells were incubated for 10 minutes at 37° C. Cells were then washed 3 times and incubated for 10 minutes at 37° C in 100 μl of assay buffer (0.1% gelatin (Sigma), 120 mM NaCl, 4.6 mM KC1, 1 mM KH2 PO4, 25 mM NaH CO3, 1.0 mM
CaCl2, 1.1 mM MgCl2, 11 mM glucose, 20mM HEPES (pH 7.4)). 50 μl of compound
(1x10"! 1 - lxl0"5 M final in the assay) was added and the plates were incubated for 10 min. at 37° C. Plates were then placed into a fluorescent light intensity plate reader (FLIPR, Molecular Probes) where the dye loaded cells were exposed to excitation light (488 nm) from a 6 watt argon laser. Cells were activated by adding 50 μl of acetylcholine (0.1-10 nM final), prepared in buffer containing 0.1% BSA, at a rate of 50 μl/sec. Calcium mobilization, monitored as change in cytosolic calcium concentration, was measured as change in 566 nm emission intensity. The change in emission intensity is directly related to cytosolic calcium levels. The emitted fluorescence from all 96 wells is measured simultaneously using a cooled CCD camera. Data points are collected every second. This data was then plotting and analyzed using GraphPad PRISM software. Methacholine-induced bronchoconstriction - potency and duration of action Airway responsiveness to methacholine was determined in awake, unrestrained Balb C mice (n = 6 each group). Barometric plethysmography was used to measure enhanced pause (Penh), a unitless measure that has been shown to correlate with the changes in airway resistance that occur during bronchial challenge with methacholine(2). Mice were pre-treated with 50 μl of compound (0.003-10 μg/mouse) in 50 μl of vehicle (10% DMSO) intranasally (i.n.) and were then placed in the plethysmography chamber a given amount of time following drug administration (15 min - 96 h). For potency determination, a dose response to a given drug was performed, and all measurements were taken 15 min following i.n. drug administration. For duration of action determination, measurements were taken anywhere from 15 min to 96 hours following i.n. drug administration. Once in the chamber, the mice were allowed to equilibrate for 10 min before taking a baseline Penh measurement for 5 minutes. Mice were then challenged with an aerosol of methacholine (10 mg/ml) for 2 minutes. Penh was recorded continuously for 7 min starting at the inception of the methacholine aerosol, and continuing for 5 minutes afterward. Data for each mouse were analyzed and plotted by using GraphPad PRISM software. This experiment allows the determination of duration of activity of the administered compound. The present compounds are useful for treating a variety of indications, including but not limited to respiratory-tract disorders such as chronic obstructive lung disease, chronic bronchitis, asthma, chronic respiratory obstruction, pulmonary fibrosis, pulmonary emphysema, and allergic rhinitis.
Muscarinic Receptor Radioligand Binding Assays Radioligand binding studies using 0.5 nM [3H]-N-methyl scopolamine (NMS) in a SPA format is used to assess binding of muscarinic antagonists to Mi, M2, M3, V and M5 muscarinic acetylcholine receptors. In a 96-well plate, the SPA beads are pre- incubated with receptor-containing membrane for 30 min at 4 °C. Then 50 mM HEPES and the test compound are added and incubated at room temperature (shaking) for 2 hours. The beads are then spun down and counted using a scintillation counter. Evaluation of potency and duration of action in isolated guinea pig trachea Tracheae were removed from adult male Hartely guinea pigs (Charles River, Raleigh, NC; 400-600 grams) and placed into modified Krebs-Henseleit solution. Composition of the solution was (mM): NaCl 113.0, KC14.8, CaCl2 2.5, KH2PO4 1.2, MgSO4 1.2, NaHCO3 25.0 and dextrose 11.0. which was gassed with 95% O2: 5% CO2 and maintained at 37°C. Each trachea was cleaned of adherent tissue and opened lengthwise. Epithelium was removed by gently rubbing the luminal surface with a cotton-tipped applicator. Individual strips were cut, approximately 2 cartilage rings in width, and suspended via silk suture in 10-ml water-jacketed organ baths containing Krebs-Henseleit solution and connected to Grass FT03C force-displacement transducers. Mechanical responses were recorded isomefrically by MPlOOWS/Acknowledge data acquisition system (BIOPAC Systems, Goleta, CA, www.biopac.com) run on Apple G4 computers. The tissues were equilibrated under a resting tension of 1.5 g, determined to be optimal by length-tension evaluation, and washed with Krebs-Henseleit solution every 15 minutes for one hour. After the equilibration period pulmonary tissues were contracted with 10 uM carbachol until reaching plateau, which served as a reference contraction for data analysis. Tissues were then rinsed every 15 minutes over 1 hour until reaching baseline tone. The preparations were then left for at least 30 minutes before the start of the experiment. Concentration-response curves were obtained by a cumulative addition of carbachol in half-log increments (Van Rossum, 1963, Arch. Int. Pharmacodyn., 143:299), initiated at 1 nM. Each concentration was left in contact with the preparation until the response plateaued before the addition of the subsequent carbachol concentration. Paired tissues were exposed to mAChR antagonist compounds or vehicle for 30 min before carbachol cumulative concentration-response curves were generated. All data is given as mean ± standard error of the mean (s.e.m.) with n being the number of different animals. For superfusion (duration of action) studies, the tissues were continuously superfused with Krebs-Henseleit solution at 2 ml/min for the duration of the experiment. Stock solutions of agonist and antagonist were infused (0.02 ml/min) via
22-guage needle inserted into the superfusion tubing. Mechanical responses were recorded isomefrically using a commercially-available data acquisition system (MPlOOWS/Acknowledge; BIOPAC Systems, Goleta, CA, www.biopac.com) interfaced with a Macintosh G4 computer (Apple, Cupertino, CA www.apple.com). The tissues were suspended under an optimal resting tension of 1.5 g. After a 60 min equilibration period, the tissues were contracted with carbachol (1 uM) for the duration of the experiment. Upon reaching a sustained contraction isoproterenol (10 uM) was administered to maximally relax the tissue, and this change served as a reference. Isoproterenol exposure was halted and the carbachol-induced tension allowed to recover. Muscarinic receptor antagonists infused at a single concentration per tissue until a sustained level of inhibition was attained. The compound was then removed and, once again, the carbachol-induced tension was allowed to recover. The following parameters were determined for each concentration of antagonist, and expressed as the mean ± S.E.M. for n individual animals. Inhibition of the carbachol-induced contraction was expressed as a percent of the reference response (isoproterenol) and the time required to reach one-half of this relaxation was measured (onset of response). The tension recovery following removal of the compound was determined as was the time required to reach one-half of the maximum tension recovery (offset of response). At 60 and 180 minutes after removal of the antagonist the remaining level of inhibition was determined and expressed as a percent of the isoproterenol reference. Antagonist concentration-response curves were obtained by plotting the maximal relaxation data at 0, 60 and 180-min following antagonist withdrawal. Recovery, termed shift, was calculated from the ratio of the 0-min inhibition curve IC50 and the concentration of compound yielding a similar tension recovery at 60 and
180 minutes. Halftimes for onset and offset of response were plotted vs. corresponding concentration and the data were fit with non-linear regression. These values were extrapolated at the IC50 (determined from the inhibition concentration-response curve) and designated Ot5Q (time required, at the IC50 concentration, to reach half of the onset response) and Rt50 (time required, at the IC50 concentration, to reach half of the recovery response). FORMULATION-ADMINISTRATION
Accordingly, the present invention further provides a pharmaceutical formulation comprising a compound of formula (I), or a pharmaceutically acceptable salt, solvate, or physiologically functional derivative (e.g., salts and esters) thereof, and a pharmaceutically acceptable carrier or excipient, and optionally one or more other therapeutic ingredients. Hereinafter, the term "active ingredient" means a compound of formula (I), or a pharmaceutically acceptable salt, solvate, or physiologically functional derivative thereof. Compounds of formula (I) will be administered via inhalation via the mouth or nose. Dry powder compositions for topical delivery to the lung by inhalation may, for example, be presented in capsules and cartridges of for example gelatine, or blisters of for example laminated aluminium foil, for use in an inhaler or insufflator. Powder blend formulations generally contain a powder mix for inhalation of the compound of the invention and a suitable powder base (carrier/diluent/excipient substance) such as mono-, di- or poly-saccharides (e.g., lactose or starch), organic or inorganic salts (e.g., calcium chloride, calcium phosphate or sodium chloride), polyalcohols (e.g., mannitol), or mixtures thereof, alternatively with one or more additional materials, such additives included in the blend formulation to improve chemical and/or physical stability or performance of the formulation, as discussed below, or mixtures thereof. Use of lactose is preferred. Each capsule or cartridge may generally contain between 20μg- lOmg of the compound of formula (I) optionally in combination with another therapeutically active ingredient. Alternatively, the compound of the invention may be presented without excipients, or may be formed into particles comprising the compound, optionally other therapeutically active materials, and excipient materials, such as by co-precipitation or coating. Suitably, the medicament dispenser is of a type selected from the group consisting of a reservoir dry powder inhaler (RDPI), a multi-dose dry powder inhaler (MDPI), and a metered dose inhaler (MDI). By reservoir dry powder inhaler (RDPI) it is meant as an inhaler having a reservoir form pack suitable for comprising multiple (un-metered doses) of medicament in dry powder form and including means for metering medicament dose from the reservoir to a delivery position. The metering means may for example comprise a metering cup or perforated plate, which is movable from a first position where the cup may be filled with medicament from the reservoir to a second position where the metered medicament dose is made available to the patient for inhalation. By multi-dose dry powder inhaler (MDPI) is meant an inhaler suitable for dispensing medicament in dry powder form, wherein the medicament is comprised within a multi-dose pack containing (or otherwise carrying) multiple, define doses (or parts thereof) of medicament. In a preferred aspect, the carrier has a blister pack form, but it could also, for example, comprise a capsule-based pack form or a carrier onto which medicament has been applied by any suitable process including printing, painting and vacuum occlusion. The formulation can be pre-metered (eg as in Diskus, see GB 2242134 or
Diskhaler, see GB 2178965, 2129691 and 2169265) or metered in use (eg as in Turbuhaler, see EP 69715). An example of a unit-dose device is Rotahaler (see GB 2064336). The Diskus inhalation device comprises an elongate strip formed from a base sheet having a plurality of recesses spaced along its length and a lid sheet hermetically but peelably sealed thereto to define a plurality of containers, each container having therein an inhalable formulation containing a compound of formula (I) preferably combined with lactose. Preferably, the strip is sufficiently flexible to be wound into a roll. The lid sheet and base sheet will preferably have leading end portions which are not sealed to one another and at least one of the said leading end portions is constructed to be attached to a winding means. Also, preferably the hermetic seal between the base and lid sheets extends over their whole width. The lid sheet may preferably be peeled from the base sheet in a longitudinal direction from a first end of the said base sheet. In one aspect, the multi-dose pack is a blister pack comprising multiple blisters for containment of medicament in diy powder form. The blisters are typically arranged in regular fashion for ease of release of medicament therefrom. In one aspect, the multi-dose blister pack comprises plural blisters arranged in generally circular fashion on a disk-form blister pack. In another aspect, the multi-dose blister pack is elongate in form, for example comprising a strip or a tape. Preferably, the multi-dose blister pack is defined between two members peelably secured to one another. US Patents Nos. 5,860,419, 5,873,360 and 5,590,645 describe medicament packs of this general type. In this aspect, the device is usually provided with an opening station comprising peeling means for peeling the members apart to access each medicament dose. Suitably, the device is adapted for use where the peelable members are elongate sheets which define a plurality of medicament containers spaced along the length thereof, the device being provided with indexing means for indexing each container in turn. More preferably, the device is adapted for use where one of the sheets is a base sheet having a plurality of pockets therein, and the other of the sheets is a lid sheet, each pocket and the adjacent part of the lid sheet defining a respective one of the containers, the device comprising driving means for pulling the lid sheet and base sheet apart at the opening station. By metered dose inhaler (MDI) it is meant a medicament dispenser suitable for dispensing medicament in aerosol form, wherein the medicament is comprised in an aerosol container suitable for containing a propellant-based aerosol medicament formulation. The aerosol container is typically provided with a metering valve, for example a slide valve, for release of the aerosol form medicament formulation to the patient. The aerosol container is generally designed to deliver a predetermined dose of medicament upon each actuation by means of the valve, which can be opened either by depressing the valve while the container is held stationary or by depressing the container while the valve is held stationary. Spray compositions for topical delivery to the lung by inhalation may for example be formulated as aqueous solutions or suspensions or as aerosols delivered from pressurised packs, such as a metered dose inhaler, with the use of a suitable liquefied propellant. Aerosol compositions suitable for inhalation can be either a suspension or a solution and generally contain the compound of formula (I) optionally in combination with another therapeutically active ingredient and a suitable propellant such as a fluorocarbon or hydrogen-containing chlorofluorocarbon or mixtures thereof, particularly hydrofluoroalkanes, e.g. dichlorodifluoromethane, frichlorofluoromethane, dichlorotetra-fluoroethane, especially 1,1,1,2-tetrafluoroethane, 1,1,1,2,3,3,3- heptafluoro-n-propane or a mixture thereof. Carbon dioxide or other suitable gas may also be used as propellant. The aerosol composition may be excipient free or may optionally contain additional formulation excipients well known in the art such as surfactants eg oleic acid or lecithin and cosolvents eg ethanol. Pressurised formulations will generally be retained in a canister (eg an aluminium canister) closed with a valve (eg a metering valve) and fitted into an actuator provided with a mouthpiece. Medicaments for administration by inhalation desirably have a controlled particle size. The optimum aerodynamic particle size for inhalation into the bronchial system for localized delivery to the lung is usually l-10μm, preferably 2-5μm. The optimum aerodynamic particle size for inhalation into the alveolar region for achieving systemic delivery to the lung is approximately .5-3 μm, preferably 1-3 μm. Particles having an aerodynamic size above 20μm are generally too large when inhaled to reach the small airways. Average aerodynamic particle size of a formulation may measured by, for example cascade impaction. Average geometric particle size may be measured, for example by laser diffraction, optical means. To achieve a desired particle size, the particles of the active ingredient as produced may be size reduced by conventional means eg by controlled crystallization, micronisation or nanomilling .The desired fraction may be separated out by air classification. Alternatively, particles of the desired size may be directly produced, for example by spray drying, controlling the spray drying parameters to generate particles of the desired size range. Preferably, the particles will be crystalline, although amorphous material may also be employed where desirable. When an excipient such as lactose is employed, generally, the particle size of the excipient will be much greater than the inhaled medicament within the present invention, such that the "coarse" carrier is non-respirable. When the excipient is lactose it will typically be present as milled lactose, wherein not more than 85% of lactose particles will have a MMD of 60-90μm and not less than 15% will have a MMD of less than 15μm. Additive materials in a dry powder blend in addition to the carrier may be either respirable, i.e., aerodynamically less than 10 microns, or non-respirable, i.e., aerodynamically greater than 10 microns. Suitable additive materials which may be employed include amino acids, such as leucine; water soluble or water insoluble, natural or synthetic surfactants, such as lecithin (e.g., soya lecithin) and solid state fatty acids (e.g., lauric, palmitic, and stearic acids) and derivatives thereof (such as salts and esters); phosphatidylcholines; sugar esters. Additive materials may also include colorants, taste masking agents (e.g., saccharine), anti-static-agents, lubricants (see, for example, Published PCT Patent Appl. No. WO 87/905213, the teachings of which are incorporated by reference herein), chemical stabilizers, buffers, preservatives, absorption enhancers, and other materials known to those of ordinary skill. Sustained release coating materials (e.g., stearic acid or polymers, e.g. polyvinyl pyrolidone, polylactic acid) may also be employed on active material or active material containing particles (see, for example, Patent Nos. US 3,634,582, GB 1,230,087, GB
1,381,872, the teachings of which are incorporated by reference herein). Intranasal sprays may be formulated with aqueous or non-aqueous vehicles with the addition of agents such as thickening agents, buffer salts or acid or alkali to adjust the pH, isotonicity adjusting agents or anti-oxidants. Solutions for inhalation by nebulation may be formulated with an aqueous vehicle with the addition of agents such as acid or alkali, buffer salts, isotonicity adjusting agents or antimicrobials. They may be sterilised by filtration or heating in an autoclave, or presented as a non-sterile product. Preferred unit dosage formulations are those containing an effective dose, as herein before recited, or an appropriate fraction thereof, of the active ingredient.
Throughout the specification and the claims which follow, unless the context requires otherwise, the word 'comprise', and variations such as 'comprises' and 'comprising', will be understood to imply the inclusion of a stated integer or step or group of integers but not to the exclusion of any other integer or step or group of integers or steps. All publications, including but not limited to patents and patent applications, cited in this specification are herein incorporated by reference as if each individual publication were specifically and individually indicated to be incorporated by reference herein as though fully set forth. The above description fully discloses the invention including preferred embodiments thereof. Modifications and improvements of the embodiments specifically disclosed herein are within the scope of the following claims. Without further elaboration, it is believed that one skilled in the art can, using the preceding description, utilize the present invention to its fullest extent. Therefore the Examples herein are to be construed as merely illustrative and not a limitation of the scope of the present invention in any way. The embodiments of the invention in which an exclusive property or privilege is claimed are defined as follows.

Claims

What is claimed is:
A compound of formula (I) as indicated below
Figure imgf000080_0001
(I) wherein:
Rl is selected from the group consisting of Cl-15 alkyl, halosubstituted Cl-15 alkyl, Cl-15 alkyl cycloalkyl, cycloalkyl, C2- 15 alkenyl, hydroxy substituted Cl-15 alkyl, Cl-15 alkyl aryl, Cl-15 alkyl heteroaryl, (CR7R7)qNRaRa, (CR7R7)qNC(O)Ra, (CR7R7)qC(O)NRaRa, (CR7R7)qC(O)Ra, (CR7R7)qOC (O)Ra, (CR7R7)qNRaC(O)NRaRa, (CR7R7)qORc and (CR7R7)qNS(O)2Ra
Rl is selected from the group consisting of:
Figure imgf000080_0002
Rl is selected from the group consisting of:
Figure imgf000080_0003
R2 and R3 are independently selected from the group consisting of aryl, Cl-4 alkyl aryl, heteroaryl, Cl-4 alkyl heteroaryl, heterocyclic and a Cl-4 alkyl heterocyclic moiety, all of which moieties may be optionally substituted; Ra is selected from the group consisting of hydrogen, Cl-15 alkyl, Cl-15 alkoxy, aryl, Cl-15 alkyl aryl, heteroaryl, Cl-15 alkyl heteroaryl, heterocyclic and a Cl-15 alkyl heterocyclic moiety, all of which moieties may be optionally substituted;
Re is selected from the group consisting of hydrogen, Cl-15 alkyl, Cl-15 alkoxy, heterocyclic and a Cl-15 alkyl heterocyclic moiety, all of which moieties may be optionally substituted;
R4 and R5 are independently selected from the group consisting of hydrogen, halogen, Cl-4 alkyl, aryl, Cl-4 alkyl aryl, cyano, nitro, (CR7R7)pORb, (CR7R7)pNRbRb, or R4 and R5 together may form a 5 to 6 membered saturated or unsaturated ring; and wherein the alkyl, aryl, arylalkyl, heteroaryl, heteroalkyl, heterocyclic, heterocyclicalkyl groups may be optionally substituted;
R6 is selected from the group consisting of hydrogen, Cl-4 alkyl;
q is 0 or an integer having a value of 1 to 15; n is an integer having a value of 1 to 14; m is an integer having a value of 1 to 15; 1 is an integer having a value of 1 to 4; t is 0 or an integer having a value of 1 to 5; p is 0 or an integer having a value of 1 to 4;
X, Y, Z and W are independently selected from the group consisting of hydrogen, Cl-4 alkyl;
V is selected from the group consisting of CH2, O, S, and NRb;
M is O or CH2;
Rb is selected from the group consisting of hydrogen, Cl-4 alkyl, aryl and Cl-4 alkyl aryl;
R7 is selected from the group consisting of hydrogen, Cl-4 alkyl, halosubstituted Cl-4 alkyl, and hydroxysubstituted Cl-4 alkyl; X- is a physiologically acceptable anion, such as chloride, bromide, iodide, hydroxide, sulfate, nitrate, phosphate, acetate, trifluoroacetate, fumarate, citrate, tartrate, oxalate, succinate, mandelate, methanesulfonate and p-toluenesulfonate.
2. A compound of formula (I) as indicated below:
Figure imgf000082_0001
(I) Rl is selected from the group consisting of Cl-10 alkyl, halosubstituted Cl-10 alkyl, Cl-10 alkyl aryl, Cl-10 alkyl cycloalkyl, cycloalkyl, hydroxy substituted Cl-10 alkyl, C2- 10 alkenyl, (CR7R7)qORc; (CR7R7)qOC (O)Ra and (CR7R7)qNS(O)2Ra;
or Rl is selected from the group consisting of:
Figure imgf000082_0002
R2 and R3 are, independently, selected from the group consisting of:
Figure imgf000082_0003
F, G, H, K and L are independently selected from the group consisting of hydrogen, halogen, Cl-4 alkyl, halosubstituted Cl-4 alkyl, hydoxysubstituted Cl-4 alkyl, and Cl- 4 alkoxy;
Ra is selected from the group consisting of hydrogen, Cl-10 alkyl, Cl-10 alkoxy, aryl and heteroaryl, all of which moieties may be optionally substituted; Rc is selected from the group consisting of hydrogen, Cl-5 alkyl, Cl-5 alkoxy, all of which moieties may be optionally substituted;
R4 and R5 are independently selected from the group consisting of hydrogen, halogen, Cl-4 alkyl, aryl, Cl-4 alkyl aryl, cyano, nitro, (CR7R7)pORb, (CR7R7)pNRbRb, or R4 and R5 together may form a 5 to 6 membered saturated or unsaturated ring;
q is 0 or an integer having a value of 1 to 5; n is an integer having a value of 1 to 4; m is an integer having a value of 1 to 5; 1 is 1 or 2; t is 0, 1 or 2; p is 0, 1 or 2;
V is O, or CH2;
R6 is selected from the group consisting of hydrogen, Cl-4 alkyl;
M is O or CH2-
Rb is selected from the group consisting of hydrogen, Cl-4 alkyl, and aryl Cl-4 alkyl R7 is selected from the group consisting of hydrogen, and Cl-4 alkyl; X- is a physiologically acceptable anion, such as chloride, bromide, iodide, hydroxide, sulfate, nitrate, phosphate, acetate, trifluoroacetate, fumarate, citrate, tartrate, oxalate, succinate, mandelate, methanesulfonate and p-toluenesulfonate.
3. A compound according to claim 1 selected from the group of :
1 -(2- { [(3 -fluorophenyl)methyl] oxy} ethyl)-4- [hydroxy (diphenyl)methyl]- 1 - azoniabicyclo[2.2.2]octane bromide
4-[hydroxy(diphenyl)methy 1] - 1 - { 2- [(pheny lmethyl)oxy] ethyl} - 1 - azoniabicyclo[2.2.2]octane bromide 1 -(2- { [(4-bromophenyl)methyl] oxy} ethyl)-4- [hydroxy(dipheny l)methyl] - 1 - azoniabicyclo[2.2.2]octane bromide l-(2-{[(4-chlorophenyl)methyl]oxy}ethyl)-4-[hydroxy(diphenyl)methyl]-l- azoniabicyclo [2.2.2] octane bromide 4-[bis(4-fluorophenyl)(hydroxy)methyl]- 1 -{2-[(phenylmethyl)oxy]ethyl} - 1 - azoniabicyclo [2.2.2] octane bromide
4-{hydroxy[bis(3-methylphenyl)]methyl}-l-{2-[(ρhenylmethyl)oxy]ethyl}-l- azoniabicyclo [2.2.2] octane bromide
1 -(2- { [(4-fluorophenyl)methyl] oxy} ethyl)-4- [hydroxy(diphenyι)methyl] - 1 - azoniabicyclo[2.2.2]octane bromide
4- [hydroxy(diphenyl)methyl] - 1 - {2- [(phenylcarbonyl)oxy] ethyl} - 1 - azoniabicyclo[2.2.2]octane bromide
1 - { 3 - [(3 -fluorophenyl)oxy] propyl } -4- [hydroxy (dipheny l)methy 1] - 1 - azoniabicyclo[2.2.2]octane bromide 4- {hydroxy [bis(4-methylphenyl)]methyl } - 1 - {2- [(ρhenylmethyl)oxy] ethyl } - 1 - azoniabicyclo[2.2.2]octane bromide
4- [hydroxy (dipheny l)methyl] - 1 - {3 - [(methylsulfonyl)amino]propyl} - 1 - azoniabicyclo [2.2.2] octane bromide
4-[bis(3-fluorophenyl)(hydroxy)methyl]-l-{2-[(phenylmethyl)oxy]ethyl}-l- azoniabicyclo[2.2.2]octane bromide
1 - { 3 - [(3 -chlorophenyl)oxy]propyl} -4- [hydroxy (diphenyl)methyl] - 1 - azoniabicyclo[2.2.2]octane bromide
4- [hy droxy(di-2-thienyl)methyl] - 1 - [3 -(phenyloxy)propyl] - 1 -azoniabicyclo [2.2.2] octane bromide 4-[hydroxy(diphenyl)methyl]-l-[3-(phenyloxy)propyl]-l-azoniabicyclo[2.2.2]octane bromide l-(2-{[(4-cyanophenyl)methyl]oxy}ethyl)-4-[hydroxy(diphenyl)methyl]-l- azoniabicy clo [2.2.2] octane bromide
1 - { 3 - [(4-bromophenyl)oxy]propyl } -4- [hydroxy (diphenyl)methyl] - 1 - azoniabicyclo[2.2.2]octane bromide
4- [bis(4-fluorophenyl)(hydroxy)methyl] - 1 - [3 -(phenyloxy)propyl] - 1 - azoniabicyclo[2.2.2]octane bromide 1 - { 3 - [(4-fluorophenyl)oxy]propyl} -4- [hydroxy (diphenyl)methyl] - 1 - azoniabicyclo [2.2.2] octane bromide
4- [hydroxy(diphenyl)methyl] -l-{2-[(l -methyl- 1 -phenylethyl)oxy] ethyl} - 1 - azoniabicyclo [2.2.2] octane bromide 4- [hydroxy(diphenyl)methyl] - 1 - {2- [(2-naphthalenylmethyl)oxy] ethyl } - 1 - azoniabicyclo[2.2.2]octane bromide
4- [hydroxy(di-3 -thienyl)methyl] - 1 - [3 -(pheny loxy)propyl] - 1 -azoniabicyclo [2.2.2] octane bromide
4- [hydroxy(diphenyl)methyl] - 1 - [2-(phenyloxy)ethyl] - 1 -azoniabicyclo [2.2.2]octane bromide
4-{hydroxy[bis(3-methylphenyl)]methyl}-l-[3-(phenyloxy)propyl]-l- azoniabicyclo [2.2.2] octane bromide
4- {hydroxy [bis(4-methylphenyl)]methyl } - 1 - [3 -(phenyloxy)propyl] - 1 - azoniabicyclo [2.2.2] octane bromide 4- [hydroxy(diphenyl)methyl] - 1 -(3 - { [4-(methyloxy)phenyl]oxy } propyl)- 1 - azoniabicyclo [2.2.2] octane bromide
4- [hydroxy(diphenyl)methyl]- 1 - [3 -(2-naphthaleny loxy)propyl] - 1 - azoniabicyclo[2.2.2]octane bromide
4- [hydroxy (diphenyl)methyl] - 1 - [2-( { [3 -(methyloxy)phenyl]methyl} oxy)ethyl]- 1 - azoniabicyclo [2.2.2] octane bromide
4-[hy droxy (diphenyl)methyl] - 1 -(2-naphthalenylmethyl)- 1 -azoniabicyclo [2.2.2] octane bromide
4- [bis(3 -fluorophenyl)(hydroxy)methyl] - 1 - [3 -(pheny loxy)propyl] - 1 - azoniabicyclo[2.2.2]octane bromide 4- [hydroxy(di-2-thienyl)methyl] - 1 - [2-(phenyloxy)ethyl]- 1 -azoniabicyclo [2.2.2] octane bromide
4-(hy droxy {bis [3 -(methyloxy)phenyl] } methyl)- 1 - { 2- [(phenylmethyl)oxy] ethyl } - 1 - azoniabicyclo[2.2.2]octane bromide
4- [hydroxy (diphenyl)methyl]- 1 - { 3 - [(4-nitrophenyl)oxy]propyl} - 1 - azoniabicyclo[2.2.2]octane bromide
1 - { 3 -[(2-fluorophenyl)oxy]propyl} -4-[hydroxy(diphenyl)methyl] - 1 - azoniabicyclo[2.2.2]octane bromide 4- [hydroxy(diphenyl)methyl] - 1 - { 3 - [(3 -nitrophenyl)oxy]propyl} - 1 - azoniabicyclo [2.2.2] octane bromide
4- [hydroxy (diphenyl)methyl] - 1 -( { 3 - [(trifluoromethyl)oxy]phenyl } methyl)- 1 - azoniabicyclo[2.2.2]octane bromide 4- [hydroxy(diphenyl)methyl] - 1 - [(5-nitro-2-furanyl)methyl]- 1 - azoniabicyclo [2.2.2] octane bromide
4- [hydroxy (diphenyl)methyl] - 1 - [2-( 1 H-indol-3 -yl)ethyl] - 1 -azoniabicyclo [2.2.2] octane bromide
1 - [3 -(4-biphenylyloxy)proρyl] -4- [hydroxy(diphenyl)methyl] - 1 - azoniabicyclo[2.2.2]octane bromide
4-[hydroxy(diρhenyl)methyl]- 1 - { 3 -[(2-methylphenyl)oxy]propyl} - 1 - azoniabicyclo[2.2.2]octane bromide
4- [hydroxy(diphenyl)methyl] - 1 -(phenylmethyl)- 1 -azoniabicyclo [2.2.2] octane bromide
4- [hydroxy (diphenyl)methyl] - 1 -(2- { [2-(methyloxy)ethyl] oxy } ethyl)- 1 - azoniabicyclo[2.2.2]octane bromide
4-[hydroxy(diphenyl)methyl]- 1 - { 3 -[(phenylmethyl)oxy]propyl} - 1 - azoniabicyclo[2.2.2]octane bromide
4- [hy droxy(diphenyl)methyl] - 1 - [4-(phenyloxy)butyl] - 1 -azoniabicyclo [2.2.2] octane bromide 1 -(1 ,3-dioxolan-2-ylmethyl)-4-[hydroxy(diphenyl)methyl]- 1 - azoniabicyclo[2.2.2]octane bromide
4- [hy droxy(diphenyl)methyl] - 1 - { 3 - [(2-hydroxyphenyl)oxy]propyl } - 1 - azoniabicyclo [2.2.2] octane bromide
1 -hexyl-4- [hydroxy(diphenyl)methyl] - 1 -azoniabicyclo [2.2.2] octane bromide 4-[hydroxy(di-3-thienyl)methyl]-l-[2-(phenyloxy)ethyl]-l-azoniabicyclo[2.2.2]octane bromide
4- [hydroxy (dipheny l)methyl] -l-[3-({4- [(pheny lmethyl)oxy]phenyl } oxy)propyl] - 1 - azoniabicyclo [2.2.2] octane bromide
1 - [(3 -bromophenyl)methyl] -4- [hydroxy(diphenyl)methyl] - 1 -azoniabicyclo [2.2.2] octane bromide
4-[hydroxy(di-2-naphthalenyl)methyl] - 1 - {2-[(phenylmethyl)oxy] ethyl} - 1 - azoniabicyclo [2.2.2] octane' bromide 4- [hydroxy (dipheny l)methyl] - 1 - [2-(methyloxy)ethyl] - 1 -azoniabicyclo [2.2.2] octane bromide
4-(hy droxy {bis [4-(methyloxy)phenyl] } methyl)- 1 - { 2- [(pheny lmethyl)oxy] ethyl } - 1 - azoniabicyclo[2.2.2]octane bromide 1 - { 3 - [(4-cyanophenyl)oxy]propyl } -4- [hydroxy(diphenyl)methyl]- 1 - azoniabicyclo[2.2.2]octane bromide
1 - [2-( 1 -benzofuran-2-yl)-2-oxoethyl] -4- [hydroxy(diphenyl)methyl] - 1 - azoniabicyclό[2.2.2]octane bromide l-[2-({[4-(l,l -dimethylethyl)phenyl]methyl} oxy)ethyl] -4- [hydroxy(diphenyl)methyl] - 1 -azoniabicyclo [2.2.2] octane bromide
4- [hydroxy(diphenyl)methyl] - 1 - { [3 -(methyloxy)phenyl]methyl } - 1 - azoniabicyclo[2.2.2]octane bromide
4-[hydroxy(diphenyl)methyl]-l-({4-[(trifluoromethyl)oxy]phenyl}methyl)-l- azoniabicyclo[2.2.2]octane bromide 4-[hydroxy(diphenyl)methyl]-l-nonyl-l-azoniabicyclo[2.2.2]octane bromide
4-[hydroxy(di-2-naphthalenyl)methyl]-l -[3-(phenyloxy)propyl]- 1 - azoniabicyclo[2.2.2]octane bromide l-[(4-fluorophenyl)methyl]-4-[hydroxy(diphenyl)methyl]-l-azoniabicyclo[2.2.2]octane bromide 1 -[(4-bromophenyl)methyl]-4-[hydroxy(diphenyl)methyl]- 1 -azoniabicyclo[2.2.2]octane bromide
4- [hydroxy(diphenyl)methyl] - 1 - { [3 -(trifluoromethyl)phenyl]methyl} - 1 - azoniabicyclo[2.2.2]octane bromide
1 - [(2-fluorophenyl)methyl] -4- [hydroxy(diphenyl)methyl] - 1 -azoniabicyclo [2.2.2]octane bromide
4-[hydroxy(diphenyl)methyl]- 1 - { [4-(trifluoromethyl)phenyl]methyl} - 1 - azoniabicyclo[2.2.2]octane bromide l-(5-hexen-l-yl)-4-[hydroxy(diphenyl)methyl]-l-azoniabicyclo[2.2.2]octane bromide
1 -(3 -cyclohexylpropyl)-4- [hydroxy(diphenyl)methy 1] - 1 -azoniabicyclo [2.2.2] octane bromide
4-[hydroxy(diphenyl)methyl] - 1 -[2-(tetrahydro-2H-pyran-2-yloxy)ethyl] - 1 - azoniabicyclo[2.2.2]octane bromide 1 - [2-( 1 ,3 -dioxo- 1 ,3 -dihy dro-2H-isoindol-2-yl)ethyl] -4- [hydroxy (dipheny l)methyl] - 1 - azoniabicyclo[2.2.2]octane bromide
4- [hydroxy (diphenyl)methyl] - 1 -(2-phenylethyl)- 1 -azoniabicyclo [2.2.2] octane bromide
1 -ethyl-4- [hydroxy(diphenyl)methyl] - 1 -azoniabicyclo [2.2.2] octane bromide 4- [hydroxy(diphenyl)methyl] - 1 - [(4-methylphenyl)methyl]- 1 - azoniabicyclo [2.2.2] octane bromide
1 -butyl-4- [hydroxy (dipheny l)methyl] - 1 -azoniabicyclo [2.2.2] octane bromide
4- [hydroxy (diphenyl)methyl] - 1 - [2-(3 -methyl- 1 H-pyrazol- 1 -yl)ethyl] - 1 - azoniabicyclo[2.2.2]octane bromide 4-(hydroxy {bis [4-(methyloxy)phenyl] } methyl)- 1 - [3 ~(phenyloxy)propyl] - 1 - azoniabicyclo[2.2.2]octane bromide
1 - [3 -(3 -biphenylyloxy)propyl] -4- [hydroxy(diphenyl)methyl] - 1 - azoniabicyclo[2.2.2]octane bromide
4- [hydroxy (diphenyl)methyl] - 1 - [( 1 S)- 1 -methyl-2-oxo-2-(phenylamino)ethyl] - 1 - azoniabicyclo[2.2.2]octane bromide
4- [hydroxy (diphenyl)methyl] - 1 -propyl- 1 -azoniabicyclo [2.2.2] octane bromide
1 - {3-[(2-bromophenyl)oxy]propyl} -4-[hydroxy(diphenyl)methyl]- 1 - azoniabicyclo[2.2.2]octane bromide
1 - [(3 -fluoropheny l)methy 1] -4 - [hydroxy (diphenyl)methy 1] - 1 -azoniabicyclo [2.2.2] octane bromide
1 - [(3 ,4-dichlorophenyl)methyl] -4-[hy droxy (dipheny l)methyl] - 1 - azoniabicyclo [2.2.2] octane bromide l-[(2-fluoro-3-methylphenyl)methyl]-4-[hydroxy(diphenyl)methyl]-l- azoniabicyclo[2.2.2]octane bromide 4- [hydroxy(diphenyl)methyl]- 1 - {4- [(phenylmethyl)oxy]butyl} - 1 - azoniabicyclo[2.2.2]octane bromide
1 - [(4-cyanophenyl)methyl] -4- [hydroxy (diphenyl)methyl] - 1 -azoniabicyclo [2.2.2] octane bromide
4-(hy droxy {bis [3 -(methyloxy)phenyl] } methyl)- 1 - [3 -(pheny loxy)propyl] - 1 - azoniabicyclo[2.2.2]octane bromide l-(3-{[3-(diethylamino)phenyl]oxy}propyl)-4-[hydroxy(diphenyl)methyl]-l- azoniabicyclo[2.2.2]octane bromide 4-[hydroxy(diphenyl)methyl]-l -(2-propen-l -yl)-l -azoniabicyclo[2.2.2]octane bromide
1 - { [4-( 1 , 1 -dimethylethyl)phenyl]methyl} -4- [hydroxy(diphenyl)methyl] - 1 - azoniabicyclo[2.2.2]octane bromide
4-[hydroxy(diphenyl)methyl]-l-(3-phenylpropyl)-l-azoniabicyclo[2.2.2]octane bromide
1 - [(2,6-difluorophenyl)methyLJ -4- [hydroxy (dipheny l)methyl] - 1 - azoniabicyclo[2.2.2]octane bromide
4-[hydroxy(diphenyl)methyl]-l-[2-({[2-(phenyloxy)-3- pyridinyl]carbonyl} amino)ethyl]- 1 -azoniabicyclo[2.2.2]octane bromide 4-[hydroxy(di-2-thienyl)methyl]-l-(2-phenylethyl)-l-azoniabicyclo[2.2.2]octane bromide
1 -(3 -bromopropyl)-4- [hy droxy (dipheny l)methyl]- 1 -azoniabicyclo[2.2.2]octane bromide
4- [hydroxy (dipheny l)methyl] - 1 -(2-hydroxyethyl)- 1 -azoniabicyclo [2.2.2] octane bromide
1 -[(3 -cyanophenyi)methyl] -4-[hydroxy(diphenyl)methyl] - 1 -azoniabicyclo [2.2.2] octane bromide l-[2-({[(2,4-dichlorophenyl)amino]carbonyl}amino)ethyl]-4-
[hydroxy(diphenyl)methyl]-l -azoniabicyclo[2.2.2]octane bromide 4- [hydroxy(diphenyl)methyl] - 1 -(4-penten- 1 -yl)- 1 -azoniabicyclo [2.2.2] octane bromide
1 - { 2- [(2,4-dibromopheny l)oxy] ethyl} -4-[hydroxy(diphenyl)methyl] - 1 - azoniabicyclo [2.2.2] octane bromide
1 - [(2,4-difluorophenyl)methyl] -4- [hydroxy(diphenyl)methyl] - 1 - azoniabicyclo[2.2.2]octane bromide 4- [hydroxy(diphenyl)methyl] - 1 - [3 -(methyloxy)propyl]- 1 -azoniabicyclo [2.2.2]octane bromide
4- [hydroxy(diphenyl)methyl] -l-[3-({2- [(pheny lmethyl)oxy]phenyl } oxy)propyl] - 1 - azoniabicyclo [2.2.2] octane bromide [ 1 -(2-aminoethyl)- 1 -azoniabicyclo [2.2.2] oct-4-yl] (diphenyl)methanolate trifluoroacetate
4-[hydroxy(di-2-thienyl)methyl]-l-(3-phenylpropyl)-l-azoniabicyclo[2.2.2]octane bromide 4- [hydroxy (dipheny l)methyl] - 1 -methyl- 1 -azoniabicyclo [2.2.2] octane bromide
4- [hydroxy(diphenyl)methyl] - 1 -(tetrahydro-2H-pyran-2-ylmethyl)- 1 - azoniabicyclo [2.2.2] octane bromide
1 - [(2,3 -difluorophenyl)methyl] -4- [hydroxy(diphenyl)methyl] - 1 - azoniabicyclo[2.2.2]octane bromide
1 - [2-(4-biphenylyl)-2-oxoethyl] -4-[hydroxy(diphenyl)methyl] - 1 - azoniabicyclo [2.2.2] octane bromide
4- [hydroxy (dipheny l)methyl] - 1 - [2-oxo-2-(4-pentylphenyl)ethyl] - 1 - azoniabicyclo[2.2.2]octane bromide l-(2-{[(2,4-dichlorophenyl)carbonyl]amino}ethyl)-4-[hydroxy(diphenyl)methyl]-l- azoniabicyclo[2.2.2]octane bromide
4- [hydroxy(diphenyl)methyl] - 1 -(3- { [2-(methyloxy)phenyl]oxy }propyl)- 1 - azoniabicyclo[2.2.2]octane bromide
4- [hydroxy(diphenyl)methyl] - 1 - [( 1 - { [(phenylmethyl)oxy] carbonyl } -4- piperidinyl)methyl]-l-azoniabicyclo[2.2.2]octane bromide
4- [hydroxy(diphenyl)methyl] - 1 - [2-(2-naphthaleny l)-2-oxoethyl] - 1 - azoniabicyclo[2.2.2]octane bromide
4- [hydroxy(diphenyl)methyl] - 1 - [(4-nifrophenyι)methyl] - 1 -azoniabicyclo [2.2.2] octane bromide l-butyl-4-[hydroxy(di-3-thienyl)methyl]-l-azoniabicyclo[2.2.2]octane bromide
4- [hydroxy(diphenyl)methyl] - 1 -(2-oxo-2-phenylethyl)- 1 -azoniabicyclo [2.2.2] octane bromide
1 - [(3 ,4-difluorophenyl)methyl] -4- [hydroxy(diphenyl)methyl] - 1 - azoniabicyclo[2.2.2]octane bromide; and l-(cyclopropylmethyl)-4-[hydroxy(diphenyl)methyl]-l-azoniabicyclo[2.2.2]octane bromide.
4. A compound according to claim 1 consisting of the group of:
The preferred compounds useful in the present invention include:
1 -(2- { [(3 -fluorophenyl)methyl]oxy } ethyl)-4- [hydroxy(diphenyl)methyl] - 1 - azoniabicyclo[2.2.2]octane bromide
4- [hydroxy(diphenyl)methyl] - 1 - { 2- [(phenylmethyl)oxy] ethyl } - 1 - azoniabicyclo[2.2.2]octane bromide
1 -(2- { [(4-bromophenyl)methyl] oxy} ethyl)-4- [hy droxy(dipheny l)methyl] - 1 - azoniabicyclo[2.2.2]octane bromide
1 -(2- { [(4-chlorophenyl)methyl] oxy} ethyl)-4- [hydroxy (dipheny l)methyl] - 1 - azoniabicyclo [2.2.2] octane bromide
4- [bis(4-fluorophenyl)(hydroxy)methyl] - 1 - {2- [(phenylmethyl)oxy] ethyl } - 1 - azoniabicyclo [2.2.2] octane bromide 4- {hydroxy [bis(3 -methylphenyl)]methyl } - 1 - {2- [(phenylmethyl)oxy]ethyl} - 1 - azoniabicyclo[2.2.2]octane bromide
1 -(2- { [(4-fluorophenyl)methyl] oxy} ethyl)-4- [hydroxy (dipheny l)methyl] - 1 - azoniabicyclo[2.2.2]octane bromide
4- [hydroxy (diphenyl)methyl] - 1 - {2- [(pheny lcarbonyl)oxy] ethyl } - 1 - azoniabicyclo[2.2.2]octane bromide
1 - { 3 - [(3 -fluoropheny l)oxy]propyl} -4- [hydroxy (dipheny l)methyl] - 1 - azoniabicyclo[2.2.2]octane bromide
4- {hydroxy [bis(4-methylphenyl)]methyl} - 1 - {2- [(phenylmethyl)oxy] ethyl} - 1 - azoniabicyclo [2.2.2] octane bromide 4-[hydroxy(diphenyl)methyl]- 1 - {3 -[(methylsulfonyl)amino]propyl} - 1 - azoniabicyclo[2.2.2]octane bromide
4- [bis(3 -fluoropheny l)(hydroxy)methyl] - 1 - {2- [(pheny lmethyl)oxy] ethyl } - 1 - azoniabicyclo [2.2.2] octane bromide
1 - { 3 - [(3 -chlorophenyl)oxy]propyl } -4- [hydroxy (dipheny l)methyl] - 1 - azoniabicyclo[2.2.2]octane bromide
4-[hydroxy(di-2-thienyl)methyl]-l-[3-(phenyloxy)propyl]-l-azoniabicyclo[2.2.2]octane bromide 4- [hydroxy(diphenyl)methyl] - 1 - [3 -(phenyloxy)propyl] - 1 -azoniabicyclo [2.2.2] octane bromide
1 -(2- { [(4-cyanophenyl)methyl] oxy} ethyl)-4- [hydroxy (diphenyl)methyl] - 1 - azoniabicyclo[2.2.2]octane bromide 1 - { 3 - [(4-bromophenyl)oxy]propyl } -4- [hydroxy(diphenyl)methyl] - 1 - azoniabicyclo[2.2.2]octane bromide
4- [bis(4-fluorophenyl)(hydroxy)methyl] - 1 - [3 -(phenyloxy)propyl] - 1 - azoniabicyclo [2.2.2] octane bromide
1 - {3 - [(4-fluorophenyl)oxy]propyl } -4- [hydroxy(diphenyl)methyl] - 1 - azoniabicyclo[2.2.2]octane bromide
4- [hydroxy (dipheny l)methyl] -l-{2-[(l -methyl- 1 -pheny lethyl)oxy] ethyl} - 1 - azoniabicyclo[2.2.2]octane bromide
4-[hydroxy(diphenyl)methyl]-l-{2-[(2-naphthalenylmethyl)oxy]ethyl}-l- azoniabicyclo[2.2.2]octane bromide 4-[hydroxy(di-3-thienyl)methyl]-l-[3-(phenyloxy)propyl]-l-azoniabicyclo[2.2.2]octane bromide
4- [hydroxy (diphenyl)methyl] - 1 - [2-(phenyloxy)ethyl] - 1 -azoniabicyclo [2.2.2] octane bromide
4- {hydroxy [bis(3 -methylphenyl)]methyl } - 1 - [3 -(pheny loxy)propyl] - 1 - azoniabicyclo[2.2.2]octane bromide
4- {hydroxy [bis(4-methylphenyl)]methyl} - 1 -[3 -(phenyloxy)propyl] - 1 - azoniabicy clo [2.2.2] octane bromide
4- [hy droxy(diphenyl)methyl] - 1 -(3 - { [4-(methyloxy)phenyl] oxy }propyl)- 1 - azoniabicyclo [2.2.2] octane bromide 4-[hydroxy(diphenyl)methyl]-l-[3-(2-naphthalenyloxy)propyl]-l- azoniabicyclo[2.2.2]octane bromide
4-[hydroxy(diphenyl)methyl]-l -[2-({ [3-(methyloxy)phenyl]methyl}oxy)ethyl]-l - azoniabicyclo[2.2.2]octane bromide
4-[hydroxy(diphenyl)methyl]-l-(2-naphthalenylmethyl)-l-azoniabicyclo[2.2.2]octane bromide
4- [bis(3 -fluoropheny l)(hydroxy)methyl] - 1 - [3 -(phenyloxy)propyl] - 1 - azoniabicyclo[2.2.2]octane bromide 4-[hydroxy(di-2-thienyl)methyl]-l-[2-(phenyloxy)ethyl]-l-azoniabicyclo[2.2.2]octane bromide
4-(hydroxy {bis [3 -(methyloxy)phenyl] } methyl)- 1 - {2- [(phenylmethyl)oxy] ethyl } - 1 - azoniabicyclo[2.2.2]octane bromide . 4- [hydroxy(diphenyl)methyl]- 1 - {3 - [(4-nitrophenyl)oxy]propyl } - 1 - azoniabicyclo[2.2.2]octane bromide; and
1 - { 3 - [(2-fluorophenyl)oxy]propyl } -4- [hydroxy (diphenyl)methyl] - 1 - azoniabicyclo[2.2.2]octane bromide.
5. A compound according to claim 4 selected from the group consisting of: The more preferred compounds useful in the present invention include:
1 -(2- { [(3 -fluorophenyl)methyl] oxy } ethyl)-4- [hydroxy(diphenyl)methyl] - 1 - azoniabicyclo[2.2.2]octane bromide 4- [hydroxy(diphenyl)methyl]- 1 - {2-[(phenylmethyl)oxy]ethyl} - 1 - azoniabicyclo[2.2.2]octane bromide
1 -(2- { [(4-bromophenyl)methyι] oxy} ethyl)-4- [hydroxy (diphenyl)methyl] - 1 - azoniabicyclo[2.2.2]octane bromide
1 -(2- { [(4-chlorophenyl)methyl] oxy} ethyl)-4- [hy droxy(diphenyl)methyl] - 1 - azoniabicyclo[2.2.2]octane bromide
4-[bis(4-fluorophenyl)(hydroxy)methyl]-l-{2-[(phenylmethyl)oxy]ethyl}-l- azoniabicyclo[2.2.2]octane bromide
4- {hydroxy [bis(3-methylphenyl)]methyl} - 1 - {2- [(phenylmethyl)oxy] ethyl} - 1 - azoniabicyclo [2.2.2] o ctane bromide 1 -(2- { [(4-fluorophenyl)methyl]oxy } ethyl)-4- [hydroxy(diphenyl)methyl] - 1 - azoniabicy clo [2.2.2] octane bromide
4-[hydroxy(diphenyl)methyl] - 1 - {2-[(phenylcarbonyl)oxy] ethyl} - 1 - azoniabicyclo [2.2.2] octane bromide
1 - { 3 - [(3 -fluoropheny l)oxy]propyl } -4- [hydroxy (diphenyl)methyl] - 1 - azoniabicyclo[2.2.2]octane bromide
4- {hydroxy [bis(4-methylphenyl)]methyl} - 1 - {2-[(phenylmethyl)oxy] ethyl} - 1 - azo'niabicyclo[2.2.2]octane bromide 4- [hydroxy (dipheny l)methyl] - 1 - { 3 - [(methylsulfonyl)amino]propyl} - 1 - azoniabicyclo[2.2.2]octane bromide
4- [bis(3 -fluoropheny l)(hydroxy)methyl] - 1 - { 2- [(pheny lmethyl)oxy] ethyl } - 1 - azoniabicyclo[2.2.2]octane bromide l-{3-[(3-chlorophenyl)oxy]propyl}-4-[hydroxy(diphenyl)methyl]-l- azoniabicyclo[2.2.2]octane bromide
4-[hydroxy(di-2-thienyl)methyl]-l-[3-(phenyloxy)propyl]-l-azoniabicyclo[2.2.2]octane bromide
4- [hydroxy (diphenyl)methyl] - 1 - [3 - (pheny loxy)propyl] - 1 -azoniabicyclo [2.2.2] octane bromide
1 -(2- { [(4-cyanophenyl)methyl] oxy } ethyl)-4- [hydroxy(diphenyl)methyl] - 1 - azoniabicyclo[2.2.2]octane bromide
1 - { 3 - [(4-bromophenyl)oxy]propyl } -4- [hydroxy (dipheny l)methyl] - 1 - azoniabicyclo[2.2.2]octane bromide 4-[bis(4-fluorophenyl)(hydroxy)methyl]-l-[3-(phenyloxy)propyl]-l- azoniabicyclo[2.2.2]octane bromide
1 - { 3 - [(4-fluorophenyl)oxy]propyl} -4- [hydroxy(diphenyl)methyl] - 1 - azoniabicyclo[2.2.2]octane bromide
4- [hydroxy(diphenyl)methyl]- 1 - {2- [(1 -methyl- 1 -phenylethyl)oxy] ethyl } - 1 - azoniabicyclo[2.2.2]octane bromide
4- [hydroxy(diphenyl)methyl] - 1 - {2- [(2-naphthalenylmethyι)oxy] ethyl } - 1 - azoniabicyclo [2.2.2] octane bromide
4- [hydroxy(di-3 -ιhienyl)methyl] - 1 - [3 -(pheny loxy)propyl] - 1 -azoniabicyclo [2.2.2] octane bromide 4-[hydroxy(diphenyl)methyl]-l -[2-(phenyloxy)ethyl]-l -azoniabicyclo[2.2.2]octane bromide; and
4- {hydroxy [bis(3 -methyrphenyl)]methyl } - 1 - [3 -(pheny loxy)propyl] - 1 - azoniabicyclo[2.2.2]octane bromide.
6. A compound according to claim 5 selected from the group consisting of: The most preferred compounds useful in the present invention include: 1 -(2- { [(3 -fluorophenyl)methyl] oxy} ethyl)-4- [hy droxy(diphenyl)methyl] - 1 - azoniabicy clo [2.2.2] octane bromide
4- [hydroxy (diphenyl)methyl] - 1 - {2- [(phenylmethyl)oxy] ethyl } - 1 - azoniabicyclo[2.2.2]octane bromide 1 -(2- { [(4-bromophenyl)methyl]oxy } ethyl)-4- [hydroxy(diphenyl)methyl] - 1 - azoniabicyclo [2.2.2] octane bromide
1 -(2- { [(4-chlorophenyl)methyl] oxy} ethyl)-4- [hydroxy(diphenyl)methyl] - 1 - azoniabicyclo[2.2.2]octane bromide
4-[bis(4-fluorophenyl)(hydroxy)methyl] - 1 - {2- [(phenylmethyl)oxy] ethyl} - 1 - azoniabicyclo[2.2.2]octane bromide
4-{hydroxy[bis(3-methylphenyl)]methyl}-l-{2-[(phenylmethyl)oxy]ethyl}-l- azoniabicyclo[2.2.2]octane bromide
1 -(2- { [(4-fluorophenyl)methyl] oxy} ethyl)-4- [hy droxy(diphenyl)methyl] - 1 - azoniabicyclo[2.2.2]octane bromide; and 4- [hydroxy(diphenyl)methyl]- 1 - {2- [(phenylcarbonyl)oxy] ethyl } - 1 - azoniabicyclo[2.2.2]octane bromide.
7. A pharmaceutical composition for the treatment of muscarinic acetylcholine receptor mediated diseases comprising a compound according to claim 1 and a pharmaceutically acceptable carrier thereof.
8. A method of inhibiting the binding of acetylcholine to its receptors in a mammal in need thereof comprising administering a safe and effective amount of a compound according to claim 1.
9. A method of treating a muscarinic acetylcholine receptor mediated disease, wherein acetylcholine binds to said receptor, comprising administering a safe and effective amount of a compound according to claim 1.
10. A method according to claim 8 wherein the disease is selected from the group consisting of chronic obstructive lung disease, chronic bronchitis, asthma, chronic respiratory obstruction, pulmonary fibrosis, pulmonary emphysema and allergic rhinitis.
11. A method according to claim 8 wherein administration is via inhalation via the mouth or nose.
12. A method according to claim 8 wherein administration is via a medicament dispenser selected from a reservoir dry powder inhaler, a multi-dose dry powder inhaler or a metered dose inhaler.
PCT/US2005/014386 2004-04-27 2005-04-27 Muscarinic acetylcholine receptor antagonists WO2005104745A2 (en)

Priority Applications (41)

Application Number Priority Date Filing Date Title
ES05746609.6T ES2392848T4 (en) 2004-04-27 2005-04-27 Muscarinic acetylcholine receptor antagonists
SI200531605T SI1740177T1 (en) 2004-04-27 2005-04-27 Muscarinic acetylcholine receptor antagonists
PT121704027T PT2570128T (en) 2004-04-27 2005-04-27 Muscarinic acetylcholine receptor antagonists
BRPI0510170A BRPI0510170B8 (en) 2004-04-27 2005-04-27 compound, pharmaceutical composition for the treatment of diseases mediated by the muscarinic acetylcholine receptor and use of the compound
DK05746609.6T DK1740177T3 (en) 2004-04-27 2005-04-27 Antagonists for muscarinic-sensitive acetylcholine receptors
AP2006003746A AP2213A (en) 2004-04-27 2005-04-27 Muscarinic acetylcholine receptor antagonists.
PL12170402T PL2570128T3 (en) 2004-04-27 2005-04-27 Muscarinic acetylcholine receptor antagonists
EA200601991A EA015033B1 (en) 2004-04-27 2005-04-27 Muscarinic acetylcholine receptor antagonists
NZ549997A NZ549997A (en) 2004-04-27 2005-04-27 Quinuclidine derivatives such as 4-[hydroxy(diphenyl)methyl]-1-{2-[(phenylmethyl)oxy]ethyl}-1-azoniabicyclo[2.2.2]octane bromide as muscarinic acetylcholine receptor antagonists
US11/568,330 US7498440B2 (en) 2004-04-27 2005-04-27 Muscarinic acetylcholine receptor antagonists
ES12170402.7T ES2600405T3 (en) 2004-04-27 2005-04-27 Muscarinic acetylcholine receptor antagonists
KR1020117001909A KR101152032B1 (en) 2004-04-27 2005-04-27 Muscarinic acetylcholine receptor antagonists
MXPA06012405A MXPA06012405A (en) 2004-04-27 2005-04-27 Muscarinic acetylcholine receptor antagonists.
DK12170402.7T DK2570128T3 (en) 2004-04-27 2005-04-27 Antagonists to muskarinerg acetylcholine.
JP2007510915A JP5014121B2 (en) 2004-04-27 2005-04-27 Muscarinic acetylcholine receptor antagonist
HUE12170402A HUE031304T2 (en) 2004-04-27 2005-04-27 Muscarinic acetylcholine receptor antagonists
EP12170402.7A EP2570128B1 (en) 2004-04-27 2005-04-27 Muscarinic acetylcholine receptor antagonists
EP05746609A EP1740177B1 (en) 2004-04-27 2005-04-27 Muscarinic acetylcholine receptor antagonists
CA2564742A CA2564742C (en) 2004-04-27 2005-04-27 Quaternary quinuclidine derivatives and their use as muscarinic receptor antagonists
AU2005237576A AU2005237576B2 (en) 2004-04-27 2005-04-27 Muscarinic Acetylcholine Receptor Antagonists
PL05746609T PL1740177T3 (en) 2004-04-27 2005-04-27 Muscarinic acetylcholine receptor antagonists
IL178152A IL178152A (en) 2004-04-27 2006-09-18 4-[hydroxy(diphenyl)methyl]-1-{2-[phenylmethyl)oxy]ethyl}-1-azoniabicyclo[2.2.2] octane bromide useful for treating muscarinic acetylcholine receptor mediated diseases, and pharmaceutical compositions comprising it
ZA2006/08565A ZA200608565B (en) 2004-04-27 2006-10-13 Muscarinic acetylcholine receptor antagonists
EC2006006940A ECSP066940A (en) 2004-04-27 2006-10-20 ANTAGONISTS OF THE MUSCARINIC ACETILCOLINE RECEIVER
NO20065417A NO338959B1 (en) 2004-04-27 2006-11-24 Muscarinic acetylcholine receptor antagonists, pharmaceutical preparations and such compounds for use.
HK07106891.0A HK1102423A1 (en) 2004-04-27 2007-06-27 Muscarinic acetylcholine receptor antagonists
US11/774,867 US7488827B2 (en) 2004-04-27 2007-07-09 Muscarinic acetylcholine receptor antagonists
US12/353,436 US8183257B2 (en) 2004-04-27 2009-01-14 Muscarinic acetylcholine receptor antagonists
US13/401,890 US8309572B2 (en) 2004-04-27 2012-02-22 Muscarinic acetylcholine receptor antagonists
US13/627,007 US8575347B2 (en) 2004-04-27 2012-09-26 Muscarinic acetylcholine receptor antagonists
HRP20120832TT HRP20120832T1 (en) 2004-04-27 2012-10-15 Muscarinic acetylcholine receptor antagonists
US14/052,816 US8853404B2 (en) 2004-04-27 2013-10-14 Muscarinic acetylcholine receptor antagonists
US14/476,940 US9045469B2 (en) 2004-04-27 2014-09-04 Muscarinic acetylcholine receptor antagonists
NL300694C NL300694I2 (en) 2004-04-27 2014-10-02
CY2014043C CY2014043I1 (en) 2004-04-27 2014-10-03 ACETYLCHOLINE MUSCARINIC RECEPTOR ANTAGONISTS
US14/707,543 US9144571B2 (en) 2004-04-27 2015-05-08 Muscarinic acetylcholine receptor antagonists
US14/849,775 US20160002220A1 (en) 2004-04-27 2015-09-10 Muscarinic acetylcholine receptor antagonists
CY20161101008T CY1118082T1 (en) 2004-04-27 2016-10-10 MUSCARINIC ACETYLCHOLINE RECEPTOR COMPONENTS
HRP20161385TT HRP20161385T1 (en) 2004-04-27 2016-10-25 Muscarinic acetylcholine receptor antagonists
NO2017017C NO2017017I1 (en) 2004-04-27 2017-05-04 umeclinidium and vilanterol
NO2017018C NO2017018I2 (en) 2004-04-27 2017-05-04 umeklidiniumbromid

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US56562304P 2004-04-27 2004-04-27
US60/565,623 2004-04-27

Related Child Applications (4)

Application Number Title Priority Date Filing Date
US11/568,330 A-371-Of-International US7498440B2 (en) 2004-04-27 2005-04-27 Muscarinic acetylcholine receptor antagonists
EP12170402.7A Previously-Filed-Application EP2570128B1 (en) 2004-04-27 2005-04-27 Muscarinic acetylcholine receptor antagonists
US11/774,867 Continuation US7488827B2 (en) 2004-04-27 2007-07-09 Muscarinic acetylcholine receptor antagonists
US12/353,436 Division US8183257B2 (en) 2004-04-27 2009-01-14 Muscarinic acetylcholine receptor antagonists

Publications (2)

Publication Number Publication Date
WO2005104745A2 true WO2005104745A2 (en) 2005-11-10
WO2005104745A3 WO2005104745A3 (en) 2006-08-03

Family

ID=35242158

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2005/014386 WO2005104745A2 (en) 2004-04-27 2005-04-27 Muscarinic acetylcholine receptor antagonists

Country Status (37)

Country Link
US (9) US7498440B2 (en)
EP (3) EP2570128B1 (en)
JP (2) JP5014121B2 (en)
KR (2) KR101037026B1 (en)
CN (2) CN1976701A (en)
AP (1) AP2213A (en)
AR (1) AR050902A1 (en)
AU (1) AU2005237576B2 (en)
BR (1) BRPI0510170B8 (en)
CA (2) CA2564742C (en)
CY (3) CY1113196T1 (en)
DK (2) DK2570128T3 (en)
EA (2) EA015033B1 (en)
EC (1) ECSP066940A (en)
ES (2) ES2600405T3 (en)
HK (1) HK1102423A1 (en)
HR (2) HRP20120832T1 (en)
HU (2) HUE031304T2 (en)
IL (1) IL178152A (en)
LT (1) LT2570128T (en)
LU (1) LU92565I2 (en)
MA (1) MA28631B1 (en)
MX (1) MXPA06012405A (en)
MY (1) MY144753A (en)
NL (1) NL300694I2 (en)
NO (3) NO338959B1 (en)
NZ (1) NZ549997A (en)
PE (1) PE20060259A1 (en)
PL (2) PL2570128T3 (en)
PT (2) PT2570128T (en)
SG (1) SG186597A1 (en)
SI (2) SI1740177T1 (en)
TW (1) TWI363759B (en)
UA (1) UA95768C2 (en)
UY (1) UY28871A1 (en)
WO (1) WO2005104745A2 (en)
ZA (1) ZA200608565B (en)

Cited By (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006085890A2 (en) * 2004-04-05 2006-08-17 Samaritan Pharmaceuticals, Inc. Anti-hiv quinuclidine compounds
WO2007122165A1 (en) 2006-04-20 2007-11-01 Glaxo Group Limited Novel compounds
WO2007144327A2 (en) 2006-06-12 2007-12-21 Glaxo Group Limited Phenyl-pyrazole derivatives as non-steroidal glucocoricoid receptor ligands
WO2008015416A1 (en) 2006-08-01 2008-02-07 Glaxo Group Limited Pyrazolo[3,4-b]pyridine compounds, and their use as pde4 inhibitors
WO2008118724A1 (en) 2007-03-23 2008-10-02 Smithkline Beecham Corporation Indole carboxamides as ikk2 inhibitors
WO2009147190A1 (en) 2008-06-05 2009-12-10 Glaxo Group Limited Novel compounds
WO2009147187A1 (en) 2008-06-05 2009-12-10 Glaxo Group Limited 4-carboxamide indazole derivatives useful as inhibitors of p13-kinases
US7767691B2 (en) * 2005-08-18 2010-08-03 Glaxo Group Limited Muscarinic acetylcholine receptor antagonists containing an azoniabiocyclo[2.2.1] heptane ring system
WO2010094643A1 (en) 2009-02-17 2010-08-26 Glaxo Group Limited Quinoline derivatives and their uses for rhinitis and urticaria
WO2010102968A1 (en) 2009-03-10 2010-09-16 Glaxo Group Limited Indole derivatives as ikk2 inhibitors
WO2010102958A1 (en) 2009-03-09 2010-09-16 Glaxo Group Limited 4-oxadiazol-2 -yl- indazoles as inhibitors of p13 kinases
WO2010106016A1 (en) 2009-03-17 2010-09-23 Glaxo Group Limited Pyrimidine derivatives used as itk inhibitors
WO2011029896A1 (en) 2009-09-11 2011-03-17 Glaxo Group Limited Methods of preparation of muscarinic acetylcholine receptor antagonists
WO2011067365A1 (en) 2009-12-03 2011-06-09 Glaxo Group Limited Benzpyrazole derivatives as inhibitors of p13 kinases
WO2011067212A1 (en) 2009-12-01 2011-06-09 Glaxo Group Limited Combinations of a muscarinic receptor antagonist and a beta-2 adrenoreceptor agonist
WO2011067366A1 (en) 2009-12-03 2011-06-09 Glaxo Group Limited Indazole derivatives as pi 3 - kinase inhibitors
WO2011067364A1 (en) 2009-12-03 2011-06-09 Glaxo Group Limited Novel compounds
WO2011110575A1 (en) 2010-03-11 2011-09-15 Glaxo Group Limited Derivatives of 2-[2-(benzo- or pyrido-) thiazolylamino]-6-aminopyridine, useful in the treatment of respiratoric, allergic or inflammatory diseases
US8067408B2 (en) 2008-02-06 2011-11-29 Glaxo Group Limited Dual pharmacophores—PDE4-muscarinic antagonistics
US8071588B2 (en) 2008-02-06 2011-12-06 Glaxo Group Limited Dual pharmacophores—PDE4-muscarinic antagonistics
US8084463B2 (en) 2004-11-02 2011-12-27 Novartis Ag Quinuclidine derivatives and their use as muscarinic M3 receptor antagonists
US8084449B2 (en) 2008-02-06 2011-12-27 Glaxo Group Limited Dual pharmacophores—PDE4-muscarinic antagonistics
WO2011160920A1 (en) * 2010-06-22 2011-12-29 Chiesi Farmaceutici S.P.A. Dry powder formulation comprising an antimuscarinic drug
WO2012032067A1 (en) 2010-09-08 2012-03-15 Glaxo Group Limited Polymorphs and salts of n- [5- [4- (5- { [(2r,6s) -2, 6 - dimethyl - 4 -morpholinyl] methyl} - 1, 3 - oxazol - 2 - yl) - 1h- inda zol-6-yl] -2- (methyloxy) - 3 - pyridinyl] methanesulfonamide
WO2012035055A1 (en) 2010-09-17 2012-03-22 Glaxo Group Limited Novel compounds
WO2012055846A1 (en) 2010-10-27 2012-05-03 Glaxo Group Limited Polymorphs and salts of 6-(1h-indol-4-yl)-4-(5- { [4-(1-methylethyl)-1-pi perazinyl] methyl} -1,3-oxazol-2-yl)-1h-indazole as pi3k inhibitors for use in the treatment of e.g. respiratory disorders
WO2012168160A1 (en) 2011-06-08 2012-12-13 Glaxo Group Limited Dry powder inhaler compositions comprising umeclidinium
WO2012168161A1 (en) 2011-06-08 2012-12-13 Glaxo Group Limited Combination comprising umeclidinium and a corticosteroid
WO2013153146A1 (en) 2012-04-13 2013-10-17 Glaxosmithkline Intellectual Property Development Limited Aggregate particles
WO2014027045A1 (en) * 2012-08-15 2014-02-20 Glaxo Group Limited Chemical process
WO2014095924A1 (en) * 2012-12-17 2014-06-26 Glaxo Group Limited Combination of umeclidinium, fluticasone propionate and salmeterol xinafoate for use in the treatment of inflammatory or respiratory tract diseases
WO2015015446A1 (en) 2013-07-30 2015-02-05 Glaxosmithkline Intellectual Property Development Limited Topical compositions for treatment of excessive sweating and methods of use thereof
WO2015055690A1 (en) 2013-10-17 2015-04-23 Glaxosmithkline Intellectual Property Development Limited Pi3k inhibitor for treatment of respiratory disease
WO2015055691A1 (en) 2013-10-17 2015-04-23 Glaxosmithkline Intellectual Property Development Limited Pi3k inhibitor for treatment of respiratory disease
EP2899191A1 (en) 2009-04-30 2015-07-29 Glaxo Group Limited Oxazole substituted indazoles as pi3-kinase inhibitors
WO2015173701A2 (en) 2014-05-12 2015-11-19 Glaxosmithkline Intellectual Property (No. 2) Limited Pharmaceutical compositions for treating infectious diseases
WO2015181262A1 (en) 2014-05-28 2015-12-03 Glaxosmithkline Intellectual Property Development Limited Fluticasone furoate in the treatment of copd
WO2016071792A1 (en) 2014-11-03 2016-05-12 Laboratorio Chimico Internazionale S.P.A. Method for the preparation of 1-(2-halogen-ethyl)-4 piperidine-carboxylic acid ethyl esters
WO2017137535A1 (en) 2016-02-12 2017-08-17 Glaxosmithkline Intellectual Property Development Limited Chemical compounds as inhibitors of kinase activity
US9751875B2 (en) 2013-07-13 2017-09-05 Beijing Fswelcome Technology Development Co., Ltd. Quinine compounds, and optical isomers, preparation method and medical use thereof
EP3248970A1 (en) 2016-05-27 2017-11-29 Zentiva K.S. Forms of umeclidinium bromide
WO2018029126A1 (en) 2016-08-08 2018-02-15 Glaxosmithkline Intellectual Property Development Limited Chemical compounds
WO2018087561A1 (en) 2016-11-14 2018-05-17 Hovione Scientia Limited Process for the preparation of umeclidinium bromide
WO2018163212A1 (en) * 2017-03-08 2018-09-13 Gbr Laboratories Pvt. Ltd A process for the preparation of umeclidinium bromide and intermediates thereof
WO2018192864A1 (en) 2017-04-18 2018-10-25 Glaxosmithkline Intellectual Property Development Limited Oxepinopyrazole derivatives as inhibitors of pi3-kinase activity
IT201700058796A1 (en) * 2017-05-30 2018-11-30 Olon Spa Procedure for the preparation of a new intermediate of synthesis of umeclidinium.
WO2019020657A1 (en) 2017-07-27 2019-01-31 Glaxosmithkline Intellectual Property Development Limited Pyridine-3-sulfonamide compounds as pi3-kinase inhibitors
WO2020254791A1 (en) 2019-06-17 2020-12-24 Hovione Scientia Limited Continuous process for the preparation of anticholinergic drugs
US11116721B2 (en) 2009-02-26 2021-09-14 Glaxo Group Limited Pharmaceutical formulations comprising 4-{(1R)-2-[(6-{2-[(2,6-dichlorobenzyl)oxy]ethoxy}hexyl)amino]-1-hydroxyethyl}-2-(hydroxymethyl) phenol
WO2021191875A1 (en) 2020-03-26 2021-09-30 Glaxosmithkline Intellectual Property Development Limited Cathepsin inhibitors for preventing or treating viral infections
WO2022053651A2 (en) 2020-09-10 2022-03-17 Precirix N.V. Antibody fragment against fap
WO2023030667A1 (en) 2021-09-03 2023-03-09 Hovione Scientia Process for the preparation of chloroalkyl substituted cyclic amines
WO2023203135A1 (en) 2022-04-22 2023-10-26 Precirix N.V. Improved radiolabelled antibody
WO2023213801A1 (en) 2022-05-02 2023-11-09 Precirix N.V. Pre-targeting

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20050250A1 (en) * 2003-07-17 2005-04-08 Glaxo Group Ltd ANTAGONISTS OF ACETYLCHOLIN MUSCARINAL RECEPTORS
EP1677796A4 (en) * 2003-10-17 2006-12-27 Glaxo Group Ltd Muscarinic acetylcholine receptor antagonists field of the invention
PE20050489A1 (en) * 2003-11-04 2005-09-02 Glaxo Group Ltd ANTAGONISTS OF MUSCARINE ACETYLCHOLINE RECEPTORS
WO2005087236A1 (en) * 2004-03-11 2005-09-22 Glaxo Group Limited Novel m3 muscarinic acetylcholine receptor antagonists
JP2007529513A (en) * 2004-03-17 2007-10-25 グラクソ　グループ　リミテッド M3 muscarinic acetylcholine receptor antagonist
JP2007529511A (en) * 2004-03-17 2007-10-25 グラクソ　グループ　リミテッド M3 muscarinic acetylcholine receptor antagonist
PE20060259A1 (en) 2004-04-27 2006-03-25 Glaxo Group Ltd QUINUCLIDINE COMPOUNDS AS ANTAGONISTS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR
JP2007537261A (en) * 2004-05-13 2007-12-20 グラクソ　グループ　リミテッド Muscarinic acetylcholine receptor antagonist
WO2006055553A2 (en) * 2004-11-15 2006-05-26 Glaxo Group Limited Novel m3 muscarinic acetylcholine receptor antagonists
US20080275079A1 (en) * 2005-08-02 2008-11-06 Glaxo Group Limited M3 Muscarinic Acetylcholine Receptor Antagonists
CA2788364C (en) * 2010-01-28 2017-10-31 Theron Pharmaceuticals, Inc. 7-azoniabicyclo[2.2.1]heptane derivatives, methods of production, and pharmaceutical uses thereof
RU2502743C1 (en) * 2012-08-03 2013-12-27 Федеральное государственное бюджетное учреждение "Российский кардиологический научно-производственный комплекс" Министерства здравоохранения и социального развития РФ (ФГБУ "РКНПК" Минздравсоцразвития России) Synthetic antigen having ability to fix autoantibodies to muscarine m2-receptor
KR101613245B1 (en) 2015-04-27 2016-04-18 주식회사 대웅제약 Novel 4-methoxy pyrrole derivatives or salts thereof and pharmaceutical composition comprising the same
CN105461710A (en) * 2015-10-23 2016-04-06 安徽德信佳生物医药有限公司 Preparation method of umeclidinium bromide
CN107200734B (en) * 2016-03-18 2019-12-24 益方生物科技（上海）有限公司 Quinuclidine derivative and preparation method and application thereof
CN108558860B (en) * 2018-06-04 2020-12-25 成都伊诺达博医药科技有限公司 Method for synthesizing umeclidinium bromide
WO2020047225A1 (en) 2018-08-30 2020-03-05 Theravance Biopharma R&D Ip, Llc Methods for treating chronic obstructive pulmonary disease
CN113387923A (en) * 2020-03-13 2021-09-14 诺华股份有限公司 Pharmaceutical compositions of lipoic acid choline ester salts and methods of treatment using the same
CN111484445B (en) * 2020-04-21 2021-05-18 广东莱佛士制药技术有限公司 Method for separating and purifying intermediate of high-purity Wumei ammonium bromide
AU2021264829B2 (en) * 2020-04-26 2024-02-01 Beijing Showby Pharmaceutical Co., Ltd. Crystal of M receptor antagonist as well as preparation method therefor and application thereof
CN112479983B (en) * 2020-11-25 2022-07-12 江苏豪森药业集团有限公司 Wumei ammonium bromide intermediate and preparation method thereof

Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1230087A (en) 1967-08-17 1971-04-28
US3634582A (en) 1967-08-08 1972-01-11 Fisons Pharmaceuticals Ltd Pharmaceutical compositions
GB1381872A (en) 1971-06-22 1975-01-29 Fisons Ltd Pharmaceutical compositions for inhalation
GB2064336A (en) 1979-12-06 1981-06-17 Glaxo Group Ltd Device for dispensing medicaments
EP0069715A1 (en) 1981-07-08 1983-01-12 Aktiebolaget Draco Powder inhalator
GB2129691A (en) 1982-10-08 1984-05-23 Glaxo Group Ltd Devices for administering medicaments to patients
GB2169265A (en) 1982-10-08 1986-07-09 Glaxo Group Ltd Pack for medicament
GB2178965A (en) 1985-07-30 1987-02-25 Glaxo Group Ltd Devices for administering medicaments to patients
WO1987005213A1 (en) 1986-03-04 1987-09-11 Chiesi Farmaceutici S.P.A. New pharmaceutical compositions for inhalation
GB2242134A (en) 1990-03-02 1991-09-25 Glaxo Group Ltd Inhalation device

Family Cites Families (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2800478A (en) * 1955-07-01 1957-07-23 Smith Kline French Lab 3-substituted-8-alkylnortropanes and the acid and quaternary ammonium salts thereof
US2800481A (en) * 1955-07-01 1957-07-23 Smith Kline French Lab Tertiary alcohol derivatives of 8-alkylnortropanes and the acid and quaternary ammonium salts thereof
AT298118B (en) * 1967-06-08 1972-04-25 Siemens Ag Method for converting voltages into digital values and device for carrying out the method
US5780466A (en) * 1995-01-30 1998-07-14 Sanofi Substituted heterocyclic compounds method of preparing them and pharmaceutical compositions in which they are present
WO1998024788A1 (en) * 1996-12-02 1998-06-11 Georgetown University Tropane derivatives and method for their synthesis
US6248752B1 (en) * 1998-02-27 2001-06-19 Charles Duane Smith Azabicyclooctane compositions and methods for enhancing chemotherapy
US6262066B1 (en) * 1998-07-27 2001-07-17 Schering Corporation High affinity ligands for nociceptin receptor ORL-1
ES2165768B1 (en) * 1999-07-14 2003-04-01 Almirall Prodesfarma Sa NEW DERIVATIVES OF QUINUCLIDINE AND PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM.
RU2282629C2 (en) * 2000-12-28 2006-08-27 Альмиралль Продесфарма Аг Derivatives of quinuclidine, method for their preparing and pharmaceutical composition based on thereof
NZ532283A (en) * 2001-10-17 2005-06-24 Ucb S Quinuclidine derivatives, processes for preparing them and their uses as m2 and/or m3 muscarinic receptor inhibitors
JP2005510523A (en) * 2001-11-09 2005-04-21 ファルマシア アンド アップジョン カンパニー リミティド ライアビリティー カンパニー Azabicyclic phenyl fused heterocyclic compounds and use of the compounds as α7NACHR ligands
EA006505B1 (en) * 2001-12-20 2005-12-29 Лабораториос С.А.Л.В.А.Т.,С.А. 1-alkyl-1-azoniabicyclo[2.2.2]octane carbamate derivatives and their use as muscarinic receptor antagonists
US6696462B2 (en) * 2002-01-31 2004-02-24 Boehringer Ingelheim Pharma Gmbh & Co. Kg Anticholinergics, processes for the preparation thereof, and pharmaceutical compositions
ES2206021B1 (en) 2002-04-16 2005-08-01 Almirall Prodesfarma, S.A. NEW DERIVATIVES OF PIRROLIDINIO.
ES2204295B1 (en) * 2002-07-02 2005-08-01 Almirall Prodesfarma, S.A. NEW DERIVATIVES OF QUINUCLIDINE-AMIDE.
TW200410951A (en) 2002-08-06 2004-07-01 Glaxo Group Ltd M3 muscarinic acetylcholine receptor antagonists
WO2004091482A2 (en) 2003-04-07 2004-10-28 Glaxo Group Limited M3 muscarinic acetylcholine receptor antagonists
PE20050250A1 (en) 2003-07-17 2005-04-08 Glaxo Group Ltd ANTAGONISTS OF ACETYLCHOLIN MUSCARINAL RECEPTORS
AR048573A1 (en) 2003-07-17 2006-05-10 Glaxo Group Ltd COMPOSITE OF 8-AZONIABICICLO [3.2.1] OCTANO REPLACED IN POSITION 3, PHARMACEUTICAL COMPOSITION THAT INCLUDES IT AND ITS USE TO PREPARE THIS LAST
UY28417A1 (en) 2003-07-17 2005-02-28 Glaxo Group Ltd ANTAGONISTS OF ACETILCOLINE MUSCARINIC RECEPTORS
AP2007004239A0 (en) 2003-10-14 2007-12-31 Glaxo Group Ltd Muscarinic acetycholine receptor antagonists
EP1677796A4 (en) 2003-10-17 2006-12-27 Glaxo Group Ltd Muscarinic acetylcholine receptor antagonists field of the invention
PE20050489A1 (en) 2003-11-04 2005-09-02 Glaxo Group Ltd ANTAGONISTS OF MUSCARINE ACETYLCHOLINE RECEPTORS
US7345060B2 (en) * 2003-11-21 2008-03-18 Theravance, Inc. Compounds having β2 adrenergic receptor agonist and muscarinic receptor antagonist activity
AR046783A1 (en) 2003-12-03 2005-12-21 Glaxo Group Ltd COMPONENT OF CYCLICAL AMMONIUM SALT QUATERNARY PHARMACEUTICAL COMPOSITION THAT INCLUDES IT AND ITS USE TO PREPARE THIS LAST
UY28645A1 (en) 2003-12-03 2005-06-30 Glaxo Group Ltd NEW ANTAGONISTS OF THE M3 ACETILCOLINE MUSCARINIC RECEPTOR
TW200534855A (en) 2004-01-13 2005-11-01 Glaxo Group Ltd Muscarinic acetylcholine receptor antagonists
WO2005087236A1 (en) 2004-03-11 2005-09-22 Glaxo Group Limited Novel m3 muscarinic acetylcholine receptor antagonists
JP2007530451A (en) 2004-03-11 2007-11-01 グラクソ　グループ　リミテッド Novel M3 muscarinic acetylcholine receptor antagonist
JP2007529513A (en) 2004-03-17 2007-10-25 グラクソ　グループ　リミテッド M3 muscarinic acetylcholine receptor antagonist
JP2007529512A (en) 2004-03-17 2007-10-25 グラクソ　グループ　リミテッド Muscarinic acetylcholine receptor antagonist
JP2007529514A (en) 2004-03-17 2007-10-25 グラクソ　グループ　リミテッド M3 muscarinic acetylcholine receptor antagonist
JP2007529511A (en) 2004-03-17 2007-10-25 グラクソ　グループ　リミテッド M3 muscarinic acetylcholine receptor antagonist
US20070238751A1 (en) 2004-04-07 2007-10-11 Laine Dramane I Muscarinic Acetylcholine Receptor Antagonists
PE20060259A1 (en) 2004-04-27 2006-03-25 Glaxo Group Ltd QUINUCLIDINE COMPOUNDS AS ANTAGONISTS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR
JP2007537261A (en) 2004-05-13 2007-12-20 グラクソ　グループ　リミテッド Muscarinic acetylcholine receptor antagonist
WO2005118594A1 (en) 2004-05-28 2005-12-15 Glaxo Group Limited Muscarinic acetylcholine receptor antagonists
WO2006005057A2 (en) 2004-06-30 2006-01-12 Glaxo Group Limited Muscarinic acetylcholine receptor antagonists
JP2008509159A (en) 2004-08-05 2008-03-27 グラクソ グループ リミテッド Muscarinic acetylcholine receptor antagonist
WO2006017767A2 (en) 2004-08-06 2006-02-16 Glaxo Group Limited Muscarinic acetylcholine receptor antagonists
US20090258858A1 (en) 2004-10-29 2009-10-15 Jakob Busch-Petersen Muscarinic acetylcholine receptor antagonists
WO2006055503A2 (en) 2004-11-15 2006-05-26 Glaxo Group Limited Novel m3 muscarinic acetylcholine receptor antagonists
WO2006055553A2 (en) 2004-11-15 2006-05-26 Glaxo Group Limited Novel m3 muscarinic acetylcholine receptor antagonists
PE20060826A1 (en) 2004-12-06 2006-10-08 Smithkline Beecham Corp OLEOPHINIC DERIVATIVE OF 8-AZONIABICICLO [3.2.1] OCTANE AND THE PHARMACEUTICAL COMBINATION THAT INCLUDES IT
PE20061162A1 (en) 2004-12-06 2006-10-14 Smithkline Beecham Corp COMPOUNDS OLEFINIC DERIVATIVES OF 8-AZONIABICICLO [3.2.1] OCTANES
WO2006065788A2 (en) 2004-12-13 2006-06-22 Glaxo Group Limited Novel muscarinic acetylcholine receptor antagonists
WO2006065755A2 (en) 2004-12-13 2006-06-22 Glaxo Group Limited Quaternary ammonium salts of fused hetearomatic amines as novel muscarinic acetylcholine receptor antagonists
WO2007018514A1 (en) 2005-07-28 2007-02-15 Glaxo Group Limited Novel m3 muscarinic acetylcholine receptor antagonists
WO2007018508A1 (en) 2005-07-28 2007-02-15 Glaxo Group Limited Novel m3 muscarinic acetycholine receptor antagonists
US20080234315A1 (en) 2005-08-02 2008-09-25 Jakob Busch-Petersen M3 Muscarinic Acetylcholine Receptor Antagonists
US20080275079A1 (en) 2005-08-02 2008-11-06 Glaxo Group Limited M3 Muscarinic Acetylcholine Receptor Antagonists
WO2007022351A2 (en) 2005-08-18 2007-02-22 Glaxo Group Limited Muscarinic acetylcholine receptor antagonists
GB0921075D0 (en) * 2009-12-01 2010-01-13 Glaxo Group Ltd Novel combination of the therapeutic agents

Patent Citations (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3634582A (en) 1967-08-08 1972-01-11 Fisons Pharmaceuticals Ltd Pharmaceutical compositions
GB1230087A (en) 1967-08-17 1971-04-28
GB1381872A (en) 1971-06-22 1975-01-29 Fisons Ltd Pharmaceutical compositions for inhalation
GB2064336A (en) 1979-12-06 1981-06-17 Glaxo Group Ltd Device for dispensing medicaments
EP0069715A1 (en) 1981-07-08 1983-01-12 Aktiebolaget Draco Powder inhalator
GB2169265A (en) 1982-10-08 1986-07-09 Glaxo Group Ltd Pack for medicament
GB2129691A (en) 1982-10-08 1984-05-23 Glaxo Group Ltd Devices for administering medicaments to patients
GB2178965A (en) 1985-07-30 1987-02-25 Glaxo Group Ltd Devices for administering medicaments to patients
WO1987005213A1 (en) 1986-03-04 1987-09-11 Chiesi Farmaceutici S.P.A. New pharmaceutical compositions for inhalation
GB2242134A (en) 1990-03-02 1991-09-25 Glaxo Group Ltd Inhalation device
US5590645A (en) 1990-03-02 1997-01-07 Glaxo Group Limited Inhalation device
US5860419A (en) 1990-03-02 1999-01-19 Glaxo Group Limited Inhalation device
US5873360A (en) 1990-03-02 1999-02-23 Glaxo Group Limited Inhalation device

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
CAULFIELD, PHARMAC. THER., vol. 58, 1993, pages 319 - 79
FRYER ET AL., LIFE SCI, vol. 64, no. 6-7, 1999, pages 449 - 55
FRYER, JACOBY, AM JRESPIR CRIT CARE MED, vol. 158, 1998, pages 154 - 60
H. M.SARAU, MOL. PHARMACOL., vol. 56, 1999, pages 657 - 663
PAUWELS ET AL., AM. J RESPIR. CRIT. CARE MED., vol. 163, 2001, pages 1256 - 1276
See also references of EP1740177A4

Cited By (89)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006085890A2 (en) * 2004-04-05 2006-08-17 Samaritan Pharmaceuticals, Inc. Anti-hiv quinuclidine compounds
WO2006085890A3 (en) * 2004-04-05 2006-12-07 Samaritan Pharmaceuticals Inc Anti-hiv quinuclidine compounds
US8084463B2 (en) 2004-11-02 2011-12-27 Novartis Ag Quinuclidine derivatives and their use as muscarinic M3 receptor antagonists
US7767691B2 (en) * 2005-08-18 2010-08-03 Glaxo Group Limited Muscarinic acetylcholine receptor antagonists containing an azoniabiocyclo[2.2.1] heptane ring system
WO2007122165A1 (en) 2006-04-20 2007-11-01 Glaxo Group Limited Novel compounds
WO2007144327A2 (en) 2006-06-12 2007-12-21 Glaxo Group Limited Phenyl-pyrazole derivatives as non-steroidal glucocoricoid receptor ligands
WO2008015416A1 (en) 2006-08-01 2008-02-07 Glaxo Group Limited Pyrazolo[3,4-b]pyridine compounds, and their use as pde4 inhibitors
WO2008118724A1 (en) 2007-03-23 2008-10-02 Smithkline Beecham Corporation Indole carboxamides as ikk2 inhibitors
US8067408B2 (en) 2008-02-06 2011-11-29 Glaxo Group Limited Dual pharmacophores—PDE4-muscarinic antagonistics
US8071588B2 (en) 2008-02-06 2011-12-06 Glaxo Group Limited Dual pharmacophores—PDE4-muscarinic antagonistics
US8084449B2 (en) 2008-02-06 2011-12-27 Glaxo Group Limited Dual pharmacophores—PDE4-muscarinic antagonistics
WO2009147187A1 (en) 2008-06-05 2009-12-10 Glaxo Group Limited 4-carboxamide indazole derivatives useful as inhibitors of p13-kinases
WO2009147190A1 (en) 2008-06-05 2009-12-10 Glaxo Group Limited Novel compounds
WO2010094643A1 (en) 2009-02-17 2010-08-26 Glaxo Group Limited Quinoline derivatives and their uses for rhinitis and urticaria
US11116721B2 (en) 2009-02-26 2021-09-14 Glaxo Group Limited Pharmaceutical formulations comprising 4-{(1R)-2-[(6-{2-[(2,6-dichlorobenzyl)oxy]ethoxy}hexyl)amino]-1-hydroxyethyl}-2-(hydroxymethyl) phenol
WO2010102958A1 (en) 2009-03-09 2010-09-16 Glaxo Group Limited 4-oxadiazol-2 -yl- indazoles as inhibitors of p13 kinases
WO2010102968A1 (en) 2009-03-10 2010-09-16 Glaxo Group Limited Indole derivatives as ikk2 inhibitors
WO2010106016A1 (en) 2009-03-17 2010-09-23 Glaxo Group Limited Pyrimidine derivatives used as itk inhibitors
EP3260453A1 (en) 2009-04-30 2017-12-27 Glaxo Group Limited Oxazole substituted indazoles as pi3-kinase inhibitors
EP2899191A1 (en) 2009-04-30 2015-07-29 Glaxo Group Limited Oxazole substituted indazoles as pi3-kinase inhibitors
WO2011029896A1 (en) 2009-09-11 2011-03-17 Glaxo Group Limited Methods of preparation of muscarinic acetylcholine receptor antagonists
AU2014204459B2 (en) * 2009-12-01 2016-08-25 Glaxo Group Limited Combinations of a muscarinic receptor antagonist and a beta-2 adrenoreceptor agonist
US9750726B2 (en) 2009-12-01 2017-09-05 Glaxo Group Limited Combinations of a muscarinic receptor antagonist and a beta-2 adrenoreceptor agonist
AU2016262698B2 (en) * 2009-12-01 2018-10-25 Glaxo Group Limited Combinations of a muscarinic receptor antagonist and a beta-2 adrenoreceptor agonist
EP2506844B1 (en) 2009-12-01 2017-12-20 Glaxo Group Limited Combinations of a muscarinic receptor antagonist and a beta-2 adrenoreceptor agonist
EP3335707A1 (en) 2009-12-01 2018-06-20 Glaxo Group Limited Combinations of a muscarinic receptor antagonist and a beta-2 adrenoreceptor agonist
AU2018282427B2 (en) * 2009-12-01 2021-04-01 Glaxo Group Limited Combinations of a muscarinic receptor antagonist and a beta-2 adrenoreceptor agonist
CN102724974A (en) * 2009-12-01 2012-10-10 葛兰素集团有限公司 Combinations of a muscarinic receptor antagonist and a beta-2 adrenoreceptor agonist
US20120309725A1 (en) * 2009-12-01 2012-12-06 Glaxo Group Limited Combinations of a muscarinic receptor antagonist and a beta-2 adrenoreceptor agonist
EA023839B1 (en) * 2009-12-01 2016-07-29 Глаксо Груп Лимитед Combinations of a muscarinic receptor antagonist and a beta-2 adrenoreceptor agonist
US11090294B2 (en) 2009-12-01 2021-08-17 Glaxo Group Limited Combinations of a muscarinic receptor antagonist and a beta-2 adrenoreceptor agonist
WO2011067212A1 (en) 2009-12-01 2011-06-09 Glaxo Group Limited Combinations of a muscarinic receptor antagonist and a beta-2 adrenoreceptor agonist
US20220047565A1 (en) * 2009-12-01 2022-02-17 Glaxo Group Limited Combinations of a muscarinic receptor antagonist and a beta-2 adrenoreceptor agonist
AU2018282427C1 (en) * 2009-12-01 2022-06-30 Glaxo Group Limited Combinations of a muscarinic receptor antagonist and a beta-2 adrenoreceptor agonist
AU2010326798B2 (en) * 2009-12-01 2014-08-07 Glaxo Group Limited Combinations of a muscarinic receptor antagonist and a beta-2 adrenoreceptor agonist
WO2011067366A1 (en) 2009-12-03 2011-06-09 Glaxo Group Limited Indazole derivatives as pi 3 - kinase inhibitors
WO2011067364A1 (en) 2009-12-03 2011-06-09 Glaxo Group Limited Novel compounds
WO2011067365A1 (en) 2009-12-03 2011-06-09 Glaxo Group Limited Benzpyrazole derivatives as inhibitors of p13 kinases
WO2011110575A1 (en) 2010-03-11 2011-09-15 Glaxo Group Limited Derivatives of 2-[2-(benzo- or pyrido-) thiazolylamino]-6-aminopyridine, useful in the treatment of respiratoric, allergic or inflammatory diseases
WO2011160920A1 (en) * 2010-06-22 2011-12-29 Chiesi Farmaceutici S.P.A. Dry powder formulation comprising an antimuscarinic drug
WO2012032067A1 (en) 2010-09-08 2012-03-15 Glaxo Group Limited Polymorphs and salts of n- [5- [4- (5- { [(2r,6s) -2, 6 - dimethyl - 4 -morpholinyl] methyl} - 1, 3 - oxazol - 2 - yl) - 1h- inda zol-6-yl] -2- (methyloxy) - 3 - pyridinyl] methanesulfonamide
WO2012035055A1 (en) 2010-09-17 2012-03-22 Glaxo Group Limited Novel compounds
WO2012055846A1 (en) 2010-10-27 2012-05-03 Glaxo Group Limited Polymorphs and salts of 6-(1h-indol-4-yl)-4-(5- { [4-(1-methylethyl)-1-pi perazinyl] methyl} -1,3-oxazol-2-yl)-1h-indazole as pi3k inhibitors for use in the treatment of e.g. respiratory disorders
EP3447055A1 (en) 2010-10-27 2019-02-27 Glaxo Group Limited Combinations of polymorphs and salts of 6-(1h-indol-4-yl)-4-(5-{[4-(1-methylethyl)-1-piperazinyl]methyl}-1,3-oxazol-2-yl)-1h-indazole as pi3k inhibitors for use in the treatment of e.g. respiratory disorders
WO2012168161A1 (en) 2011-06-08 2012-12-13 Glaxo Group Limited Combination comprising umeclidinium and a corticosteroid
WO2012168160A1 (en) 2011-06-08 2012-12-13 Glaxo Group Limited Dry powder inhaler compositions comprising umeclidinium
WO2013153146A1 (en) 2012-04-13 2013-10-17 Glaxosmithkline Intellectual Property Development Limited Aggregate particles
US9763965B2 (en) 2012-04-13 2017-09-19 Glaxosmithkline Intellectual Property Development Limited Aggregate particles
US9273001B2 (en) 2012-08-15 2016-03-01 Glaxo Group Limited Chemical process
CN104619706B (en) * 2012-08-15 2017-06-20 葛兰素集团有限公司 Chemical method
US9657011B2 (en) 2012-08-15 2017-05-23 Glaxo Group Limited Chemical process
AU2013304102B2 (en) * 2012-08-15 2016-09-01 Glaxo Group Limited Chemical process
WO2014027045A1 (en) * 2012-08-15 2014-02-20 Glaxo Group Limited Chemical process
AU2016213768B2 (en) * 2012-08-15 2018-01-04 Glaxo Group Limited Chemical process
EP3401316A1 (en) * 2012-08-15 2018-11-14 Glaxo Group Limited Chemical process
US9795561B2 (en) 2012-12-17 2017-10-24 Glaxo Group Limited Combination of umeclidinium, fluticasone propionate and salmeterol xinafoate for use in the treatment of inflammatory or respiratory tract diseases
WO2014095924A1 (en) * 2012-12-17 2014-06-26 Glaxo Group Limited Combination of umeclidinium, fluticasone propionate and salmeterol xinafoate for use in the treatment of inflammatory or respiratory tract diseases
US9751875B2 (en) 2013-07-13 2017-09-05 Beijing Fswelcome Technology Development Co., Ltd. Quinine compounds, and optical isomers, preparation method and medical use thereof
WO2015015446A1 (en) 2013-07-30 2015-02-05 Glaxosmithkline Intellectual Property Development Limited Topical compositions for treatment of excessive sweating and methods of use thereof
WO2015055691A1 (en) 2013-10-17 2015-04-23 Glaxosmithkline Intellectual Property Development Limited Pi3k inhibitor for treatment of respiratory disease
WO2015055690A1 (en) 2013-10-17 2015-04-23 Glaxosmithkline Intellectual Property Development Limited Pi3k inhibitor for treatment of respiratory disease
WO2015173701A2 (en) 2014-05-12 2015-11-19 Glaxosmithkline Intellectual Property (No. 2) Limited Pharmaceutical compositions for treating infectious diseases
WO2015181262A1 (en) 2014-05-28 2015-12-03 Glaxosmithkline Intellectual Property Development Limited Fluticasone furoate in the treatment of copd
US10987363B2 (en) 2014-05-28 2021-04-27 Glaxosmithkline Intellectual Property Development Limited Fluticasone furoate in the treatment of COPD
WO2016071792A1 (en) 2014-11-03 2016-05-12 Laboratorio Chimico Internazionale S.P.A. Method for the preparation of 1-(2-halogen-ethyl)-4 piperidine-carboxylic acid ethyl esters
US10023535B2 (en) 2014-11-03 2018-07-17 Olon S.P.A. Method for the preparation of 1-(2-halogen-ethyl)-4 piperidine-carboxylic acid ethyl esters
WO2017137535A1 (en) 2016-02-12 2017-08-17 Glaxosmithkline Intellectual Property Development Limited Chemical compounds as inhibitors of kinase activity
EP3248970A1 (en) 2016-05-27 2017-11-29 Zentiva K.S. Forms of umeclidinium bromide
WO2018029126A1 (en) 2016-08-08 2018-02-15 Glaxosmithkline Intellectual Property Development Limited Chemical compounds
EP3831826A1 (en) 2016-11-14 2021-06-09 Hovione Scientia Limited Process for the preparation of umeclidinium bromide
US10759801B2 (en) 2016-11-14 2020-09-01 Hovione Scientia Limited Process for the preparation of umeclidinium bromide
IL266589B2 (en) * 2016-11-14 2023-07-01 Hovione Scientia Ltd Process for the preparation of umeclidinium bromide
CN110167931A (en) * 2016-11-14 2019-08-23 好利安科技有限公司 The method for preparing umeclidinium
WO2018087561A1 (en) 2016-11-14 2018-05-17 Hovione Scientia Limited Process for the preparation of umeclidinium bromide
IL266589B1 (en) * 2016-11-14 2023-03-01 Hovione Scientia Ltd Process for the preparation of umeclidinium bromide
AU2017357653B2 (en) * 2016-11-14 2021-11-04 Hovione Scientia Limited Process for the preparation of umeclidinium bromide
US11427584B2 (en) 2016-11-14 2022-08-30 Hovione Scientia Limited Process for the preparation of umeclidinium bromide
WO2018163212A1 (en) * 2017-03-08 2018-09-13 Gbr Laboratories Pvt. Ltd A process for the preparation of umeclidinium bromide and intermediates thereof
WO2018192864A1 (en) 2017-04-18 2018-10-25 Glaxosmithkline Intellectual Property Development Limited Oxepinopyrazole derivatives as inhibitors of pi3-kinase activity
WO2018220501A1 (en) * 2017-05-30 2018-12-06 Olon S.P.A. Process for the preparation of a novel umeclidinium synthesis intermediate
US11028082B2 (en) 2017-05-30 2021-06-08 Olon S.P.A. Process for the preparation of a novel umeclidinium synthesis intermediate
IT201700058796A1 (en) * 2017-05-30 2018-11-30 Olon Spa Procedure for the preparation of a new intermediate of synthesis of umeclidinium.
WO2019020657A1 (en) 2017-07-27 2019-01-31 Glaxosmithkline Intellectual Property Development Limited Pyridine-3-sulfonamide compounds as pi3-kinase inhibitors
WO2020254791A1 (en) 2019-06-17 2020-12-24 Hovione Scientia Limited Continuous process for the preparation of anticholinergic drugs
WO2021191875A1 (en) 2020-03-26 2021-09-30 Glaxosmithkline Intellectual Property Development Limited Cathepsin inhibitors for preventing or treating viral infections
WO2022053651A2 (en) 2020-09-10 2022-03-17 Precirix N.V. Antibody fragment against fap
WO2023030667A1 (en) 2021-09-03 2023-03-09 Hovione Scientia Process for the preparation of chloroalkyl substituted cyclic amines
WO2023203135A1 (en) 2022-04-22 2023-10-26 Precirix N.V. Improved radiolabelled antibody
WO2023213801A1 (en) 2022-05-02 2023-11-09 Precirix N.V. Pre-targeting

Also Published As

Publication number Publication date
US20150238470A1 (en) 2015-08-27
HUE031304T2 (en) 2017-07-28
TW200605887A (en) 2006-02-16
BRPI0510170B1 (en) 2018-12-18
US20070249664A1 (en) 2007-10-25
US20140080863A1 (en) 2014-03-20
EA200601991A1 (en) 2007-02-27
WO2005104745A3 (en) 2006-08-03
AP2213A (en) 2011-03-01
IL178152A (en) 2011-05-31
CY1118082T1 (en) 2017-06-28
DK1740177T3 (en) 2012-10-29
US20160002220A1 (en) 2016-01-07
MXPA06012405A (en) 2007-01-17
US9045469B2 (en) 2015-06-02
CA2755954C (en) 2014-02-18
AR050902A1 (en) 2006-12-06
NO2017017I1 (en) 2017-05-04
PT2570128T (en) 2016-10-07
US8853404B2 (en) 2014-10-07
MA28631B1 (en) 2007-06-01
NO2017018I1 (en) 2017-05-04
KR20070015412A (en) 2007-02-02
US7488827B2 (en) 2009-02-10
JP2007534769A (en) 2007-11-29
ZA200608565B (en) 2019-12-18
ES2392848T3 (en) 2012-12-14
DK2570128T3 (en) 2016-11-07
BRPI0510170B8 (en) 2021-05-25
UA95768C2 (en) 2011-09-12
NL300694I1 (en) 2015-12-29
PE20060259A1 (en) 2006-03-25
US8575347B2 (en) 2013-11-05
EP1740177B1 (en) 2012-08-08
LU92565I2 (en) 2014-12-02
CY1113196T1 (en) 2015-12-09
AU2005237576A1 (en) 2005-11-10
EP1740177A2 (en) 2007-01-10
EA201100019A1 (en) 2011-12-30
ES2600405T3 (en) 2017-02-08
TWI363759B (en) 2012-05-11
HRP20120832T1 (en) 2012-11-30
MY144753A (en) 2011-10-31
CA2755954A1 (en) 2005-11-10
KR101152032B1 (en) 2012-06-11
CY2014043I2 (en) 2015-12-09
NL300694I2 (en) 2015-12-29
EA015033B1 (en) 2011-04-29
HUS1400053I1 (en) 2017-07-28
CA2564742A1 (en) 2005-11-10
EP2570128B1 (en) 2016-08-10
EP3111936A1 (en) 2017-01-04
HRP20161385T1 (en) 2016-12-02
CN102040602A (en) 2011-05-04
KR20110010841A (en) 2011-02-07
ECSP066940A (en) 2006-12-20
EP1740177A4 (en) 2010-05-05
JP2012162559A (en) 2012-08-30
NO2017018I2 (en) 2018-05-14
US20070185155A1 (en) 2007-08-09
SI2570128T1 (en) 2016-11-30
US20090124653A1 (en) 2009-05-14
US8183257B2 (en) 2012-05-22
US9144571B2 (en) 2015-09-29
HK1102423A1 (en) 2007-11-23
US20140371264A1 (en) 2014-12-18
ES2392848T4 (en) 2014-10-01
BRPI0510170A (en) 2007-10-02
JP5398871B2 (en) 2014-01-29
CY2014043I1 (en) 2015-12-09
LU92565I9 (en) 2019-01-17
NZ549997A (en) 2010-10-29
SG186597A1 (en) 2013-01-30
US8309572B2 (en) 2012-11-13
PL2570128T3 (en) 2017-09-29
EP2570128A1 (en) 2013-03-20
PT1740177E (en) 2012-11-02
UY28871A1 (en) 2005-11-30
LT2570128T (en) 2016-10-10
NO20065417L (en) 2006-12-29
PL1740177T3 (en) 2012-12-31
CN1976701A (en) 2007-06-06
KR101037026B1 (en) 2011-05-25
JP5014121B2 (en) 2012-08-29
AU2005237576B2 (en) 2012-01-12
NO338959B1 (en) 2016-11-07
US7498440B2 (en) 2009-03-03
SI1740177T1 (en) 2012-12-31
IL178152A0 (en) 2006-12-31
US20130030015A1 (en) 2013-01-31
CA2564742C (en) 2012-01-10
EA021994B1 (en) 2015-10-30
US20120157491A1 (en) 2012-06-21
AP2006003746A0 (en) 2006-10-31

Similar Documents

Publication Publication Date Title
CA2564742C (en) Quaternary quinuclidine derivatives and their use as muscarinic receptor antagonists
US7767691B2 (en) Muscarinic acetylcholine receptor antagonists containing an azoniabiocyclo[2.2.1] heptane ring system
US7598267B2 (en) Muscarinic acetylcholine receptor antagonists
AU2012202307B2 (en) Muscarinic acetylcholine receptor antagonists

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 2005237576

Country of ref document: AU

Ref document number: 200607695

Country of ref document: ZA

WWE Wipo information: entry into national phase

Ref document number: AP/P/2006/003746

Country of ref document: AP

WWE Wipo information: entry into national phase

Ref document number: 178152

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 5413/DELNP/2006

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 12006501850

Country of ref document: PH

Ref document number: 549997

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 2005746609

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2005237576

Country of ref document: AU

Date of ref document: 20050427

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2005237576

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 06108728

Country of ref document: CO

WWE Wipo information: entry into national phase

Ref document number: 1020067022276

Country of ref document: KR

Ref document number: PA/a/2006/012405

Country of ref document: MX

Ref document number: 2564742

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2007510915

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Ref document number: DE

WWE Wipo information: entry into national phase

Ref document number: DZP2005000574

Country of ref document: DZ

Ref document number: DZP2006000574

Country of ref document: DZ

WWE Wipo information: entry into national phase

Ref document number: 1200601950

Country of ref document: VN

WWE Wipo information: entry into national phase

Ref document number: 200601991

Country of ref document: EA

WWE Wipo information: entry into national phase

Ref document number: 200580021536.0

Country of ref document: CN

WWP Wipo information: published in national office

Ref document number: 2005746609

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1020067022276

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 11568330

Country of ref document: US

Ref document number: 2007185155

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 11568330

Country of ref document: US

ENP Entry into the national phase

Ref document number: PI0510170

Country of ref document: BR